annual report performance n n v n e n g age n reporting solid results roche prevention life employees propose increase extending medicines important proud work roche dividend th year pipeline breakthroughs find company running discover new included hpv test create great chairman christoph franz cervical cancer survival workplace people feel plans build strong data nearly years engaged inspired foundation roche breast cancer medicine best work contents opening section innovation roche diverse approaches rd business priorities innovative rd targeted therapies leading innovations pipeline innovative approaches clinical studies letters reliable supply patients health interpreting big data letter chairman spotlight hpv testing board directors value diagnostic test results letter ceo building partnerships around world corporate executive committee conducting responsible rd pharmaceuticals pipeline business review market environment access healthcare solid growth divisions enormous global challenge big picture improving affordability focusing value increasing availability innovative products access healthcare strengthening infrastructure technological advances increasing awareness patient support growth emerging markets spotlight africa diagnostics responsible business good sales growth integrity core everything setting new industry standards new instruments increasing transparency adding value healthcare engaging stakeholders diagnostics business model managing risk crisis spotlight diagnostics korea safeguarding patients spotlight mental health pharmaceuticals people solid performance key products performing well engaging energising people significant breakthroughs recognising rewarding employees making innovation accessible appreciating everyones contribution spotlight biomarkers preparing workplace future developing full potential leaders making employee careers spotlight professional development environment community reducing environmental footprint occupational mental health environmental sustainability security pharmaceuticals environment legislation compliance remediation management spotlight sustainability making difference philanthropy corporate governance remuneration report corporate governance remuneration report report statutory auditor closing section assurance report web impressum purpose statement roche roche roche roche researchbased healthcare company founded headquartered basel switzerland focus creating truly innovative medicines diagnostic tests areas unmet medical need business model drives ambition make significant difference patients reaching many people need possible whilst continuously reinvesting innovation develop diagnostic tests breakthrough treatments billion swiss francs swiss francs sales core earnings per share billion swiss francs market capitalisation employees pharmaceuticals diagnostics product pipeline esbriet approved idiopathic pulmonary new molecular testing systems cobas antipdl immunotherapy medicine fibrosis cobas launched bladder cancer roactemra approved early rheumatoid hpv test primary screening cervical lampalizumab geographic atrophy arthritis cancer approved eye avastin approved cervical cancer new diagnostic test syphilis launched cobimetinib zelboraf advanced platinumresistant ovarian cancer investment million swiss francs melanoma gazyvaro approved chronic lymphocytic next three years new diagnostic ace innovative bispecific antibody leukemia manufacturing facility china hemophilia unless otherwise stated growth rates report constant exchange rates cer average full year roche annual report roche roche biotech oncology vitro diagnostics hospital market acquisitions sustainability group intermune idiopathic pulmonary fibrosis dow jones sustainability indices group christoph franz elected chairman seragon pharmaceuticals hormone leader sixth year running roche board directors receptorpositive breast cancer global access programme test viral loads billion swiss francs investments ariosa diagnostics noninvasive prenatal people hiv infections launched announced stateoftheart r testing million people treated years production facilities infrastructure genia technologies nextgeneration gene phelophepa train mobile increase dividend proposed sequencing health clinic south africa th consecutive year iquum molecular diagnostics fully engaged employees new external partnerships roche annual report roche business priorities business priorities clear set business priorities aimed achieving sustainable growth delivering value stakeholders focus patients excellence science personalised healthcare focus exclusively developing innovative strive address unmet medical needs combine strengths pharmaceuticals medicines diagnostic tests help excellence science breakthrough diagnostics better fit treatments patients live longer better lives two thirds innovation science technology patients genetic differences known diseases either still increasingly allow us understand precisely identified efficacy safety medicines treated adequately treated malfunctioning body improved enormously end medical need enormous challenge develop drugs counter problem companion diagnostic strategy better diagnostics medicines focus oncology immunology infectious every molecule develop make huge difference lives millions diseases ophthalmology neuroscience patients families however remain flexible follow science new insights become available performance million patients roche top selling new molecular entities nmes personalised healthcare collaborations medicine pipeline within roche million women tested hpv pharmaceutical product approvals companion tests development billion test strips blood manuscripts puplished nmes companion diagnostic glucose monitoring sold toptier journals programmes pipeline roche annual report business priorities roche access healthcare great workplace sustainable value aim bring medicines diagnostic committed constantly maintaining run business way ethical tests many people need possible strengthening highly attractive aims create longterm value shareholders every healthcare system comes different workplaces every person feels valued stakeholders want create challenges customise solutions respected grow value developing medical solutions individual markets work many full potential people make business aim many people benefit different local partners reduce barriers discover develop manufacture possible believe success accessing healthcare establish innovative products ensure reach patients lies ability develop strategies sustainable ways bring effective need believe key industry society benefit affordable healthcare patients success lies ability attract retain sustainable way motivate highly skilled diverse workforce performance women screened breast cancer employees proud improvement ecoimpact north africa roche mobile unit work roche th consecutive year dividend million infants tested hiv part fully engaged employees increase proposed roches amplicare programme total workforce women times group leader dow jones global access programme hiv viral sustainability indices load testing launched roche annual report letter shareholders christoph franz roche annual report christoph franz letter shareholders supporting strategy lasting success another successful year roche solid business performance highly promising medical advances groundbreaking investments board directors proposing dividend increase dear shareholders bladder cancer devastating disease limited treatment options main goal always use cuttingedge first year chairman board directors science offer patients better quality life pleased present solid results possible cure help live longer despite challenging conditions markets particularly europe delivered strong sales growth across roche invested close billion swiss francs divisions reported strong net income billion research development convinced swiss francs enormous potential modern biosciences continue rigorously pursue efforts investments area also notable successes research worlds largest biotech company best development thanks medicines helped possible position use knowledge disease biology improve treatment leukemia pulmonary diseases develop new treatments tests better tailored skin disorders also introduced test specific patient groups making safer detection virus causing cervical cancer effective course always better prevent millions people treated medicines treat global leader healthcare diagnostics thanks diagnostic tests even received roche playing crucial role early screening reliable diagnosis basis targeted successful personalised medicines products help overcome treatment major challenges healthcare systems facing today main objective remains innovation heart us means offer patients better quality open good ideas including ones generated outside roche fact one third pharmaceutical life possible cure products born partnership usually help live longer smaller biotech firm university maintain impressive global partnership network spanning alliances underpinned targeted acquisition technologies last years annual general meeting made commitment active ingredients expertise entered continue course roche set ensure number important strategic partnerships acquisition group remains driver innovation healthcare biotech company intermune example significantly sector particularly impressed large number strengthened portfolio area respiratory projects pharmaceutical diagnostic pipelines disorders esbriet treatment fatal lung disease tackling serious diseases high unmet need roche annual report letter shareholders christoph franz next along unique challenges system facing sustainable success demands success hinges giving employees sufficient longterm thinking responsibility latitude adapt local situation context decentralised management style core strength want continue foster another important achievement group certainly selection dow jones sustainability nonetheless providing access innovative tests indices worlds sustainable company life medicines economically weaker countries major sciences sector sixth year running challenge particularly oncology treatments another indicator right track sustainable complex demands made facilities expertise success true roche requires resources high need work local partners longterm thinking commitment comes best understand local barriers find ways help implementation development longterm strategy patients also improve preventive screening roche benefits tremendous advantage thanks guidance support trust provided hoffmann whilst primary focus always developing innovative oeri families one groups biggest treatments tests also year site expansions strengths largely provide space growing workforce additional research infrastructure increased production capacities biggest investment announced roches decentralised basel headquarters aim invest management style strength billion swiss francs next decade primarily new modern research centre second stateofthe want continue foster art office building addition spend million swiss francs increasing production capacity china threeyear period order meet growing visited many sites around world demand diagnostic tests also investing meet employees also get know companys key hub another site switzerland modern research stakeholder groups really stood laboratories south san francisco expanding vast differences one national healthcare system research production capacities germany roche annual report christoph franz letter shareholders delighted propose bernard poussot professor light good performance richard lifton new members board directors propose dividend increase two prominent figures would bring wealth experience pharmaceutical sector basic swiss francs per share biomedical research respectively bernard comes nonvoting equity security wyeth spent years leading company positions including president ceo chairman director yale center genome analysis richard roche successful company excellent prospects awardwinning scientist provided valuable insights however know personal experience requires member advisory boards various leading much effort keep company top pharmaceutical companies get roche unique focused sciencedriven innovation cooperative despite clear strategic focus innovative medicines decentralised structure rooted switzerland open diagnostics roche well positioned continue growing world deeply committed sustaining board directors management committed distinctive culture future ensuring roche remains one worlds successful researchbased healthcare companies whilst look forward addressing person th annual general meeting agm roche holding ltd would like take opportunity extend sincere thanks march would like highlight two important items entire board directors agenda employees well corporate executive committee achievements proposing two prominent also wish thank valued shareholders figures wealth experience confidence company pharmaceutical sector new board members light strong performance solid outlook board directors proposing dividend increase swiss francs per share nonvoting equity security christoph franz subject approval th consecutive chairman board dividend increase addition reelection existing members agm see changes board directors art levinson decided step roche board directors avoid potential conflicts interest following appointment ceo research institution art major contributor genentechs success years leadership genentech become one important biotech companies world joined board directors roche following integration genentech behalf board would like thank sincerely invaluable contribution companys overall success roche annual report roche board directors board directors prof sir john irving bell dame deanne julius b e b e prof pius baschera dr christoph franz andr hoffmann e c e chairman representative shareholder group posted voting rights c e vicechairman roche annual report board directors roche corporate governance sustainability committee e nonexecutive director roche board directors b audit committee f executive director december c remuneration committee committee chairperson presidiumnomination committee paul bulcke prof beatrice weder di mauro dr severin schwan b e b e f dr andreas oeri peter r voser representative shareholder group c e posted voting rights e roche annual report letter shareholders severin schwan roche annual report severin schwan letter shareholders building capabilities future testament strength portfolio commitment employees able achieve eleven pharmaceutical product approvals launch fourteen new diagnostic instruments tests dear shareholders net income decreased result costs relating restructuring part debt innovation based strategy focus excellence well impairments restructuring programmes science led us number significant breakthroughs underlying strength company affected patients highlight unprecedented without items net income would higher clinical trial results perjeta one medicines core earnings per share swiss aggressive type advanced breast cancer francs higher constant exchange rates excluding showed could help patients live long five onetime double charge relating us branded years another new hpv test detect prescription drug fee core earnings per share virus cause cervical cancer earlier higher approved primary screening united states worked deliver next generation medicines continue make good progress product tests financial performance remained solid pipeline alone three medicines granted breakthrough therapy designation fda reflecting demand products high divisions potential benefit medicines could offer patients growth pharmaceuticals diagnostics antipdl one immunotherapy medicines showed pleased see substantial contribution coming encouraging results advanced bladder cancer disease new products particularly perjeta kadcyla seen advances treatment years positive breast cancer oncology portfolio continues affects people worldwide lucentis eye grow strongly immunology portfolio especially medicine already approved number different actemra medicine rheumatoid arthritis xolair indications use diabetic retinopathy esbriet chronic hives asthma medicine brought portfolio last year increase group sales pharmaceutical product approvals fda breakthrough therapy designations diagnostic product launches unless otherwise stated growth rates report constant exchange rates cer average full year roche annual report letter shareholders severin schwan acquisition intermune approved primary endpoints one clinical trials us treatment lung fibrosis october gantenerumab treating early stages alzheimers disease discontinued results however also positive data combination new greatly helped advance understanding neurological compound cobimetinib zelboraf demonstrated psychiatric disorders neuroscience area rapidly remarkable improvements patients advanced evolving science high unmet medical need melanoma deadly form skin cancer new molecules development remain focus area roche innovation comes million people inherent risk failure treated avastin since first approved developing highly innovative medicines comes equally high risk medicine development may work hoped regard exception whilst medicine kadcyla shown encouraging see many existing significantly help patients secondline therapy medicines approved additional indications one positive breast cancer last years trial results patients cancer medicines avastin approved two new previously untreated firstline advanced breast cancer indications cervical cancer platinumresistant unfortunately show improvements ovarian cancer avastin used treat seven different hoping kadcyla groundbreaking innovation cancers still forefront new generation treatment aggressive disease continue treatment september positive preliminary data study different settings combinations avastin combination immunotherapy drug candidate antipdl renal cancer well positive setbacks neuroscience year phase iii results combination chemotherapy bitopertin medicine developed treat medicine xeloda hernegative breast cancer negative symptoms schizophrenia reach roche annual report severin schwan letter shareholders achievements come difference employees diagnostic testing critically make committed ensuring innovation important treatment decisions culture thrives roche diverse perspectives reflect global business continuing invest new facilities infrastructure employees modern diagnostics area huge potential science aim retain industryleading levels managing disease early diagnosis monitoring employee engagement would like thank every avoiding illness first place launched employee difference made thank new test assess fertility levels well test predict shareholders continued confidence likelihood preeclampsia serious condition affecting roche pregnancies also able speed development diagnostic test ebola virus looking ahead expect low midsingle digit fda approved emergency use another group sales growth constant exchange rates core significant milestone diagnostics business earnings per share targeted grow ahead sales launch new fully integrated laboratory testing systems constant exchange rates also expect cobas cobas deliver faster increase dividend accurate molecular test results convinced uncompromising focus medical innovation continue drive business success well millions people access future innovative medicines world away whilst science medicine progressing incredible rate gaps access quality healthcare growing believe healthcare company severin schwan important part solution improve access quality chief executive officer medicines diagnostic tests alone barriers accessing healthcare provision multiple complex working partnerships world overcome barriers infrastructure affordability training supply awareness year strengthened approach new framework analyse barriers access healthcare analyse root causes individual healthcare systems systematically identify right partners work support improvements also saw launch new strategy bring innovative medicines subsaharan africa access difficult another initiative particularly proud global access programme hiv viral load testing also launched outlook excludes benefit swiss francs related divestment filgrastim rights roche annual report roche corporate executive committee corporate executive committee roland diggelmann silvia ayyoubi dr gottlieb keller coo division roche diagnostics head group human resources general counsel dr alan hippe dr stephan feldhaus chief financial officer head group communications roche annual report corporate executive committee roche member enlarged corporate executive committee roche corporate executive committee dr richard scheller retired december dr michael varney became head gred december member enlarged corporate executive committee january dr richard scheller dr severin schwan osamu nagayama daniel oday head genentech research ceo roche group chairman ceo chugai coo division roche early development gred pharmaceuticals dr sophie kornowskibonnet prof john c reed head roche partnering head roche pharma research early development pred roche annual report key facts business review market environment business review market environment roche annual report business review market environment key facts billion swiss francs sales million swiss francs core operating profit swiss francs core earnings per share sales growth regions north america europe japan asiapacific latin america unless otherwise stated growth rates report constant exchange rates cer average full year roche annual report roche business review market environment solid growth divisions demand remained high innovative medicines diagnostic tests year significant medical breakthroughs strategic acquisitions build new capabilities group sales reached billion swiss francs swiss franc rose number currencies growth pharmaceuticals driven medicines mainly japanese yen along number latin herpositive breast cancer well avastin american currencies us dollar overall led new products perjeta kadcyla negative impact results reported swiss francs positive breast cancer made significant contribution growth offsetting declining sales xeloda positive news pipeline three medicine faces generic competition breakthrough therapy designations fda also also strong demand immunology medicines notably positive results clinical trial study actemra rheumatoid arthritis xolair combination perjeta herceptin chemotherapy chronic hives allergic asthma sales tamiflu increased survival time patients advanced increased considerably late year result positive breast cancer almost five years diagnostics us flu epidemic fda along number health authorities approved hpv test primary screening cervical diagnostics sales continued driven cancer overall advances science reflected professional diagnostics business grew whilst strength pharmaceuticals medicine pipeline molecular diagnostics higher also diagnostics innovation information please see positive early uptake new molecular laboratory innovation chapter annual report testing systems launched year cobas cobas key figures millions chf millions chf change change cer chf group sales pharmaceuticals division diagnostics division core operating profit core net income ifrs net income core earnings per share chf cer constant exchange rates average full year ifrs international financial reporting standards roche annual report business review market environment roche building capabilities strategic acquisitions francs lead interest savings longer roche made number acquisitions year term intangible impairments increased billion swiss including intermune developer esbriet medicine francs particular tissue diagnostics following idiopathic pulmonary lung fibrosis seragon reassessment product latestage development pharmaceuticals researching treatment cuts us laboratory test reimbursement costs hormone receptorpositive breast cancer diagnostics restructuring increased million swiss francs due acquisitions made expand pointofcare nonrecurring onetime income effect molecular testing add new technology gene ifrs results sequencing performance underlying business remained core operating profit cash generation strong core earnings per share higher constant core operating profit increased reflecting double exchange rates stable swiss francs excluding charge million swiss francs us branded onetime double charge us branded prescription prescription drug fee following final regulations issued drug fee core earnings per share higher based internal revenue service advanced timing strong business results board directors recording liability excluding double charge core recommended th consecutive dividend increase operating profit higher swiss francs per share operating free cash flow billion swiss francs strong cash generation underlying operations offset higher capital investments manufacturing swiss facilities site development projects resulting francs decrease constant exchange rates free cash flow billion swiss francs higher constant core earnings per share exchange rates restructuring impairments ifrs net income negatively impacted debt outlook restructuring impairments restructuring costs expect low midsingle digit group sales group restructured part debt take growth constant exchange rates core earnings per share advantage low interest environment net tax targeted grow ahead sales constant exchange measure resulted onetime loss million swiss rates also expect increase dividend us annual fee branded prescription drug manufacturers importers outlook excludes benefit swiss francs related divestment filgrastim rights roche annual report roche business review market environment big picture outlook healthcare industry remains positive significant challenges worlds growing ageing population driving demand healthcare services whilst supply coming increasing pressure increasing access healthcare expensive business declining fertility rates also played role governments healthcare sector life sciences changing demographics proportion elderly companies faced challenge delivering people continuing increase medical breakthroughs innovation value environment cost containment meant many people live longer whilst public budget restrictions treated chronic conditions chronic diseases however still leading cause mortality worldwide addition world witnessed major gains life illnesses heart disease stroke cancer chronic expectancy recent decades lowincome countries respiratory diseases diabetes cause deaths made progress increasing average life expectancy illnesses amongst costly good nine years increased life expectancy comes news often preventable increased healthcare costs proportion people aged years growing faster age group combined trends ageing populations increase trend potential transform societies globally chronic disease expected drive demand see millions people living chronic diseases healthcare services average annual worldwide spending healthcare forecast rise next three years average life expectancy increased six years years women years men since ch ron ic diseases l r e dy account europes billion healthcare bill roche annual report business review market environment roche focusing value countries face formidable challenge managing healthcare companies means closer scrutiny rapidly increasing cost healthcare whilst simultaneously new medicines medical devices ever improving patient outcomes access care companies must clearly demonstrate evidence better continuing pressure healthcare budgets combined health outcomes reasonable costs increasingly muted economic growth last years broad range stakeholders include health led many countries introduce costcontrol measures technology assessment agencies insurers payers including prescription drug price cuts evidencebased patient advocacy groups hospital administrators medicine shift volume valuebased healthcare amongst others playing increasingly important rewards providers improving care lowering costs role selection purchase medical products way make health systems sustainable primary effect trend raise barriers reimbursement highvalue innovative drugs especially cancer treatments cost alzheimers care expected reach trillion us healthcare stakeholders however share goal define measure improve value care delivered dollars us alone patients access healthcare access healthcare remains global challenge healthcare improving access healthcare objective many varies significantly one country another even countries central many reform efforts finding within region country life expectancy romania affordable effective solutions enormous task instance nine years less spain countries sophisticated medicines tests widely available whilst governments face challenges many fronts addition others little basic infrastructure even rising cost healthcare workforce shortages established markets medicines take years become poor healthcare infrastructure also hamper efforts available patients improve care patients often live remote healthcare spending worldwide varies dramatically data available applicable world health statistics deloitte global healthcare outlook shared challenges shared opportunities efpia contribution public consultation european commissions green paper mobile health alzheimers association alzheimers disease facts figures alzheimers dementia use costs healthcare longterm care hospice efpia health growth working together healthy europe vision towards life sciences strategy europe health financing per capita total expenditure health average exchange rate usd roche annual report roche business review market environment difficulttoreach regions population towards achieving universal health coverage india also makes access healthcare difficult defined everyone access quality health improve services without financial hardship practice aim healthcare costs shared amongst entire populations prepayment riskpooling rather number doctors every shouldered sick aim people worldwide populations independent household income expenditure wealth place residence gender least expected remain virtually essential health services coverage well throughout financial protection pocket expenses incidence breast lung gastric colorectal cancer many countries also rising rapidly especially urban areas emerging markets adoption western diets sedentary habits cigarette smoking environmental pollution contributed increase cancer rates access proper treatment patchy best whilst number cancer patients increasing percentage getting access treatment million people ageing population increased unemployment fall poverty economic pressures aggravate inequalities access healthcare every year trying eighty countries backed consortium supra access healthcare national bodies including world health organization world bank save children taking steps technological advances companies life sciences sector long embraced systems data helps payers providers assess technology today rapid accelerating technological value treatment guidelines patient pathways specific advances transforming imaging genomics proteomics interventions importantly also help identify patients diagnostics disciplines new technology risk developing specific diseases early using combined medical breakthroughs also playing algorithms disease risk factors patient data important role new approaches improving patient challenge pharmaceuticals industry however outcomes reducing costs innovations find ways properly compare use inhouse personalised healthcare realworld data subject different interpretations inconsistencies even readily available inexpensive technologies like text messaging smartphone apps helping improve biggest challenge lives developing countries middle east asia africa instance wireless mobile telecommunication generate meaningful conclusions enabled patients living isolated areas gain access enormous volumes data healthcare engage care monitoring medical conditions promoting health key also data clinical trials provides insight overcoming challenges requires new investment effectiveness treatment safety disease technology partnerships amongst healthcare management combined realworld data stakeholders considerable potential benefit patients healthcare universal health coverage uhc economist intelligence unit healthcare idf diabetes atlas sixth edition roche annual report business review market environment roche growth emerging markets healthcare spending percentage gross domestic diabetes example growing exponentially emerging product gdp varies considerably around world markets expected reach globally million people gdp north america western living diabetes europe latin america around asia australasia middle eastafrica however significant challenges emerging markets ranging lack infrastructure trained professionals affordability major differences spending healthcare growing local private public healthcare significantly many emerging market growth healthcare sector closely connected markets gdp growth population growth ageing population government spending regions rising wealth despite challenges emerging markets expected although clear disparities different represent third global pharmaceutical market markets growing prosperity better nutrition shifting disease patterns driving growth emerging markets rise emerging markets healthcare spending billion us dollars rank size rank size rank size usa usa usa japan japan china france china japan germany germany brazil italy france germany uk brazil france spain italy italy canada spain india china canada russia brazil uk canada emerging markets placement movement source ims health roche annual report key facts diagnostics diagnostics roche annual report diagnostics key facts billion swiss francs sales million swiss francs investment china sales growth professional diagnostics diagnostic products launched unless otherwise stated growth rates report constant exchange rates cer average full year roche annual report roche diagnostics good sales growth diagnostics division sales continued increase strongly billion swiss francs professional diagnostics sales growth main growth contributor led immunodiagnostics business sales molecular diagnostics increased professional diagnostics business major growth underlying molecular businesses sales contributor divisional performance regions tissue diagnostics diabetes care especially asiapacific continued strong sales china sales growth across diagnostics division driven demand asiapacific region strong cobas new automated instrument performance china sales also increased urine analysis elecsys syphilis elecsys anti europe middle east africa emea additional mllerian hormone tests launched also new study contributions came north america latin results highlighted value elecsys preeclampsia america japan sales flat tests predicting preeclampsia pregnant women test already available eu countries accepting professional diagnostics ce mark market authorisation designation outperforming market regions professional additional usage tests broadens portfolio diagnostics demonstrated strong growth growth womens health reconfirms commitment primarily driven immunodiagnostics business area represents divisional sales supported clinical chemistry business coagulation monitoring sales growth diagnostics division region emea north america asiapacific latin america japan roche annual report diagnostics roche topselling diagnostics millions swiss francs cobas e accuchek aviva nano cobas c benchmark ultra cobas immunodiagnostics blood glucose meters clinical chemistry tissue diagnostics virology molecular diagnostics tissue diagnostics sales rose strong growth underlying sales rose driven growth advanced molecular businesses excluding sequencing staining portfolio includes immunohistochemistry major contributions coming virology human reagents cintec franchise cervical cancer papillomavirus hpv screening regions except diagnosis grew showing continued good uptake japan showed positive sales development biggest regionally growth driven emea north america growth contribution coming north america result asiapacific north america sales increased despite strong performance hpv blood screening reimbursement reductions hepatitis c virus monitoring diabetes care fully automated cobas systems sales despite continuing challenging market assays blood screening well virology testing conditions blood glucose monitoring portfolio launched markets accepting ce mark cobas major markets including us sales increased emea hpv test approved primary screening cervical asiapacific latin america strengthened cancer australia canada us three additional business units global market leadership position blood diagnostic tests mrsasa cdifficile hsv expand glucose monitoring north america however sales cobas menu launched countries accepting result medicare changes ce mark reimbursement test strips us changes number reimbursed strips canada japan sales roche also made several important acquisitions space declined impacted strong competition including iquum inc genia technologies inc ariosa biannual price cut health authorities diagnostics inc completed early iquum provides roche access liattm laboratoryinatube sales premium product accuchek mobile grew system performs rapid pointofcare molecular accuchek avivaperforma grew accuchek diagnostic testing analyser two initial assays cobas insight system new insulin delivery system combining influenza ab cobas strep ce marked fda insulin pump blood glucose metre accuchek cleared importantly genia brings roche singlemolecule connect system connects blood glucose metre semiconductorbased dna sequencing platform using mobile applications via smartphones webbased nanopore technology finally ariosa adds highly targeted platforms diabetes care selfmanagement launched accurate noninvasive prenatal testing service eu additionally efficiencies gained roches portfolio ariosas proprietary harmonytm prenatal across business area implementation specific test blood test performed early ten weeks initiatives started helping streamline processes pregnancy designed assess risk decisionmaking syndrome genetic abnormalities roche annual report roche diagnostics setting new industry standards innovative instruments fully automated instruments molecular testing enhanced result reliability staff safety roche launched cobas cobas systems new fully automated urine testing system cobas two integrated fully automated molecular testing consists two modular analysers combining urine strip systems europe markets accepting ce mark testing digital urinary microscopy allows tests parameters help diagnose diseases urinary cobas system cobas system represent tract infection kidney disease diabetes offers new class molecular diagnostic instruments highest throughput market ensures highquality developed meet evolving needs medium results increases laboratory productivity significantly high volume molecular diagnostics laboratories whilst reducing manual steps contamination risks systems setting new industry standards technical laboratory staff system available worldwide except innovation throughput speed results automation us launch coincides fda flexibility clearance cobas u cobas u modules portfolio launched includes cobas system additional diagnostic tests womens health system next generation tests donor blood cervical cancer third common cancer women screening well multiple tests viral load monitoring approximately women dying disease year common cause cervical cancer hpv infection setting new industry standards throughput speed results approvals cobas hpv test primary screening australia canada us followed ce mark automation flexibility designation europe new indication roches cintec histology test newly fully automated cintec plus cytology kit offer comprehensive cervical system provides results first tests less cancer screening portfolio industry supporting hours cobas system delivering physicians across globe screen diagnose treat results eighthour shift cobas women precancerous lesions fullblown cancer system generating results amount develops time systems also allow simultaneous processing multiple assays designed enable eight caught early cervical cancer one preventable hours cobas system four hours cobas curable cancers survival rate system walkaway time minimal user interaction cases disease advanced time diagnosis average fiveyear survival rate around roche annual report diagnostics roche see spotlight catherine behrens worked ariosas proprietary harmonytm prenatal test blood test cobas hpv test performed early ten weeks pregnancy evaluating circulating fetal dna found maternal blood test designed assess risk syndrome survival rate cervical genetic abnormalities cancer caught fertility pregnancy testing breast cervical early ovarian cancer management monitoring management chronic agerelated conditions like osteoporosis tests strengthen broad portfolio tests assessment ovarian reserve pregnancy womens health providing clarity women every stage fertility issues affect one ten couples accounting lives million people globally number rise roche launched new elecsys antimllerian hormone identifying syphilis routine samples fertility test increases accuracy ovarian reserve donated blood assessment compared conventional methods syphilis sexually transmitted infection caused bacterium treponema pallidum million people prognosing preeclampsia currently infected syphilis worldwide million results prognosis study helping support new cases reported every year elecsys syphilis extended use elecsys preeclampsia test predict immunoassay helps detect patients infected syphilis absence preeclampsia pregnant women one week routine clinical practice make sure donated blood development preeclampsia within subsequent infected syphilis disease reemerged four weeks test results enable healthcare professionals health concern number developed nations avoid unnecessary hospitalisations optimise prenatal care past decade improve outcomes mother child prenatal testing acquisition ariosa diagnostics inc brought highly targeted accurate noninvasive prenatal testing service roches portfolio key launches area product name description market instrumentsdevices cobas next generation molecular pcr systems ww laboratories cobas automated urinalysis work area platform eu ventana connect middleware providing connectivity laboratory information systems ww accuchek insight next generation insulin pump blood glucose monitoring system eu diabetes care accuchek connect blood glucose meter connectivity mobile applications cloud eu tests mpx next generation blood screening test us mpx hiv hcv hbv full nat blood screening menu cobas ww hev dpx wnv oncology hiv hbv hcv hbv virology tests cobas cobas ww hsv herpes simplex virus detection cobas eu syphilis treponema pallidum detection immunoassay eu mrsasa next generation assay cobas eu microbiology cdifficile diagnosis infections associated diarrhea eu amh assessment ovarian reserve fertility eu womens health pe prognosis shortterm prediction preeclampsia pregnancy claim extension eu excluding us parvovirus b hepatitis virus west nile virus sexual reproductive health new guidance prevention control cervical cancer national cancer institute seer stat fact sheets cervix uteri cancer global incidence prevalence selected curable sexually transmitted infections roche annual report roche diagnostics adding value healthcare huge potential modern diagnostics keeping people disease getting worse even starts healthy preventing diseases guiding treatment decisions modern diagnostics reduce costs diminishing health often overlooked value diagnostics lies knowing problems decreasing hospitalisation avoiding tests performed patients tissue samples blood unnecessary treatment future sustainable healthcare fluids provide crucial answers disease whether depends diagnostics approximately three billion risk disease patients response treatment tests conducted roche tests excluding diabetes sample blood gives physicians caretakers critical care supporting physicians decisionmaking knowledge enabling intervene early actively manage health conditions three billion test results three today diagnostics longer stepping stone billion decision points supporting treatment intervention better disease optimal patient care management better patient care preventing business model instruments reagents calibration services controls sales customers needs instruments tests services polymerase chain reactionbased molecular diagnostic depend specific focus way organise testing tissue analysis business turn results diversity commercial models roche offers meet demand overall running broad portfolio tests installed base sales generated predominantly reagents allows economies scale customers since helps business additional contributions come sales laboratories optimise operations ensuring instruments fees calibration controls well efficient usage resources including people services provided laboratories market leader space upon regulatory approval new tests run vitro diagnostics roche operates large number without delay existing instrumentation rapidly instruments laboratories worldwide benefit patients worldwide high number roche instruments immunodiagnostics clinical instruments placed laboratories immunodiagnostics chemistry alone beyond also offer systems clinical chemistry broad test menu systems key contributor continued strong sales generated predominantly reagents growth division reported many years reagents business environment recent years vitro ivd diagnostic market grown instruments annually billion swiss francs expected reach billion swiss francs future growth prospects continue positive basis technological scientific advances growing global patient popultion roche annual report diagnostics roche sales immunodiagnostic tests swiss francs diagnostics market continues financially attractive regulatory requirements becoming fragmented many countries expanding guidelines time regulations china eu us becoming increasingly stringent whilst dynamics create headwinds overall market tend favour companies roche extensive regulatory expertise experience market characterised differing testing technologies continued innovation competitive landscape new opportunities triggered new knowledge fragmented despite consolidation driven mergers constantly expanding knowledge molecular causes acquisitions new entrants coming diseases increasing availability targeted medicines various industries emerging markets provide largest require complementary diagnostics capabilities opportunities healthcare access infrastructure developments support physicians approaches treatment developments driving growth decisionmaking classic blood testing market immunodiagnostics additionally companion tests support payer decisions clinical chemistry continues exhibit robust growth allowing reimbursement targeted medicines opportunity efficient expanded testing patients high likelihood benefit roche molecular diagnosis market including sequencing company diagnostics pharmaceuticals considered highest growth segment divisions combination continues position roche ivd tissue diagnostics benefit market forefront personalised healthcare penetration globally pointofcare diagnosis increase importance technologies advance decentralised beyond reemergence infectious diseasecausing diagnosis expands microorganisms eg bacteria viruses fungi including tuberculosis multidrugresistant strains micro meanwhile diabetes selftesting continue face organisms increasing need fast reliable testing reimbursement economic challenges fundamental need blood glucose monitoring increase eones new diagnostic laboratory roche leadingedge technology incheon south korea see roche annual report diagnostics spotlight diagnostics korea roche annual report spotlight diagnostics korea diagnostics passion teamwork keys success eunock kim eunocks first task project manager huge challenge construct roches advanced diagnostics system south koreas largest commercial laboratory complete record time roche annual report race time install leadingedge technology first largescale use cobas connection modules means faster reliable test results thousands patients completing masters degree bioengineering task bring together teams directly involved kyung hee university seoul korea began working installation workflow information technology customer roche diagnostics korea sales representative service one smoothly functioning operating unit transferred workflow team bridge gaps eones needs also received chosen lead project top customer eone invaluable support services finance logistics project consultant sales marketing communications colleagues throughout roche diagnostics korea eone south koreas largest commercial laboratory serving dozens hospitals clinics lab screens mobilise everyone meet tough deadlines drew blood samples performs million people communication skills learned types diagnostic tests every month physicians sales representative relied checklists project patients depend eone accurate timely results management software stay top thousands details track progress well continuous demand testing rising every year eones commitment everybody team motto existing diagnostic platforms reaching capacity palli palli phrase used korea mean hurry hurry limits summer staff members approached roche constructing new laboratory incheon germany roche diagnostics manufacturing teams one hour away existing lab seoul pressure deliver hightech equipment record time chief operating officer eones requirements included nine advanced roland diggelmann ensured project top analytical diagnostic platforms cobas well priority december equipment arrived six p preanalytical platforms latest innovation able assemble test new systems cobas connection modules ccm ccms transport test samples automatically closed tubes multiple intense phase project analytical preanalytical systems speeding little two months finish one screening process reducing chance human error largest projects ever task required presence site time one roche diagnostics korea ever installed cobas connection modules scale addition eone needed complete laboratory project completed end lunar new year holiday february months millions koreans returned work meant eight months complete job normally takes one two years instead monthsspotlight diagnostics korea diagnostics ca pac throughput testing increased increased around clock many us complications ensued another leading laboratory korea seoul clinical customer suddenly asked additional laboratories wants partner roche constructing capabilities separating data readouts new diagnostics centre signed contract august screening tests based immunology based customer needs lab completed chemistry information technology team worked end lunar new year holiday february top speed new requests largest laboratory incheon site coordinate work biological samples used test diagnostics roche diagnostics korea ever systems arrived midnight relied installed energy drinks coffee get night us driven passion succeed leading project well experience gained commitment total eone help us large support functions roche number complex tasks complete short timeframe diagnostics korea helped us achieve nearly impossible task finished project time golive date needed two weeks stabilise system eliminate remaining bugs older system taken six months stabilise eone extremely pleased results understand roche leader field told us new laboratory running staff could see immediate difference capacity testing increased overall throughput speed rose news eones new laboratory spread fast representatives labs wanted see action particularly cobas connection modules arranged schedules visitors australia china india portugal poland egypt visitors poland egypt returned home convinced colleagues acquire similar diagnostics systems makes proud roche diagnostics regular operation two weeks customer pleased rapid korea share best practices countries stabilisation processes increased capacity throughput new laboratory roche annual report key facts pharmaceuticals pharmaceuticals roche annual report pharmaceuticals key facts billion swiss francs sales growth oncology growth immunology contribution personalised healthcare unless otherwise stated growth rates report constant exchange rates cer average full year roche annual report roche pharmaceuticals solid performance sales increased pharmaceuticals division strong growth coming oncology immunology portfolios sales increased pharmaceuticals division positive sales however reflect demand oncology portfolio performing strongly particularly patients us currently transitioning patient medicines herpositive breast cancer sales assistance programme normal commercial supply new cancer products made significant contribution sales avastin higher immunology europe higher sales driven solid growth sales also grew strongly treatment rheumatoid arthritis germany uk particularly sales herpositive actemraroactemra mabtherarituxan breast cancer medicines uk also indication sales xolair chronic hives stockpiling tamiflu ongoing pricing pressure asthma also higher increases impact sales number markets however demand offset lower sales oral chemotherapy drug xeloda remained high generic competition key markets hepatitis medicine pegasys faced competition sales international region higher strong new generation treatment tamiflu also grew growth latin america particular venezuela argentina strongly towards end year result brazil well algeria russia sales declined flu epidemic us significantly result local economic conditions whilst sales middle east impacted change us sales higher medicines distributor china sales higher demand positive breast cancer driving growth along tamiflu increasing fourth quarter continued strong xolair avastin also grew significantly growth key products herceptin mabthera respectively xolair fdaapproved treat rituxan actemraroactemra growth negatively new indication form chronic hives early uptake impacted base effect strong tamiflu sales esbriet newly acquired medicine lung fibrosis well competition tarceva sales growth pharmaceuticals division region europe asiapacific north america latin america japan roche annual report pharmaceuticals roche growthdriving products millions swiss francs avastin herceptin actemraroactemra perjeta kadcyla oncology oncology immunology oncology oncology japan higher sales driven strong demand performance also reflected continued increased herpositive breast cancer medicines well avastin contribution personalised healthcare key focus actemra osteoporosis segment solid roche patients respond way medicine sales growth edirol well bonviva early uptake however using specific diagnostic tests possible strong newly approved alecensa alectinib predict well patient responds treatment alkpositive lung cancer diseases conditions sales products companion diagnostic test label represent pharmaceuticals division sales therapeutic area pharmaceuticals division sales change strong contribution personalised healthcare therapeutic area mchf mchf cer oncology immunology infectious diseases ophthalmology neuroscience therapeutic areas total sales roche annual report roche pharmaceuticals key products performing well avastin advanced colorectal breast lung kidney lucentis us eye conditions wet age cervical ovarian cancer glioblastoma type brain related macular degeneration macular edema following tumour sales us driven growing retinal vein occlusion diabetic macular edema growth demand colorectal cervical ovarian cancer whilst driven largely increased adoption lucentis europe growth stemmed increased demand treating diabetic macular edema lucentis granted treatment ovarian cancer strong demand across priority review breakthrough therapy designation indications japan sales higher sales fda treatment diabetic retinopathy breast cancer well ovarian cancer malignant glioma international region growth driven actemraroactemra rheumatoid arthritis launches number markets ovarian cancer systemic juvenile idiopathic arthritis polyarticular treatment well colorectal cancer juvenile idiopathic arthritis demand strong regions particularly us europe herceptin perjeta kadcyla herpositive japan driven increased use monotherapy breast cancer herceptin herpositive metastatic earlier use treatment rheumatoid arthritis advanced gastric cancer herceptin sales particularly significant uptake new subcutaneous formulation strong us demand increased use international region sales higher driven combination perjeta treating herpositive breast strong launches china turkey continued fast cancer europe subcutaneous formulation uptake australia argentina roactemra approved available many markets sales increased sales treat earlystage rheumatoid arthritis eu japan higher use perjeta international region sales growth strong latin zelboraf braf v mutationpositive america high demand public sector well metastatic melanoma standard care moving asia growth came particularly china combination targeted therapy advanced melanoma patient assistance programme perjeta sales million zelboraf intense competitive pressure swiss francs grew regions strong uptake expected particularly us europe sales stable us germany france kadcyla sales million swiss international region strong francs continued grow well europe us growth number markets including argentina japan kadcyla approved early brazil clinical trial data zelboraf combination uptake positive cobimetinib shown positive results data filed fda ema zelboraf mabtherarituxan common forms blood approved japan cancers nonhodgkins lymphoma follicular lymphoma chronic lymphocytic leukemia well rheumatoid gazyvagazyvaro million swiss francs treatment arthritis certain types ancaassociated vasculitis chronic lymphocytic leukemia initial uptake europe sales europe demand increased positive whilst limited use chlorambucil treatment follicular lymphoma well chronic chemotherapy medicine approved gazyva well lymphocytic leukemia us sales higher competition impacted uptake us late reflected base effect release sales reserves december fda approved supplemental biologics b programme excluding effect licence application expanding gazyvas label include data sales us higher international showed significant improvements gazyva plus region sales impacted economic conditions chlorambucil mabtherarituxan plus chlorambucil russia sales remained strong latin america january gazyva approved different demand increased key markets countries worldwide increase sales medicines herpositive breast cancer roche annual report pharmaceuticals roche avastin first medicine target inhibit vegf activity thereby inhibiting angiogenesis critical process tumour development significant breakthroughs positive clinical trial results important approvals year positive metastatic breast cancer particularly aggressive including gazyvaro chronic lymphocytic leukemia form disease saw unprecedented data perjeta europe esbriet treat idiopathic pulmonary fibrosis combined chemotherapy herceptin us esbriet developed intermune company increased survival time patients almost five years acquired year alecensa alectinib advanced melanoma also good clinical trial approved japan treat alkpositive lung results combination cobimetinib zelboraf cancer global studies medicine ongoing halved risk disease worsening roche different combination therapies oncology innovation course inherent risk failure pipeline unfortunately disappointing clinical trial results year bitopertin negative symptoms schizophrenia meet primary endpoints cancer immunotherapy key one gantenerumab studies earlystage focus area roche alzheimers disease discontinued futility analysis making important advances immunotherapy also study antibodydrug conjugate uses bodys immune system fight cancer kadcyla alone combination perjeta first investigational medicines types cancer currently line treatment herpositive advanced breast cancer development advanced investigational medicine results show hoped superiority herceptin area antipdl granted fda breakthrough therapy chemotherapy however results impact designation treatment bladder cancer also existing use perjeta kadcyla showed promising early results combination avastin shown extend survival type breast cancer renal cell carcinoma solid tumours also positive news two phase iii studies avastin information pipeline found hernegative breast cancer avastin approved innovation chapter annual report platinumresistant ovarian cancer cervical cancer year used treat seven different cancers hemophilia early data ace innovative bispecific antibody showed encouraging reduction bleeding rates patients trial lampalizumab first potential treatment geographic atrophy initiated phase iii clinical trials september roche annual report roche pharmaceuticals product approvals pharmaceuticals division approvals product description us approval xolair chronic idiopathic urticaria hives avastin cervical cancer avastin platinumresistant ovarian cancer esbriet idiopathic pulmonary fibrosis eu approval mabthera subcutaneous formulation nonhodgkins lymphoma roactemra subcutaneous formulation rheumatoid arthritis gazyvaro chronic lymphocytic leukemia roactemra early rheumatoid arthritis avastin platinumresistant ovarian cancer japanese approval alectinib alkpositive nonsmall cell lung cancer zelboraf brafpositive metastatic melanoma roche annual report pharmaceuticals roche making innovation accessible populations age life expectancy increases demands initiatives healthcare systems growing exponentially healthcare costs rising innovative medicines expensive world help patients need develop access medicines aim medicines available anyone needs took significant steps improving access medicines launched new framework systematically analyse barriers healthcare different markets supporting affiliates identify root causes find new solutions also launched strategy working closely healthcare authorities improve access womens cancer hepatitis medicines healthcare stakeholders develop solutions bring subsaharan africa area access innovative medicines patients medicines particularly difficult challenge barriers accessing healthcare multiple information found access complex ranging lack trained medical professionals healthcare chapter annual report necessary infrastructure supply medicines safely low levels awareness affordability issues initiatives range medical training education screening programmes patient assistance programmes funding solutions also developing innovative pricing models better reflect benefits medicine brings different indications roche annual report pharmaceuticals spotlight biomarkers roche annual report spotlight biomarkers pharmaceuticals understand biology need able measure michael cannarile michael colleagues discovered biomarkers helped identify optimal dose new cancer drug use biomarkers similar therapeutic molecules gaining acceptance roche roche annual report biomarker model almost predictive using biomarkers cancer receptor antibody early stage accelerated dose selection maximise therapeutic benefit patients scientist incredibly exciting receive confirmation roche offers experimental molecule actually works humans way hypothesised especially true six medicines molecule designed fight lifethreatening disease like cancer requiring companion became interested science teenager could test contribute understand available cure cancer people die determined understand biological basis disease ultimately went pharmaceutical research joined roche work biomarker experimental medicine leader roche pharma research early development penzberg germany focus developing biomarker sales roches strategies explain predict responses patients pharmaceuticals division treated drug candidates simple terms biomarker biological parameter used indicator disease process drug response roche biomarker teams play vital supporting role links pharmaceuticals diagnostics early stages discovery biomarkers provide us insights disease biology mode action therapeutic molecule roches pipeline diagnostics colleagues involved early phases developed within project collaboration quite unique roche ultimate goal develop reliable biomarkerbased p e r nali e test known companion diagnostic help us predict patients respond targeted therapies h e l h c r e central concept personalised healthcarespotlight biomarkers pharmaceuticals nearing end preclinical testing promising new cancer therapy anticsf receptor antibody receptor overexpressed surface tumour cells receptor also present specific types macrophages white blood cells normally beneficial part bodys immune system macrophages present many tumour types tumours sometimes hijack macrophages use stimulate tumour growth prevent cells attacking tumour efficiently therefore colleagues drug discovery developed antibody binds eliminates csf receptorexpressing cells point experiments csfr antibody performed laboratory preclinical tests still data clinical version antibody targeting human macrophages next step clinical development antibody per regulatory requirements test safety profile michael early close collaboration roche pharmaceuticals roche saw opportunity beyond safety parameters diagnostics crucial development reliable biomarkerbased tests wanted know whether biomarker hypothesis assays accurate whether dose dependent response therapy another goal using biomarkers early enabled develop mathematical model correlating drug exposure biochemical physiological response body us avoid exposing study participants excessive doses amending standard toxicity testing protocol however presented challenges implementation compound related biomarkers increased complexity budget potential side effects significantly furthermore additional data generation interpretation represented potential risk tight development timelines phase clinical testing hence needed explain expected benefits patient progressed phase monotherapy colleagues end help colleagues studies new cancer drug candidate look discovery pharmaceutical sciences successfully back see biomarker model generated incorporated markers study protocol preclinical testing almost predictive happened later humans results encouraging supported hypothesis mode action antibody validated result implementation biomarkers assays provided rationale appropriate dose pharmacodynamics biochemical physiological treat first patient meant need responses well mode action primate studies expose study participants insufficient excessive doses gaining acceptance roche new type therapy thus potential side effects shortening targeted therapy clinical development anti standard dose escalation procedures also accelerated csfr antibody focus identifying predictive marker timelines phase trial enables physicians select patients highest likelihood response identification predictive marker trigger development companion test safe effective use therapeutic drug roche diagnostics personalised healthcare currently developing knowing medicines work specific group patients yet important step understanding cancer best treat new companion tests roche annual report key facts innovation innovation roche annual report innovation key facts new molecular entities clinical development cancer drug combinations clinical development pharmaceutical product approvals diagnostic launches roche annual report roche innovation diverse approaches research development significant progress made find new medicines transform way treat diseases today answers illnesses metastatic melanoma years ago effective therapies however millions people worldwide continue suffer partnerships alliances external debilitating conditions limited treatment companies institutes compounds successfully options poor prognosis roche invest research developed gred pred chugai partners development r transform science medicines progress global latestage development diagnostic tests address patient needs organisation draw expertise within company partners knowhow experts pharmaceuticals throughout world maximise productivity diagnostics divisions molecular cellular biology diverse approach research early development well biochemical signalling pathways diseases carried four organisations genentech research basis developing innovative medicines offer early development gred roche pharma research significant benefits patients need expertise also early development pred chugai pharmaceutical co ltd allows development tests screen disease japan member roche group diagnostics causing factors body division roches partnering functions maintain close links external research organisations currently core research development expenditure million cer roche group swiss francs sales million cer pharmaceuticals swiss francs sales million cer diagnostics swiss francs sales unless otherwise stated growth rates report constant exchange rates cer average full year roche annual report innovation roche innovative r focus targeted therapies basic research latestage development innovative technology leading proprietary platform discover approaches applied throughout entire r process develop new rnabased therapies advances include use new industryleading technology platforms discover targeted therapies clinical advancing antibody engineering technologies trial modelling innovative patient recruitment methods long history antibody development clinical studies production roche also leader highly sophisticated antibody engineering technologies including future rna therapeutics research antibodydrug conjugates majority todays medicines small molecules glycoengineering manufactured chemical synthesis well bispecific antibodies defined chemical structures large molecules including brain shuttle technology monoclonal antibodies represent class medicines produced animal plant cells many disease antibodydrug conjugates adcs new class highly targets challenging even impossible reach potent biologic medicines built attaching small molecule small molecules antibodies therapeutic agent antibody either permanent stable linker antibody targets specific antigen found target cells binds cell roche leader highly triggers internalisation antibody together sophisticated antibody medicine delivers medicine high specificity target cells maximising efficacy minimising engineering technologies systemic exposure side effects roche several adcs clinical studies different types cancer neurological disorders infectious diseases overcome limitations roche developing socalled ribonucleic acid rna targeted medicines new glycoengineering approaches generate new kinds therapeutic modality representing entirely new class antibodies attachment sugar molecules medicines rna therapeutics expected broaden significantly enhances capacity recruit immune cells like range drugable disease targets roche natural killer nk cells macrophagesmonocytes acquired santaris pharma danish biopharmaceutical neutrophils designing controlling types sugar company pioneered locked nucleic acid lna molecules specific region antibody affinity roches leading capabilities antibody engineering enabled creation new antibody variants improve treatments complex diseases cancer viral infections inflammatory diseases antibodycytokine fusions antibodydrug conjugate glycoengineered antibody brain shuttle antibody fusion antibody brain shuttle bispecific antibody roche annual report roche innovation antibody immune effector cells increased one approach innovative bispecific antibody platform allows effective antibodydependent cellular greatly boosts antibody penetration brain cytotoxicity improved targeting cancerous cells binding transferrin receptor molecule normally transports another protein brain one arm bispecific antibodies new generation biologically bispecific antibody connected transferrin receptor engineered antibody medicines developed roche arm inhibits activity secretase engineered bispecific antibodies combine binding molecule required production toxic specificity two antibodies one molecule amyloid peptide hypothesised cause alzheimers antibodies pioneered applying roche invented disease crossmab technology others different inhouse proprietary technologies bispecific antibodies designed series highprofile publications research team bind two molecules simultaneously applications reported key features transferrin receptorbispecific bispecific antibodies broad including neutralising antibody design including optimal affinity vivo safety two different diseasecausing proteins time molecular cellular mechanisms also recently conditions aberrant blood vessel growth shown transferrin receptorbispecific platform angiogenesis physically bringing two types cells works nonhuman primates setting stage testing close proximity cancer cells immune cells humans potentially opening human brain addition cancer drugs candidates also tested wide range antibody therapeutics ophthalmology asthma hemophilia second approach socalled brain shuttle also uses antibodies powerful therapeutic agents use transferrin receptors transfer investigational antibodies treating brain disorders alzheimers disease blood bloodbrain barrier difficult bloodbrain barrier limits brain employing different type antibody design uptake antibodies central nervous system cns preclinical mouse model alzheimers disease roche different technologies developed within roches scientists showed enhanced transport antibodies early research development organisations overcome barrier associated marked natural barrier improvement amyloid reduction brain increasing target engagement brain fold compared parent antibody leading innovations pipeline take focused approach increase chance oncology success highly complex diseases focus select roche forefront cancer research group disease areas including oncology hematology years discovering developing cancer neuroscience immunology inflammation ophthalmology diagnostics treatments aim giving patients infectious rare diseases better options constantly improving outcomes tremendous progress seen treatment many forms cancer including breast cervical colorectal decreases cancer mortality agestandardised rate per lung skin cancers especially good progress men blood cancers progress cancer care led better patient outcomes including decreased mortality rates nonetheless cancer continues major public health issue incidence rates rise globally according france uk japan usa australia world health organization million people source died cancer million patients roche annual report innovation roche priming activation trafficking tcells tumours apcs tcells ctls ceailv antiox infiltration tcells tumours blood vessel ctls endothelial cells avastin lymph node tumour cancer antigen presentation recognition cancer dendritic cellsapcs cells tcells anticd ctls cancer cells antipdl anticeatcb release cancer killing cancer cells cell antigens immune cancer cells cancer cell death ido inhibitor anticsfr source chen mellman immunity apc antigen presenting cells ctl cytotoxic tlymphozytes dying lung breast colorectal cervical cancers inhibitor cobimetinib plus zelboraf vemurafenib braf alone expects absolute number cancer inhibitor lived significantly longer without disease cases continue grow estimates worsening death compared zelboraf alone million people diagnosed cancer within combined therapy reduced risk disease worsening next two decades death half median progressionfree survival months cobimetinib plus zelboraf compared increasing understanding underlying disease months zelboraf alone phase iii study results biology confident provide even better cobrim study filed eu us authorities cancer medicines tests years come development medicines target attack nextgeneration medicine metastatic breast cancer specific way cancer cells work grow communicate every year women die breast cancer main focus cancer research led almost breast cancers depend hormone development number targeted therapies estrogen estrogen receptor grow spread combining targeted therapies block cell socalled hormone receptorpositive breast cancer current signalling leads cancer growth initiate signalling treatment approaches limited effect leads cancer cell death thus improving treatment outcomes broad pipeline including cancer nextgeneration class selective estrogen receptor immunotherapy portfolio allows range earlystage degraders designed block estradiol action combinations inhouse drug candidates estrogen receptor also eliminate estrogen receptor cell altogether lead compound rg promising study results fight solid tumours orally administered selective estrogen receptor antagonist metastatic melanoma aggressive deadly degrader currently phase clinical trials patients form skin cancer approximately half melanomas hormone receptorpositive breast cancer cancercausing braf mutation melanoma failed current hormonal agents diagnosed early generally curable disease people advanced melanoma poor prognosis cancer immunotherapy people worldwide currently roche investing heavily cancer immuno diagnosed melanoma therapies help persons immune system fight cancer cancer immunotherapy r programme presented september results phase iii comprised investigational candidates cobrim study demonstrated people previously cancer immunotherapy potential fundamentally untreated braf v mutationpositive advanced change treatment paradigm people cancer melanoma received roches investigational mek sci transl med ra sci transl med ra j ex med vol sci transl med ra niewoehner j et al neuron globocan estimated cancer incidence prevalence worldwide boyle p et al state oncology roche annual report roche innovation one investigational monoclonal antibodies rg cancer immunotherapy antipdl mpdla designed interfere protein called pdl targets pdl receptors expressed potential paradigm shift cancer tumour cells tumourinfiltrating immune cells treatment preventing binding corresponding receptors surface tcells thus blocking bodys immune defence inhibiting pdl rg may enable activation tcells restoring ability effectively october genentech partnering entered detect attack tumour cells results phase strategic collaboration newlink genetics corporation openlabel study showed rg shrank tumours discovery development smallmolecule ido people mostly pretreated metastatic indoleamine dioxygenase pathway inhibitors urothelial bladder cancer mubc whose tumours treatment cancer believe ido compelling target characterised pdlpositive diagnostic test cancer immunotherapy interested developed roche study responding combining rg investigational immunotherapies patients ongoing responses time data cutoff pipeline rg antipdl rg median duration response reached fda antiox ability leverage molecules granted rg breakthrough therapy designation mubc pipeline evaluate biologically driven combinations gives us competitive advantage cancer immunotherapy combination strategies central component rg space development believe play important role future treatment options currently studying boosting bodys defences multiple combinations approved investigational decades scientists strived fuse antitumour medicines addition immune doublets within antibodies interleukin il immunestimulatory outside pipeline across broad range protein goal delivering il tumours tumours first combination data investigational thereby targeting immune response needed cancer immunotherapy rg avastin untreated administered untargeted manner il patients metastatic renal cell carcinoma show highly toxic causing nonspecific autoimmunity combination safe well tolerated inflammation roche scientists worked increase affinity il target tumour antigen instead new agonist antibody rg mox development inhibit ox receptor tcells leading example roches highly sophisticated promotes antigendependent effector tcell activation capabilities antibody engineering rg regulatory tcell inhibition preclinical research shows carcinoembryonic antigeninterleukin variant antibody durable tumour responses antiox agonism ceailv rg represents major advance phase clinical trial rg started enrolment taming targeting il improved cancer immuno fall therapy avoiding challenges related autoimmune molecular modelling computerbased threedimensional representation molecules ideal approach visualise large molecules proteins nucleic acids roche annual report innovation roche side effects delivering ils anticancer potential dosing scheduling modifications needed molecule combines engineered implemented minimise risk tls going forward version il better safety profile antibody date additional cases reported protein expressed several cancers cea modified protocol new interleukin variant designed reduce stimulation immunosuppressive regulatory tcells also shows late earlystage data venetoclax well reduced pulmonary toxicity rg phase clinical mdm antagonist rg presented acute studies myeloid leukemia aml common acute leukemia adults mdm protein blocks tumour targeting colonystimulating factor receptor suppressing activity p leading survival humanised monoclonal immunoglobulin g antibody proliferation cancer cells rg designed disrupt rg specifically targets colonystimulating factor interaction p mdm help restore receptor csfr attacking subset immune cells activity stops tumour growth promotes apoptosis known macrophages macrophages contribute tumour growth suppressing local immune system representative roches highly innovative antibodydrug promoting growth cancer cells rg conjugates polatuzumab vedotin consists anticdb designed target deplete tumourassociated monoclonal antibody linked potent microtubule macrophages expressing csfr tumour tissue disrupting agent combining highly selective antibody thanks innovative trial designs roche able potent chemotherapy drug polatuzumab vedotin start early combination studies chemotherapy deliver cellkilling payload directly cancer cells treatment breast ovarian cancer completing sparing normal tissues compound phase dose escalation studies single agent current data ii clinical studies nhl form blood cancer kills show rg well tolerated broad people per year worldwide applicability combination therapy across various tumour types phase ib combination studies ongoing establish new approach hemophilia depletion tumourassociated macrophages supports outside blood cancers roche also developing immune system fighting tumours leading enhanced medicines blood disorders high unmet need efficacy malignancies hemophilia common type hemophilia genetic disorder results reduced levels lack hematology clotting factor viii worldwide incidence estimated years roche developing people approximately people medicines redefine treatment hematology diseases hemophilia around world still receive inadequate blood roches pipeline includes smallmolecule treatment access treatment current bcl inhibitor venetoclax developed treatment approach hemophilia intravenous infusion collaboration abbvie antibodydrug conjugate replacement factor viii concentrate prevent stop polatuzumab vedotin anticdb smallmolecule bleeds antagonist mdm rg bispecific antibody mimics function factor venetoclax designed selectively block function viii simultaneously binding factors ixa x bcl proteins goal reactivating self thus promote blood clotting patients lacking factor destruct mechanism cancer cells called apoptosis bcl viii developed inhibitors plays central role suppressing cell death encouraging factor viii rg first bispecific antibody developed tumour growth causing resistance chemotherapy hemophilia licensed chugai japan summer bcl becomes highly active cancers non orphan drug designation granted europe hodgkins lymphoma nhl chronic lymphocytic leukemia us december january cll bcell neoplasms well many solid tumours types breast colon lung data presented december demonstrate prostate cancer antifactor ixax antibody given subcutaneously highly effective hemophilia patients significantly phase ib study venetoclax tested combination reducing number bleeding episodes also roches anticd antibody mabtherarituxan showed shown welltolerated safe showing evidence remarkable clinical activity patients relapsed thrombogenic events excessive blood clotting refractory cll clinical study also revealed strategies improving safety powerful drug combination neuroscience particularly starting lower gentler doses venetoclax roche active diseases affecting central avoid potential toxicities caused rapid killing nervous system cns since introduced leukemia cells socalled tumour lysis syndrome tls innovative medicines including madopar treatment national hemophilia foundation bleeding disorders roche annual report roche innovation parkinsons disease today roche one colombia banner alzheimers institute genentech industrys largest diversified pipelines jointly lead study collaboration national investigational medicines neurological disorders institutes health goal develop effective treatment options people chronic potentially devastating diseases investigational fully human monoclonal antibody gantenerumab designed decrease levels aggregated developing better treatments alzheimers disease amyloid enrolment phase iii study today million people worldwide dementia gantenerumab people mild dementia due ad alzheimers disease ad represents marguerite road initiated recruitment ongoing cases number diagnoses expected quadruple additionally gantenerumab included washington making ad one serious health issues universitysponsored dominantly inherited alzheimer st century current ad treatments focus networktrials unit diantu study worldwide clinical alleviating symptoms unable stop disease study evaluating multiple investigational medicines destroying memory thinking skills leading individuals risk type early onset ad inevitable stage patients longer able care caused genetic mutation december roche announced decision discontinue phase iii scarlet road study incidence dementia gantenerumab prodromal predementia ad based expected quadruple results preplanned futility analysis therapy investigational monoamine oxidaseb roche broad ad r pipeline focuses several inhibitor rg aims reduce decline cognition proteins pathways believed play important role function ameliorate behavioural problems mild disease amyloid protein accumulates tomoderate ad phase iib mayflower road study brains people ad hypothesised play investigating months treatment rg addon central role disease development progression roche standard care ad complete developing multiple molecules including crenezumab gantenerumab target pathway several programmes multiple sclerosis multiple sclerosis ms autoimmunemediated disease crenezumab investigational fully humanised cns one leading causes neurological monoclonal antibody designed target forms disability young adults ms malfunctioning immune amyloid two phase ii studies abby blaze system attacks healthy nerve tissue affects evaluated whether crenezumab delayed cognitive transfer electrical signals within cns functional decline people mildtomoderate ad cns body approximately million people although abby meet coprimary endpoints worldwide affected ms people mildtomoderate ad showed positive trend cognition observed greater effect people ocrelizumab recombinant humanised monoclonal mild disease received high dose crenezumab antibody selectively depletes cdexpressing bcells intravenously similar treatment effect observed preserving capacity bcell reconstitution blaze smaller study investigated primarily effects preexisting humoral immunity innate immunity total disease biomarkers crenezumab also evaluated tcell number affected bcells believed separate alzheimers prevention initiative api trial contribute nerve cell myelin damage brain millions people alzheimers disease us ages ages ages source alzheimers dementia journal alzheimers association roche annual report innovation roche spinal cord people ms phase ii study compound alongside improvements social behaviour patients relapsingremitting ms ocrelizumab met communication primary endpoint significantly reducing signs disease activity compared placebo furthermore exploratory addition started phase ii trial investigating analyses ocrelizumab significantly reduced signs disease gabaa negative allosteric modulator rg activity compared interferon commonly people syndrome preclinical data shown prescribed ms treatment selectively modulating gabaa receptors brain may possible stimulate learning memory ocrelizumab currently investigated two phase iii pathways leading improvements cognition trials people relapsing forms disease well behaviour syndrome expect trial report another phase iii trial people primary progressive ms results trials expected novel pain therapies roche also partnered inception sciences versant chronic pain another area significant unmet medical ventures explore groundbreaking new science need impacting roughly worlds population advance treatment ms objective individuals experience moderate severe pain collaboration develop novel therapies promote achieve adequate relief currently available remyelination damaged nerve sheaths result ms treatment options part due combination insufficient disease progression efficacy doserelated side effects example opioid drug class associated poor tolerability eg partnering parkinsons disease nausea dizziness respiratory depression constipation roche reentered parkinsons disease pd field potential addiction abuse result area made significant progress past significant need novel pain medicines new development madopar tasmar mechanisms action partner prothena initiated early development monoclonal antibody rg prx targeting synuclein voltagegated sodium na channel nav expressed molecule may cause motor cognitive primarily painsensing nerve fibres identified functions pd phase study evaluate safety potential target novel pain therapies notably humans tolerability compound healthy volunteers rare genetic defect results defective function gene unable experience acute inflammatory upcoming data neurodevelopment disorders pain suggesting pharmacological inhibition roche continues commitment finding new treatment channel could effects pain sensations options patients neurodevelopment disorders collaboration xenon pharmaceuticals potent expect phase ii trial investigating va receptor isoformselective inhibitors nav channel antagonist rg people autism spectrum disorder promising preclinical profiles discovered first complete evaluate safety nav inhibitor rg currently phase clinical trials alzheimers disease international dementia statistics global voice dementia national multiple sclerosis society gets ms roche annual report roche innovation immunology inflammation asthma attacks reduced lebrikizumab roches immunology medicines include rheumatoid arthritis treated patients high level biomarker periostin treatments mabtherarituxan actemraroactemra compared patients low level xolair asthma pulmozyme cystic fibrosis periostin data also showed patients high addition immunology medicines roches late periostin levels lebrikizumab improved lung function stagepipeline projects include etrolizumab studied results phase iii clinical trials expected ulcerative colitis lebrikizumab severe asthma companion test developed roche inflammatory bowel disease ibd chronic disease gastrointestinal tract ibd commonly presents either ophthalmology crohns disease ulcerative colitis associated globally agerelated macular degeneration amd ranks significant morbidity including surgical interventions third cause blindness cataract glaucoma hospitalisations increased risk colon cancer primary cause blindness industrialised us alone crohns disease may affect many countries phase iii clinical studies initiated people lampalizumab investigational drug geographic atrophy ga advanced form amd result etrolizumab gutselective antibody targets beta blindness phase iii study programme two trials resulting dual mechanism action blocking protein called chroma gx spectri gx called alphabeta keep white blood cells entering evaluating safety efficacy lampalizumab gut also blocking another protein called potential slow progression ga studies also alphaebeta alphaebeta thought keep white blood confirm ga patients specific genetic biomarker cells lodged mucosa gut dual mode complement factor may benefit lampalizumab action may make etrolizumab effective treatment may also mean pretreatment alphaebeta level could biomarker disease companion test diabetic retinopathy common diabetic eye developed within roches personalised healthcare disease us impacts nearly million people strategy etrolizumab phase iii development leading cause new cases blindness due emerging diabetes epidemic diabetic retinopathy toward new option advanced asthma increasing global health issue december lucentis million people suffer asthma worldwide ranibizumab injection granted breakthrough therapy die asthma year mild moderate forms designation status diabetic retinopathy fda disease treated adequately current approved diabetic retinopathy fourth indication medications around three million people us lucentis europe suffer severe uncontrolled asthma currently developing lebrikizumab treatment roche also pioneering development highly severe uncontrolled asthma new data lute innovative bispecific monoclonal antibody rg targeting verse phase iib studies investigating lebrikizumab two angiogenic growth factors anti vegf ang patients severe uncontrolled asthma showed novel approach explored diseases eye agerelated macular degeneration negatively impacts vision thirdleading cause blindness roche annual report innovation roche including wet amd diabetic macular edema wider net influenza treatment compound rg currently phase trial seasonal influenza flu acute viral infection circulates year serious public health concern infectious diseases cause severe illness death highrisk populations recently highlighted bacterial resistance young elderly chronically ill estimated common antibiotics reached alarming levels many seasonal influenza causes three five million cases parts world settings treatment severe illness year worldwide resulting options remain effective common infections deaths vaccination influenza seen effective way prevent infection separately global public health authorities come together antivirals tamiflu valuable treatments reducing declare without urgent coordinated action world symptoms complications patients influenza heading toward postantibiotic era common although need given within hours onset infections treatable decades could kill symptoms effective us least two million people become infected antibioticresistant bacteria least roche developing antibody rg targets people die year result infections seasonal strains influenza binding conserved people die eu according report part hemagglutinin protein surface virus antimicrobial resistance change season season antibody inhibits hemagglutininmediated fusion viral hosts cell roche long impactful history development membranes prevents replication virus blocking antibiotics including rocephin bactrim entry viral rna cell nucleus committed research development medicines treatment drugresistant infections lead preclinical survival data indicate rg may compound rg new class antibiotic designed effective single agent additive benefit may treat severe hospitalacquired bacterial infections caused provided combination antiinfluenza drugs pseudomonas aeruginosa bacteria accounts one tamiflu inhibits release new virus every ten hospitalacquired infections us listed infected cell molecule successfully completed one six dangerous drugresistant microbes phase iia clinical study demonstrating significant antiviral activity improved clinical symptoms global phase iib partnership polyphor swissbased company clinical study patients hospitalised influenza rg currently phase ii trials compound infection initiated flu season designated qualified infectious disease product qidp treatment pseudomonas aeruginosa hepatitis remaining challenge infections qidp designation provides certain incentives hepatitis b continues major global health problem development new antibiotics including priority review despite availability hepatitis b vaccine since eligibility fasttrack status fiveyear extension effective preventing infection disease market exclusivity product approved us results approximately deaths every year due seasonal risk areas influenza novemberapril aprilnovember yearround corren j et al lebrikizumab treatment adults asthma new journal medicine prevention blindness visual impairment priority eye diseases europe new report antibiotic resistance global health threat antimicrobial resistance global report surveillance maximum amount air forcibly exhaled one second roche annual report roche innovation acute chronic consequences infection roche discontinued fragile x development programme pegasys one mainstays chronic hepatitis basimglurant rg due lack efficacy however b treatment adults continuing legacy primary indication molecule continues area composition one advanced treatmentresistant major depressive disorder recent early development pipelines industry phase ii trial produced encouraging results basimglurant added top standardofcare anti extending commitment virology china depressant therapy patients previously failed roche innovation center shanghai china key respond conventional medicines hub research development treatments infectious diseases celebrated th anniversary phase iii metlung study failed show clinical efficacy year infectious diseases remain major causes onartuzumab combination tarceva nonsmall morbidity mortality china substantial cell lung cancer stopped evaluating progress control led significant implications study results well knowledge expertise china phase ii studies across onartuzumab clinical programme led decision discontinue commitment fight infectious diseases development compound roche invest million swiss francs development stateoftheart research centre shanghai centre alzheimers disease ad phase iii scarlet road focal point r efforts shanghai study gantenerumab prodromal ad predementia facilitate collaboration scientific excellence internally discontinued late decision based results chinese scientific community building preplanned futility analysis however roche continues expected completed broad research programme targeting different mechanisms alzheimers disease progression includes phase rare diseases iii marguerite road study gantenerumab people roche building portfolio investigational medicines mild dementia due ad rare diseases spinal muscular atrophy sma roche developing smn rnasplicing modifier unique advanced breast cancer abc phase iii marianne collaboration biotech ptc therapeutics study evaluated three hertargeted regimens kadcyla patient organisation sma foundation subsequent plus perjeta kadcyla alone herceptin plus taxane singledose study healthy volunteers phase ib chemotherapy previously untreated patients moonfish multipledose study initiated positive abc study showed three regimens helped evaluate safety tolerability compound people live without disease worsening pfs adults children sma similar amount time meeting noninferiority endpoint however neither kadcylacontaining treatment arms projects missed key milestones significantly improved pfs compared herceptin research development innovative medicines chemotherapy approved indications perjeta areas unmet medical need highrisk venture kadcyla help people herpositive abc live longer readouts several key studies led us discontinue reevaluate related development programmes bitopertin schizophrenia programme discontinued review totality data phase iii studies show consistent evidence clinical efficacy support development time continue evaluate bitopertin phase ii trial addon treatment selective serotonin reuptake inhibitors treatment obsessive compulsive disorder global alert response gar hepatitis b roche annual report innovation roche emmas compelling data visualisations analytics deliver realtime insights patient enrolment management innovative approaches design recruitment clinical studies multiple methods used design clinical trials imaging precision medicine needed show safety efficacy new drugs scientists working cutting edge imaging many alternatives exist establish dosing regimen patient science develop deploy new tools visualise profile sample size trial duration measures drug effect effect new medicines patients data gathered helps drug combinations roche constantly asking inform drug development decisions treatment options optimise clinical trial methodologies bring patients ultimately leading improved outcomes medicines diagnostic solutions patients faster imaging scientists roche working collaboration roche diagnostics academic groups develop computer modelling clinical trial design innovative new ways assessing efficacy new one key challenge trial design evaluating class treatments performance possible designs outset clinical trial simulation cts tool uses computer simulations datadriven clinical operations environment predict outcomes different possible clinical trials focus innovation also helped drive better helps select informative datadriven clinical trial management helping accelerate transition new molecules early within roche clinical pharmacology function latestage product development several approaches developing new cts capabilities redefine way investigated including new programme called navigate develop drugs optimise dose drugs clinical launched multiyear initiative integrating pharmacologists long experts pharmacokinetic process latest information technology empower pharmacodynamic modelling used study transform study teams use data enrolment link doses drugs respective effects measurement management application emma help optimise choice dose modelling informs one first automated clinical trial tools created us possible effects drug studying navigate enabling study teams accurately combined modelling disease provides plan track manage patient screening enrolment capability simulate potential clinical trial scenarios bestinindustry tool emma collects large quantities implementing cts requires new software tools roche operational data real time synthesises makes collaborated external partners develop simulo information immediately available study teams form innovative cloudbased drug trial simulator provides graphic visualisations userdefined tables ability ability simulate analyse virtually limitless numbers see trials performance multiple perspectives helps clinical studies shorten clinical development lifecycle roche annual report roche innovation reliable supply patients roche pharma global technical operations tasked manufacturing network hosts approximately total ensuring availability roche medicines worldwide global biologic production capacity making roche engaged activities ranging scaleup largest manufacturer biotech sector production processes aspects manufacturing drug substance packaging ultimately delivery activities reopen previously idled drug substance medicines countries globally executing production unit vacaville california track responsibilities dynamic complex business increase roches biologic manufacturing capacity regulatory environment requires constant vigilance significantly company invest million swiss innovation francs offer work places additional highly skilled people additional vacaville capacity expected operational first quarter ensuring reliable supplies patients worldwide oceanside site california roche investing approximately million swiss francs second clinical studies newly approved purification line increase manufacturing products flexibility enable site process two products simultaneously oceanside plans add approximately highly skilled positions expected operational roches current pipeline new medical entities nmes first quarter one strongest industry scaling production meeting increasing stringent regulatory requirements manufacturing site penzberg germany roche preparing launch multiple new products also expand biologics capabilities company providing medicines patients upon approval investing total million swiss francs coming extraordinary challenge technical operations four years expansion project operational ensure technical operations deliver roches robust pipeline including compounds received fda new production facilities breakthrough therapy designation implemented basel switzerland roche begun construction several innovative processes methods include production centre antibodydrug conjugates adcs establishing seamless handover processes streamlined new adc facility support manufacturing product launch sourcing decisions well increasing kadcyla firstofitskind medicine used treatment organisations capacity capability breast cancer well future antibodydrug conjugates new centre cost approximately million swiss biologics capacity expansion francs planned operational august worlds sophisticated biopharmaceutical production plants roche roche annual report innovation roche roche pipeline small molecules requires special progress made includes clearer facilities highly potent drugs may governance sourcing decisions better defined construction launch facility basel highpotent strategic supply plans product lifecycle active pharmaceutical ingredients approved new stateoftheart facility support commercial launch supplier relationship centre south san francisco early market supply important products co roche established dedicated supplier relationship location launch facility technical development centre src order work closely key team enable effective efficient knowledge transfer suppliers innovation roche increased scope thus help simplify registration processes src form innovation centre excellence authorities include external partners drive innovative strategies introduced new fasttrack process endtoend product management deliver ideas value shorter time date order manage supply chain effectively innovative business cases approved endtoend basis enhanced technical product progress implemented management approach implemented significant health interpreting big data whilst datadriven business models employed prior drawing conclusions potential strategic industries quite time complexity opportunities resulting health big data healthcare environment represents major challenges data regulatory aspects data ownership confidentiality mining usage big data need addressed within clinical studies huge volumes data several initiatives ongoing enhance realworld data generated example oncology rwd realworld evidence rwe capabilities sequencing cancer tissues identify cancerdriving roche rwdrwe provide information benefits mutations crossanalysis large patient cohorts followup risks medicines realworld settings helps patients time studies combining several drug us make informed decisions development strategy candidates generate enormous volumes data need improve medical practice make medicines understood interpreted combining inhouse accessible right patient right time many information external realworld data poses challenges countries already using rwdrwe informed terms comparability information since large part reimbursement decisions medicines expected realworld data unstructured prone subjective grow future activities setting initial interpretation thus generating meaningful conclusions foundation enhance infrastructure capabilities benefit patients healthcare systems extremely leveraging rwdrwe challenging new function real world data science rwds nevertheless several areas demonstrate potential created product development purpose activities rwds translate rwd evidence insights identifying patients risk developing specific enable better decisions medicines improve patient diseases early using algorithms combine different care rwds influence global teams appropriately diseaserelated risk factors using patient data incorporate rwd options meet global affiliate needs supporting physicians decisionmaking complex rwds focuses building rwd capabilities roche diseases cancer intrinsic complexity fostering partnerships shape rwd environment cancer many subgroups multiple disease strategic partner research development drivers combined increasing number targeted commercial organisations rwds aspires effective medicines require new approaches medical data connector across organisation understanding interpretation longterm patient care evidence needs medicines knowledge analysing realworld patient data collaborating available data sources analytical expertise capacity healthcare providers patient registries related rwds well equipped generate rwdrwe sources understand benefits risks cost benefit various organisations roche well effectiveness treatments realworld settings people need differentiated products roche annual report innovation spotlight hpv testing roche annual report spotlight hpv testing innovation dream always direct impact womens health catherine behrens catherine trained gynecologist led team effort get fda approval new indication using human papilloma virus hpv test primary screen cervical cancer diagnostic tool potential reduce incidence cervical cancer women roche annual report new options detect virus causes cancer catherine ventured far comfort zone testifying fda advisory panel obtain approval cobas hpv test primary screening getting phd molecular endocrinology began working roche consultant university california san francisco went medical clinical trial new dnabased hpv test asked school stanford also completed residency join company six months later clinical leader programme obstetrics gynecology study known athena gynecologist became committed patient care postponed dream direct impact womens health plans return research sometimes though wondered much impact athena unprecedented scope complexity women saw day much would american women sites states research screened using roches dnabased cobas hpv test tell many extra hours colleagues issue troubled screening procedure put study cervical cancer standard care detecting cervical precancer using cytology known pap smear makes cobas hpv test unique ability reduced incidence cervical cancer impressive detect high rate accuracy highest risk test however involved looking tissue samples subtypes genotypes hpv including strains hpv microscope means chance human error responsible also many borderline pap smears cervical cancers provide us physicians clear basis making decisions hand began think hpv fda approved cobas hpv test adjunct principal cause cervical cancers would better test pap smear exciting moment target screening team course work every year cervical cancer kills cervical cancer women caused hpv infectionsspotlight hpv testing innovation submitted new data fda purpose highrisk genotypes screened getting cobas hpv test approved firstline pap smear see interventions warranted primary screening test cervical cancer cobas hpv test could important women around since evaluating new primary screening tool hpv world according deaths occur uncharted territory fda appointed advisory every year due cervical cancer number countries panel comprising leading experts field clinical lack infrastructure training perform leader athena expected present trial data pap smears may make sense leapfrog answer questions panel convened technology go directly screening process using outside washington dc cobas hpv test largely automated never done anything like meant going feel truly priviledged well comfort zone knew good preparation key worked closely hpv team practised part global team could presentation often colleagues tried anticipate impact future possible questions prepared approximately backup slides additional data womens healthcare march faced members fda advisory panel audience people nine cobas hpv test complements products hours testimony questionandanswer period roche portfolio cintec cintec plus tissuebased recorded video posted online part tests approved europe helping identify hpv public record positive women would benefit treatment early disease precancer stages conclusion hearing three questions posed fda representatives advisory panel experts avastin cancer medicine roche approved regarding safety effectiveness cobas hpv test us treat metastatic cervical cancer primary screening tool panel voted unanimously affirmative three questions colleagues really pleased faced fda advisory panel nine hours presentations questions voted unanimously favour cobas hpv test following fda approval transition period cotesting many physicians continue screening pap smear add cobas hpv test outside us test made available eu preparing filing filed number countries broaden availability test women around world methods testing work well together primary screen cobas hpv test increased sensitivity casts wide net detect presence virus women test positive dangerous hpv strains subtypes undergo catherine athena study caused enormous amount extra hours many us checking precancerous cells women test positive enormously gratifiying work developing test could help save lives human papilloma virus hbs sexual reproductive health new guidance prevention control cervical cancer roche annual report roche innovation value diagnostic test results diagnosing heart attacks preeclampsia going develop disease heart attack acute myocardial infarction ami short term economical perspective common cardiac event blood supply area may help save expenditures healthcare systems heart interrupted causing cardiac muscle unnecessary hospital admissions excessive medical cells die seven million fatalities ami treatment worldwide annually fast reliable diagnosis heart attacks critical ami patients every delay tumour characterisation therapy monitoring onset symptoms treatment increases mortality liquid biopsy innovative alternative method risk assessing cancer genetic status based blood drawn patient currently patients advanced cancer require rochesponsored trapidami clinical study showed invasive tumour tissue biopsy diagnosis requiring novel approach diagnose exclude heart attacks tissue sent laboratory review molecular patients acute chest pain reduces typical testing clinicians rely identification correct observation time three six hours one hour molecular target take right treatment decisions accelerated onehour approach based elecsys including targeted drug therapies occasionally cardiac troponin high sensitive test roche enough tissuebased sample material available patient enable physicians treat patients much earlier case healthy enough tissue biopsy procedure heart attack saving time avoids additional damage performed case alternative solution heart important maximise efficaciousness valuable studies shown tumours release proteins treatment additionally cases diagnosis nucleic acids cancerous cells blood heart attack excluded faster exclusion may reduce patient blood samples easily obtained concept anxiety help alleviate emergency room workload bloodbased biopsy long held promise noninvasive complement traditional biopsy techniques improving prediction preeclampsia preeclampsia affects one twenty pregnancies new molecular test lung cancer patients one leading causes fetal maternal morbidity development roche enable clinicians evaluate mortality current guidelines diagnosis current health status patients determine preeclampsia based clinical parameters biopsy perform tissue liquid ultimately allow hypertension proteinuria poor predicting clinicians bring right treatment right patient clinical onset disease disease progression ensure therapy selected remains relevant results prognosis study showed elecsys next generation sequencing immunoassay sfltplgf ratio useful shortterm roche developing integrated genomics portfolio prediction preeclampsia provides physicians next generation sequencing ngs adding internal reliable tool identify women high risk developing potential breakthrough technologies acquired genia preeclampsia require intensified monitoring technologies inc bina technologies inc ariosa time elecsys immunoassay sfltplgf test allows diagnostics inc well technology abvitro physicians confidently release women suspected avansci collaboration agreements stratos genomics fast reliable diagnosis heart attacks critical initiation specific medical care conventional troponin test high sensitivity troponin test faster rulein faster appropriate therapy trapidami reduced time diagnosis faster ruleout reduced emergency department crowding source hamm et al eur heart j time since admission hours roche annual report innovation roche modern diagnostic tests allow identification specific cancercausing genetic mutations thus enabling physicians apply targeted therapies garvan institute cornell university university focus advance ngs specific application areas washington complement acquisitions ariosa first series efforts expand menu ngs market ariosas harmonytm prenatal test genias proprietary singlemolecule electrical detection noninvasive prenatal diagnosis using circulating fetal dna technology could reduce cost sequencing circulation dna promise providing noninvasive increasing speed sensitivity roche expert team early testing many segments including pregnancy cancer actively working stratos xpandomer transplantation acquisition bina complements conversion chemistry developed roche likely existing technologies enables development explore use genias protein nanopore platform endtoend sequencing workflow solution diagnostics division key product launches planned area product name description market instrumentsdevices cobas c dedicated hbac analyzer eu cobas core laboratory coagulation analyzer eu laboratories cobas v integrated pre postanalytical solution ww cobas medium highvolume automated realtime pcr us ventana automated staining platform ww accuchek active nocode next generation blood glucose meter coding test strips ww diabetes care accuchek connect blood glucose meter connectivity smartphones mobile applications cloud us point care coaguchek pro ii professional system pt aptt testing eu tests blood screening mpx test multiplex blood screening test cobas systems us infectious influenza ab rsv test pointofcare detection cobas liat us diseases htlv test human tlymphotropic virus test eu hbv test quantitative hbv viral load test cobas eu hiv test quantitative hiv viral load test cobas eu virology hcv test quantitative hcv viral load test cobas eu hbv test quantitative hcv viral load test cobas eu genomics oncology egfr test v detection egfr mutations plasma eu cardiology cobas h troponin test pointofcare test version elecsys ctnths eu ww worldwide pt prothrombin time aptt activated partial thomboplastin time roche annual report roche innovation building partnerships leading institutions around world roche one first healthcare companies innovation roche maintains close contact academia recognise importance external innovation well biotechnology companies candidate compound genentech partnering roche partnering go series checkpoints studies driven established organisational structures objective jointly partner roche increase likelihood marry external scientific expertise technology success clinical development ultimately provide breakthroughs roches internal drug discovery pipeline new options patients aligned overall r strategy focus well defined therapeutic areas optimal synergies externally sourced compounds external innovation roches r portfolio developmentmanufacturing expertise resulting contribute one third diversity views cultures approaches pipeline pharmaceuticals hallmark r roche promotes creativity innovation total sales roche partnering roche partnering rp founded ten years ago mission follow science find true innovation provide company additional pillar innovation build strong winwin alliances partners rp screens opportunities year early includes earlystage collaborations leading academic development platform technologies phase iii centres foster development novel targets molecules merger acquisition opportunities molecules technologies platforms rp managing close external partnerships around world roches r pipeline compounds externally sourced rochepartnered products contribute third total pharmaceuticals sales rp signed new agreements including three acquisitions four product transactions research new technology collaborations product outlicensing agreements rp team searches novel compounds external partnerships address unmet medical needs potential across roche group become firstinclass bestinclass bestindisease medicines committed discovering truly cuttingedge roche annual report innovation roche rp comprised multidisciplinary workforce strong complement small largemolecule antibodies expertise therapeutic areas business development protein therapeutics research offices basel new york south san francisco tokyo shanghai rp works closely internal partners example roche technology supports partners multiple functions enabling indepth expert assessments r agreement developed roche select promising external projects overarching prothena tackle parkinsons disease includes principle seeking best external innovation programme test use roche brain shuttle create fruitful synergies roches inhouse technology potentially increase delivery antibodies pipeline expertise targeting synuclein brain improve potency treatment parkinsons disease innovative agreements beyond traditional partnerships genentech partnering roche offers creative deal structures go beyond genentech partnering genentechs research traditional partnership agreement create winwin alliances contracts group signed new agreements including tailored assets partner companies roches one acquisition five product transactions research partners also benefit roche technologies technology collaborations academic research brain shuttle technology partners also take advantage collaborations roches expertise diagnostics identify suitable patients treatment well measure acquisition seragon pharmaceuticals inc effect drug privately held biotechnology company based san diego california completed roche group obtained recent example new partnering approach build rights seragons portfolio investigational next tobuy deal versant ventures inception sciences generation oral selective estrogen receptor degraders collaboration resulted new startup company called serds potential treatment hormone receptor inception research develop novel small positive breast cancer breast cancer claimed molecule therapies aim promote remyelination lives nearly women us half nerve sheaths damaged result disease progression women disease driven estrogen multiple sclerosis patients inception builds recent receptor although medicines approved discoveries field use proprietary screening treatment hormone receptorpositive breast cancer platform developed investigators university decades treatment options needed california san francisco pursuing multiple molecular investigational serds complement existing r targets remyelination versant provides equity financing programmes strengthen pipeline could one day company roche fund research based redefine standard care hormone receptorpositive series milestones roche retains exclusive option breast cancer acquire inception upon first lead compound reaching filing stage investigational new drug application neuroscience field entered second collaboration strategic partner xenon pain rare diseases area roche collaborating genetics goal discovering validating new canadian venture firm amorchem develop new therapeutic targets mechanisms treating pain therapeutic approach myotonic muscular dystrophy pursuit targets human genetic validation core type steinert disease currently approved pain strategy developing drugs treatment available slow stop disease progression targets highly competitive collaboration seeks put based research carried university montreal genentech firstinclass position novel therapeutics new approach aims interfere splicing alteration treat pain leveraging xenons expertise genetic caused genetic defect discovery take place validation targets aim discover highly validated amorchems medicinal chemistry contract research targets could yield novel nonopioidbased mechanisms organisation nuchem therapeutics university treat pain montreal laboratories roche provide scientific support contribute r funding together amorchem propel discovery rnatargeting therapeutics roche acquired santaris pharma denmark integrated r organisation roche innovation center copenhagen rna therapeutics research may produce new modality unique class medicines breastcancerorg us breast cancer statistics roche annual report roche innovation conducting responsible r r activities conducted highest roche clinical trial statistics ethical standards published several position number patients clinical trials world bank country classification papers r activities areas genetics stem cells animal research routinely review update low income positions policies research involving either humans animals taking account scientific middle income developments public concerns upper middle income clinical trials high income clinical trials critical determining safety efficacy new medicines clinical trials source world bank july compliant good clinical practice guidelines international quality standard information animal welfare trials shared regulatory authorities payers continue seek alternatives use animals studies technologies computer simulation vitro testing using differentiated cells induced pluripotent stem cells switzerland support r patients involved research foundation funds development improvement methods based r strategy clinical trials approach aims use alternatives animal testing whenever possible replace improve existing methods fewer laboratory animals required reduce improve clinical trials existing methods animals experience little discomfort distress possible refine number clinical trials used animals internal research number healthcare decrease number animals used centres involved contract research organisations working roches behalf number patients phase iiv clinical trials decreased compared approximately animals used mice rats roche annual report innovation roche major research sites awarded continued full overall policy goes beyond european american reaccreditation status association assessment industry guidelines came effect january accreditation laboratory animal care international forefront datasharing underscoring commitment ensuring animal welfare movement identifying new ways share clinical research scientific community october plans announced build new vivo research facility basel site switzerland details please see wwwrochetrialscom new stateoftheart building planned completion datasharingpolicyinformationaction meet highest requirements animal welfare set new standard industry preclinical vivo biology research clinicaldata sharing january roche announced next step sharing clinical trial data providing access analysable patient level data researchers since june roche also provided access clinical study reports csrs summary reports new approach provides balance commitment sharing data trials safeguarding patient confidentiality regulatory process csrs analysable patientlevel data anonymised respect privacy patients participating trials accordance relevant laws regulations wwwclinicalstudydatarequestcom based gross national income per capita low income usd less lower middle income usd usd upper middle income usd usd high income usd roche annual report roche pharmaceuticals pipeline pharmaceuticals pipeline focus select group disease areas including oncology hematology neuroscience immunology inflammation ophthalmology infectious rare diseases project id projectproduct indication phase il ill iv oncology rg cobimetinib zelboraf metastatic melanoma rg mabthera sc cll rg avastin recurrent cervical cancer rg perjeta bc neoadjuvant rg avastin glioblastoma st line rg avastin ovarian cancer st line rg avastin relapsed ovarian cancer platinumsensitive rg avastin nsclc adjuvant rg perjeta mbc nd line rg perjeta bc adjuvant rg perjeta gastric cancer st line rg kadcyla gastric cancer nd line rg kadcyla perjeta mbc st line rg kadcyla bc adjuvant rg kadcyla perjeta bc adjuvant rg kadcyla perjeta bc neoadjuvant rg gazyva dlbcl st line rg gazyva inhl rituximab refractory rg gazyva follicular lymphoma st line rg zelboraf melanoma adjuvant rg pdl mab nsclc nd line rg venetoclax bcl cll relapsedrefractory rg venetoclax gazyva cll st line rg alectinib alk inhibitor nsclc rg avastin tarceva egfr mut nsclc rg kadcyla nsclc rg fixafx bispecific mab hemophilia rg serd er herneg mbc rg csfr mab pvns solid tumours rg angvegf mab colorectal cancer rg pictilisib solid tumours rg cobimetinib paclitaxel triple negative breast cancer rg ipatasertib akt inhibitor solid tumours rg pdl mab nsclc ndrd line rg pdl mab avastin renal cell carcinoma rg pdl mab bladder cancer rg polatuzumab vedotin cdbadc hematologic tumours rg lifastuzumab vedotin napibadc platinumresistant ovarian cancer rg venetoclax bcl cll relapsedrefractory p deletion rg venetoclax bcl dlbcl rg venetoclax bcl rituxan relapsedrefractory follicular lymphoma rg taselisib mutant selective solid tumours rg glypican mab liver cancer rg lsd inhibitor aml rg serd er herneg mbc rg hif alpha lna solid tumours rg ido inhibitor solid tumours rg mab solid tumours rg csfr pdl mab solid tumours rg raf mek dual inhibitor solid tumours rg mdm ant solid hematologic tumours rg pdl mab tarceva nsclc egfr rg pdl mab zelboraf cobimetinib metastatic melanoma rg pdl mab avastin chemo solid tumours rg pdl mab cobimetinib solid tumours rg pdl mab ipilimumifn solid tumours rg pdl mab solid tumours rg pdl mab gazyva lymphoma rg steap adc prostate cancer rg heregfr daf cobimetinib kras mut rg venetoclax bcl gazyva cll rg venetoclax bcl hematology indications roche annual report pharmaceuticals pipeline roche project id projectproduct indication phase il ill iv oncology rg chk inhibitor solid tumours lymphoma rg mdm iv prodrug aml rg msln pe cfp oncology rg cea cd tcb solid tumours rg cea ilv solid tumours rg adc solid tumours rg erk inhibitor solid tumours rg cd imab pdl mab solid tumours rg adc ovarian cancer rg antiox mab solid tumours inflammation immunology rg actemra giant cell artheritis rg lebrikizumab severe asthma rg etrolizumab ulcerative colitis chu actemra largevessel vasculitis chu suvenyl enthesopathy chu ilr mab neuromyelitis optica rg actemra systemic sclerosis rg lebrikizumab idiopathic pulmonary fibrosis rg esbriet ssc interstitial lung disease chu ilr mab atopic dermatitis rg nme autoimmune diseases rg nme autoimmune diseases infectious iseases us rg danoprevir hcv fda submission decision pending rg flu mab influenza approved us submitted eu rg setrobuvir hcv submitted us rg lptd antibiotic bacterial infections rg dbo lactamase inhibitor bacterial infections personalised healthcare project rg nme infectious diseases rgno roche genentech managed rg tlr agonist hbv chu chugai managed rg abthera branded metaboliccardiovascular rituxan us japan chu urat inhibitor gout rg ctemra branded rg gipglp dual ago type diabetes roactemra eu rg aldosterone synthesis inhibitor metabolic diseases neuroscience aml acute myeloic leukemia rg gantenerumab alzheimers disease amd agerelated macular degeneration rg ocrelizumab rms wamd wet amd rg ocrelizumab ppms bcc basal cell carcinoma rg maob inhibitor alzheimers cll chronic lymphocytic leukemia rg gabra nam syndrome cmv cytomegalovirus rg bitopertin obsessive compulsive disorders dlbcl diffuse large b cell lymphoma rg basimglurant mglu nam treatment resistant depression dme diabetic macular edema rg v receptor antagonist autism egfr epidermal growth factor receptor rg crenezumab alzheimers disease er estrogen receptor rg pdea inhibitor schizophrenia hbv hepatitis b virus rg mglu pam schizophrenia hcv hepatitis c virus rg taups mab alzheimers disease mab monoclonal antibody rg taar ago schizophrenia mbc metastatic breast cancer rg nav inhibitor pain inhl nonhodgkins lymphoma rg smn splicer spinal muscular atrophy nsclc nonsmall cell lung cancer rg asynuclein mab parkinsons disease ppms primary progressive multiple sclerosis ra rheumatoid arthritis ophthalmology rms relapsing multiple sclerosis rg lucentis diabetic retinopathy rvo retinal vein occlusion rg lampalizumab factor geographic atrophy sc subcutaneous rg lucentis sustained delivery amdrvodme ssc systemic sclerosis related interstitial rg vegfang mab wamd lung disease roche annual report key facts access healthcare access healthcare roche annual report access healthcare key facts million patients treated roche top selling product million infants tested hiv subsaharan africa patients treated herceptin china roche patient assistance programme pathologists surgeons techicians trained roche sphere programme asia roche annual report roche access healthcare enormous global challenge significant breakthroughs diagnosing treating serious diseases well improvements delivery healthcare steadily improved health outcomes increased life expectancy recent decades universal access medical innovation quality healthcare developing innovative approaches collaboration however remains global challenge particularly emerging international local players roche strives make developing countries many countries severe significant impact addressing disparity many shortages equipment medical professionals medicine patients around world supporting universal supplies lack awareness disease prevention healthcare coverage goal aims everyone added adoption western dietary access quality healthcare services without financial habits sedentary lifestyles incidence cancer hardship rising countries healthcare infrastructure often inadequate innovative solutions required address problems make sure patients need access medicines diagnostic testing billion roche developed comprehensive strategy improve situation systematically analysing people lack access root cause barriers individual market developing well established markets basic healthcare also identifying key healthcare stakeholders partner support improvements access roche annual report access healthcare roche reaching patients need improving affordability developing new pricing strengthening infrastructure established models tailored benefit product delivers programmes strengthen local national regional along ability local payers pay rather capacities including health systems building facilities uniform global price also working expanding training healthcare professionals transferring skills reimbursement public market along private expertise health insurance increasing awareness patient support increasing availability innovative products support community partners run screening awareness exploring ways bring innovative medicines counselling support programmes empower tests market faster supporting regulatory people knowledge safeguard manage harmonisation supply chain issues barriers health improving affordability recognise despite improvements healthcare personalised reimbursement models differentiate infrastructure funding innovative medicines price reflect benefit treatment delivers diagnostics remain beyond reach many patients patients need people may access quality healthcare private sector example incomes higher personalised reimbursement models potential public health system may offer level significant value stakeholders speeding access patient access innovative treatments reducing financial pressure prescribing enabling benefit medicine better reflected price however even countries advanced implement kind model need able track healthcare systems treatment may use medicines requires close collaboration healthcare providers well supporting fully reimbursed infrastructure share data easily without compromising patient confidentiality result many patients unable either start initiated number pilot projects europe treatment continue full treatment course ease last two years address issues work closely barriers developed innovative pricing local healthcare stakeholders bring concept models tailored needs patients different fruition uk example completed healthcare systems pilot phase working national health service nhs unique dataset cancer personalised reimbursement models medicine use systemic anticancer therapy dataset increased understanding disease pathology sact potential provide better intelligence realised similar mechanisms pathways cancer drugs used benefits relevant different types tumours progress bring patients able demonstrate tangible science brought us medicines improve patient benefits pilots data outcomes variety diseases extent basis flexible commercial schemes linking benefit patients differ diseases price specific benefit patients nhs also increasing number combination therapies also allows sact data used administer developed require one medicine achieve necessary commercial schemes ensure budget optimal outcomes patients led us create efficiencies nhs universal health coverage roche annual report roche access healthcare reimbursement driven benefit therapy patient today future unitbased pricing personalised reimbursement models reimbursement driven volume therapy used reimbursement driven value therapy delivers patient price differentiated indication undifferentiated price per vial price differentiated combination price differentiated treatment course pilot programmes demonstrating similar benefits includes ukraine georgia ecuador egypt also underway throughout europe notably spain pakistan india worked government personalised reimbursement models included new regulations patient assistance programmes last two years roche building awareness recognise many patients including living understanding concept well best developed countries affordability significant implement supporting technologies several projects barrier starting continuing treatment even patients underway different regions build patient registries insurance may able pay treatment records determine value medicines fully covered individual insurance plans reduce treatment catalonia population database barrier provide patient assistance programmes million people infrastructure personalised help underinsured uninsured patients access reimbursement available medicines differential pricing china example roche entered partnership countries little private insurance public cancer foundation china increase access reimbursement people often required pay majority breast cancer treatment herceptin fully costs address disparity piloting covered public healthcare system course number differential pricing models including local therapy patients pay first six treatments roche packaging second brands products partnership provides remaining eight free charge via local manufacturers government organisations foundation addition roche china working regional governments help reimburse patients programmes include reduced prices governments part outofpocket expenses result facilitate reimbursement medicines prescribed patients treated herceptin since public healthcare systems establishing differential launch programme patients otherwise pricing programmes number countries would access alone patients therapies including pegasys hepatitis c b mabthera accessed herceptin patient assistance rituxan nonhodgkins lymphoma chronic lymphocytic programme leukemia herceptin herpositive breast gastric cancer learn programmes plan another way working make sure expand differential pricing new innovative products medicines affordable philippines limited public funding healthcare government second brands owned philippine healthcare insurance corporation provides emerging markets sell second brands basic national healthcare coverage excludes products manufactured sites treatment biologics relatively new class drugs subject quality control original roche includes herceptin targeted therapy herpositive product however package second brands breast cancer different names may produce slightly different forms vials rather syringes second improve access herceptin help patients adhere brand programme expanded countries full treatment duration established roche patient roche annual report access healthcare roche assistance programme physicians refer financially many countries insurance constrained patients programme assessment independent third party ability pay patients policies difficult design unable pay full price herceptin receive discounted data survival rates price based financial status treatment costs hard find helping establish health insurance patients access innovative treatments including cancer depends number factors funding key improve availability usability information one public health systems guarantee pay roche made concerted global effort share data timely access appropriate treatments private cancer frequency cost treatment aim insurance funds often alternative enable insurers better understand predict cost cancer insurance outofpocket payments become financially catastrophic individuals million insurance private health insurance play key role providing policies coverage offers access treatment well four years cover protection financial risks cancer care china result roche initiative working closely insurance companies help design products local markets colombia collaborating fasecolda colombias association private health insurers collect cancerrelated data country data published become publicly available enabling insurers create coverage protects cancer patients financial impact disease offers greater access healthcare possibilities developing similar programmes countries latin america well asia africa countries public healthcare system fails cover costs treatments private insurance invaluable way bridge gap ensure patients fall poverty result healthcare costs roche annual report roche access healthcare increasing availability innovative products although inadequate infrastructure lack trained access innovative medicines medical professionals often barriers stopping patients accessing medicines slow inconsistent regulatory especially difficult subsaharan processes along poor supply chain management africa also present barriers working local level address challenges help reduce bureaucracy inefficiencies healthcare systems africa continent potential next common delay regulatory approval process china economic growth many countries improving many developing countries first require certificate healthcare spending increasing however development pharmaceutical product ema fda healthcare systems varies considerably healthcare starting approval process however infrastructure often poor supply chains complex recent years emerging markets become expensive properly trained medical professionals autonomous requiring european us thin ground launched strategy approvals medicines approval well address improve access innovative medicines roche working closely local authorities global areas africa readily available organisations harmonise regulatory processes allowing aim initially focus key diseases believe approvals happen parallel rather sequentially make difference hepatitis well breast enables companies start process much earlier ovarian cervical cancers december roche signed shave many months even years approval agreement government ivory coast develop programme increase access viral hepatitis distribution biologic medicines require constant breast cancer treatments cool temperatures also significant challenge work closely governments local manufacturers partnerships governments distributors provide training develop locally stakeholders aim build disease solutions appropriate supply chain capabilities ensure safe reliable support infrastructure development support training delivery highquality medicines patients asia roche education improve supply chain also plan working suppliers develop qualify work private insurers create policies cover portable medication mobility kit enable patients carry treatment cancer regional rather cold medicines pharmacy home local risk pool also plans develop centres excellence well create panafrican platform healthcare professional education train specialists enormous scope make difference patients part world roche annual report access healthcare roche increasing availability innovative products strengthening infrastructure roche established number programmes aimed improving local national regional capabilities infrastructure range educating training healthcare professionals helping establish clinics laboratories strengthening local manufacturing capabilities supply chains pathologists surgeons believe activities technicians trained sustainable means addressing local health needs helping develop healthcare systems future roche sphere programme asia improving testing capabilities timely reliable diagnostic tests provide valuable information patients health status improves patient care also helps control healthcare initiative calls improving laboratory capacity costs ensure people living hiv linked effective highquality hiv treatment services support initiative committed expanding access populations age burden hiv tests special pricing scheme qualifying chronic disease increases organisations eligible countries importance diagnostics socioeconomic burden illness achieving good health illness profound impact patients families also put significant burden society especially lower middle income countries breast cancer testing asean region roche conducting study conjunction asiapacific helping improve awareness testing george institute global health assess treatment breast gastric cancers broader burden cancer region aim study sphere programme scientific partnership testing support policy makers making informed choices excellence aim integrate testing patients cancer resource allocation improve support cancer single point diagnosis help patients receive prevention testing well treatment looks accurate diagnosis disease appropriate selection specifically economic impact cancer patients treatment families well variation management hospital nonhospital costs impact quality sphere operates markets asia bangladesh life hope analysis report provide china hong kong india indonesia korea malaysia strong basis proper investment cancer care myanmar philippines taiwan thailand vietnam hiv viral load testing expanded access hiv viral load testing joining global regional partners launch global access programme key action step response diagnostics access initiative launched international aids conference july partners include joint united nations programme hivaids clinton health access initiative united states presidents emergency plan aids relief global fund fight aids tuberculosis malaria roche annual report roche access healthcare increasing awareness patient support healthcare education awareness important psychiatrists advocacy groups recommends fivepoint patients wellbeing proper medical diagnosis policy programme address problem social inclusion treatment reason help local partners also actively participating number initiatives run screening awareness counselling programmes created g world dementia council well seek empower people worldwide knowledge facilitating bringing together patient caregiver safeguard manage health support groups recently established international dementia holistic approach healthcare producing newsletters forum forum aims advance understanding magazines publications aimed helping people impact dementia daily lives patients make healthy choices changing behaviours prevent families role therapeutics play disease also brought delegates together supporting patient organisations world covering different therapeutic collaborate patient organisations starting early areas international experience exchange vienna clinical trial phase voice patients austria share best practice bringing policy families organisations help us learn change understanding care similar event like live disease role drug therapies held delegates representing patient groups play management disease also support asean region kuala lumpur malaysia chugai patient groups efforts change public policy academy advanced oncology founded chugai member roche group also established similar event japan experience exchange patient interactions patient organizations held two meetings groups help us develop right another initiative year build findings support tools products rochefunded completely independent report state oncology based report findings made significant progress partnering supporting healthcare patient groups carers organisations field mental health specifically focused heavily social inclusion often countries overlooked mental healthcare yet one biggest represented challenges one concrete results subsequent grant award publication oxford health policy roche international forum schizophrenia time commit policy change patient group exchange report document written leading international roche annual report access healthcare roche roche latin america hosted forum guadalajara mexico japans top oncologists hearing world discuss improve cancer care today disease experts latest developments cancer treatment responsible deaths mexico experts research region came together concluding right level political latin america could provide global model increasing awareness disease cancer control could used regions education understanding disease treatment available important improving access healthcare educating healthcare professionals roche undertakes disease awareness programmes healthcare professionals conduct training sessions world help patients understand disease risks proper use products well publish treatments avoidance strategies united arab present research findings help physicians others emirates uae hepatitis c serious problem stay abreast latest information diagnostic tests disease often symptoms uae treatment options understanding medical urgent need education risk infection practitioners drugs diagnostic products contaminated instruments certain traditional habits better treatment patients help achieve raise awareness hepatitis c uae launched publish extensive range educational instructional national hepatitis c awareness campaign late materials host support medical congresses together emirates gastroenterology hepatology events society campaign reached population million million people one example commitment providing medical education therapeutic areas significant indonesia working increase understanding unmet need ongoing support annual european breast cancer access screening society medical oncology esmo congress ranges earlydetection campaign oncology doctors general major financial sponsorship sciencefocused booth practitioners family welfare programme trainers educational symposia grants fellowships midwives teach healthcare professionals proper scientists doctors participate contribute technique clinical breast exam campaign success congress roche honoured conducted partnership indonesia cancer esmo ongoing support clinical fellowships foundation ge healthcare indonesia translational fellowships japan chugai doctors midwives family welfare programme academy advanced oncology held annual conference trainers trained selection roche initiatives improve access healthcare initiative country countries description impact amplicare subsaharan africa parts multifaceted programme enabling early million infants south america asia diagnosis infants born hiv positive tested hiv mothers changing diabetes countries africa increase access care children children children southeast asia type diabetes received free care genentech access usa help patients uninsured denied patients care foundation coverage receive rochegenentech supported medicines free charge sphere training markets asia train surgeons pathologists lab healthcare programme technicians improve breast cancer testing professionals trained mobile breast cancer north africa provide free mammographies women women screening buses remote desert areas screened patient assistance china improve awareness testing treatment patients treated programme breast gastric cancer herceptin roche scientific africa purposebuilt training centre train lab lab technicians campus technicians strengthen diagnostics trained capabilities countries second brand egypt increase access hepatitis c treatment patients treated programme differential pricing via second brand transnetphelophepa south africa provide general healthcare disease people healthcare train awareness health education rural areas reached novo nordisk programme roche annual report access healthcare spotlight africa roche annual report spotlight africa access healthcare want people see africa continent opportunities charles fordjour charles passionate increasing patient access treatment africa project leader roche africa strategy aims improve access innovative medicines subsaharan africa roche annual report mission improve healthcare africa charles fordjour knows medical realities africa story shows one persons perseverance ability motivate others make difference grew village brong ahafo region southern fighting chance left gave remaining free ghana father civil servant mother sample vials antibiotic schoolteacher modest salaries struggled support seven brothers sisters three days later returned hospital doctor asked knew child running halls boys playing soccer often laughing playing explained girl stay bed high fever sweating nausea coma almost wept ill often kids called sickler doctor instrumental writing protocol many years later learned cause illness became institutional policy teaching hospital ghana probably malaria disease kills children treating severe infections roche antibiotic every week africa first hours change healthcare policy saved many lives consequence illness lot time read devoured every book could get hands helped worked way field force manager school soon became best pupil class roche affiliate ghana asked become country manager nigeria africas populous country secondary school went see pharmacist million people told regular bouts fever prescribed roche antimalarial medicine fansidar symptoms disappeared decided become pharmacist worked way university transporting raw materials mixing medicines lecturers sold four pharmacies graduating joined roche affiliate ghana sales representative teaching hospitals called eight hours apart car dusty badly maintained roads turned mud rainy season times people one day arrived hospital saw young girl hepatitis hiv coma due bacterial infection doctor told wanted treat roche antibiotic subsaharan africa rocephin expensive pleaded treat girl least first hours give herspotlight africa access healthcare estimated women die cervical cancer africa every year nigeria healthcare authorities mainly focused communicable diseases like malaria tuberculosis hiv decisionmakers unaware real disease burden hepatitis womens cancers patient access nigeria hepatitis diagnosis treatment increased dramatically worked global organisation roche grant obtain reliable epidemiological figures starting hepatitis data analysed prevalence hepatitis population significantly higher estimate provided world health organization time three times higher prevalence hiv shocked healthcare authorities action charles wants achieve breakthrough patient access medicines national policy nigeria diagnose treat hepatitis tests africa b c roche diagnostics leased sophisticated screening tools minimal charge roche pharmaceuticals made large price reduction hepatitis drug convinced experience nigeria serve pegasys blueprint rest subsaharan africa dynamic urbanising region already cities result patient access nigeria hepatitis diagnosis population one million treatment increased dramatically lives population expected reach two billion saved still much done working implement approach breast achieve breakthrough patient access ovarian cervical cancer continent must invest long term work local authorities shape healthcare policy roche alone need partner international passionate creating foundations private companies nongovernmental healthcare environment africa organisations un good diagnostic centres believe eradicate hepatitis greatly improve affordable medicines broad cancer treatments want roche known leader finding solutions insurance coverage global statistics aidsgov panafrican medical journal globalcan cervical cancer roche annual report key facts responsible business responsible business roche annual report responsible business key facts llion swiss francs support patient organisations countries roche group speakup line operation business partner representatives completed training roche supplier code conduct supplier sustainability audits roche annual report roche responsible business integrity core everything demand highest standards ethics integrity employees business partners commitment goes well beyond legal regulatory requirements compliance fundamental part business continued strengthen compliance conflict interest abuse company assets expense fraud throughout operations well external harassment discrimination remainder related partners year employees violations company integrity good practice trained new integrity directive launched marketing antitrust false records allegations end directive designed specify unfounded still investigation clarify expectations outlined roche group founded allegations subject careful code conduct focuses four areas bribery investigation allegations founded adequate granting advantages gifts entertainment dealing sanctions taken employment contracts business partners conflict interest terminated grounds unethical behaviour agreements business partners also terminated reason believe integrity key longterm success expect standards business partners roche supplier code conduct included contracts offer training support two additional directives also formalised also launched new internet site give guidance year first interaction healthcare professionals compliancerelated topics current prospective organisations second grants sponsorships business partners guidance includes code well donations training education directives anticorruption compliance questionnaire also begin conducted supplier sustainability audits worldwide using riskbased approach findings employees roche trained code conduct audits collaborated suppliers supported help advice line employees involved resolve quickly conducted followup seek guidance interpretation code aim audits information please see suppliers create open culture discuss issues prevent website wwwrochecomsustainabilityforpartnership violations employees also able report non suppliershtm compliant behaviour tolerate retaliation employees raising compliance concern good faith employees contacted roche group speak line available languages countries also expanded scope code conduct reporting system include allegations breaches whether material across roche affiliates increases transparency gives us employees comprehensive picture noncompliance allegations handled locally overall new reporting system trained new chief compliance officer received reports relating integrity directive alleged violations code conduct vast majority reports related personal integrity roche annual report responsible business roche increasing transparency roche believe transparency critical productive franc range overall less total contributions responsible business environment donations clinical trial results rochesponsored studies employees united states make personal reported rochetrialscom clinicaltrialsgov well political contributions roches good government published journals congresses roche data committee genentechs political action committee sharing policy reflects commitment increasing genenpac voluntary political action committees transparency sharing clinical trial information whilst employees donated us dollars political safeguarding patient confidentiality regulatory campaigns committees process policy provides opportunity request global clinical study reports summary reports addition researchers may obtain access analysable contributions healthcare institutions patientlevel data clinical trials requests total amount million swiss francs reviewed approved independent panel experts access approved basis scientific education healthcare professionals merit cases data anonymised respect education patients privacy patients participating trials accordance general public relevant laws regulations research work closely healthcare institutions patient organisations areas particular expertise provide support education fund many kinds activities including seminars professionals patient contributions patient organisations organisations well workshops training total amount million swiss francs roche remains independent political affiliation treatment adherence projects however support number associations political institutions switzerland spent around workshops seminars meetings million swiss francs includes payments interpharma economiesuisse scienceindustries educational grants swissholdings various chambers commerce financial services contracted assistance trade unions donations political parties patient organisations cantonal federal level donations political parties lowdoubledigit thousand swiss disease awareness general education roche annual report roche responsible business engaging stakeholders engaging stakeholders essential stakeholders contribute expertise issues understanding expectations needs concerns insurance coverage expansion biosimilars drug embedding feedback strategy safety security corporate tax payment delivery daily business able address common issues reform develop longterm solutions employees working government officials interact stakeholders variety expected follow good practice guidelines act communication channels corporate websites appropriate ethical professional manner publications addition participate formal structured engagement meetings forums nonfinancial reporting events carry consultations surveys adopted global reporting initiative gri g reporting guidelines disclose core established groupwide guidelines policies application level also report number additional govern interactions key stakeholder groups indicators relevant business stakeholders capture stakeholder concerns local level rechannel go beyond requirements core level global list strategic communication priorities helps us incorporate stakeholder interests materiality strategic plans well focus communication ensure identified topics affect topics relevance stakeholders stakeholders relevant longterm success conducted materiality analysis political industry engagement corporate level amongst key stakeholders line well engaging healthcare professionals strategic framework described related patient organisations also active consulting roche website see first step government officials industry bodies stakeholders defined integrated process criteria inclusion main think tanks academic institutions participate drivers materiality assessment second step debate develop effective laws regulations gathered stakeholder feedback various policies public health key areas discussion eu internal external sources conferences well regular example regulations number topics interviews oneonone discussions conducted roche including clinical trials innovative medicines initiative experts enabled us include topics imi data protection medical devices vitro stakeholder groups consider important diagnostic tests business healthcare sector patient organisations employees media investors payers regulators us landscape remained heavily influenced governments also identified key corporate business development healthcare reform ensuing risks opportunities internal risk framework debates around genentech worked closely see roche annual report responsible business roche final step combined various insights process results materiality analysis identified material topics stood highly relevant endorsed roche corporate sustainability us key stakeholders significant committee chief executive officer economic environmental social impact material topics reflected business priorities build moving forward maintain constant engagement concrete actions relating operational key stakeholders global local level regularly activities measure performance defined update materiality analysis indicators described related roche website see step step step defining materiality process collecting stakeholder feedback identifying material topics preparing assessment views stakeholders material topics confirm process criteria identify key stakeholders map significant drivers assess materiality collect feedback surveys economic environmental key topics internal experts social topics longterm determine ability influence success topics opportunities address operational differentiation view roche activities align identify key corporate business strategic priorities risks opportunities plan ongoing proactive established risk framework engagement key stakeholders material topics actively managed roche stakeholders roche compliance executive compensation occupational accidents growth strategy employee engagementretention compensationbenefits data transparency clinical trials pricing patent policies organisational effectiveness product portfolio strategy disease awareness treatment education r pipeline strategy leadership commitments personalised healthcare drug efficacy safety counterfeiting community engagement sponsorship patient environmental responsibility organisations sustainable healthcare supply chain management biosimilars area high interest stakeholders areas strategic interest roche stakeholders area high interest roche roche annual report roche responsible business managing risk crisis place full risk management policy sets also updated group influenza pandemic policy approach identifying managing reporting supporting materials based latest world health internal external risks opportunities also use organization interim guidance guidance risk stakeholder feedback help manage social environmental based evaluated nationallocal level group economic risks opportunities policy reiterates strategy promote preventative measures reduce infection risk social distancing using consistent methodologies processes routinely personal protective equipment vaccination provision perform risk assessments levels organisation possible use antivirals part influenza group risk report covers material risks pandemic management plan annually discussed corporate executive committee reviewed board directors regularly sustainability risks opportunities update risk management processes raise awareness business sustainability risks include risks affecting multiple understanding risk throughout roche group parts company well risks may longer term impact roche enhanced business group risk management team provides advisory sustainability risk assessment approach allows us services sites affiliates project product teams assess emerging risks annual basis integrate monitors risk patterns specialist areas social existing group risk management process media security compliance sustainability elearning using approach potential business sustainability risks programmes classroom training workshops risk identified literature review risk intelligence roundtables place improve understanding sources workshops corporate sustainability risk help employees manage appropriately committee risks assessed risk forum concept involving group internal thought expert crossfunctional team resulting short list five leaders launched order raise risk awareness across business sustainability risks integrated organisation group risk management process additionally established incident management five business sustainability risks identified teams throughout roche group ensure act quickly emergency teams regularly rehearse earthquake basel tokyo south san francisco different crisis scenarios alerts escalation procedures inadequate strategies cloud mhealth use mobile continue strengthen business continuity devices ehealth use electronic devices social management bcm ensure sites respond media effectively catastrophic events deliver minimum cyber attack acceptable level key products services group issue response yet optimised bcm policy guideline place facilitating consistent thirdparty relationships aligned local implementation currently rolling new bcm framework across group make sure roches operations resilient capable effectively responding major disruptions roche annual report responsible business roche safeguarding patients priority make sure therapeutic benefits unreported adverse event reports completed safety medicine outweigh risks side effects assessment impacted product medicine cause side effects important us understand monitor adverse events patients may november european medicines agency ema experienced whilst medicines end confirmed roche assessment based available regularly audit quality processes systems safety information benefitrisk balance medicines internally addition supporting regulatory authority concerned impacted medicines remain inspections also maintain strict product recall authorised without changes treatment advice procedures ensure withdraw products patients healthcare professionals corrective rapidly quality safety problems arise preventative actions resulting health authority inspections completed completed systemised process reinspection authorities november ensure every product december resulted additional findings addressed parallel ema initiated procedure safe effective throughout investigate whether roche infringed legal lifecycle obligations relating reporting adverse events april ema issued report european commission deciding proceed roche employees required complete training matter adverse events immediately report issue relating safety quality medicines adverse events reinforced processes throughout stored global database reviewed qualified organisation optimise understanding management physician reported promptly appropriate communication safety profile medicines regulatory authorities required report company adverse event experienced patient strive go beyond roche drug included companys safety database used regularly evaluate whether benefits required protect medicine still outweigh risks health safety patients following internal quality review end roche rely products identified unreported missed adverse events patient assistance program united states following discussions relevant health authorities roche fully committed meeting highest standards conducted retrospective global search identify good clinical practice gcp good pharmacovigilance roche annual report roche responsible business strengthening compliance across organisation also separated commercial medical organisations differentiating clearly non promotional activities medical scientific intent processes promotional activities separation also allowed procedures fully transparent budgeting costs well new definitions roles responsibilities support separation established pharma plan healthcare compliance office ensure clear governance oversight decisionmaking across organisation strategy continuous records governance improvement anticounterfeiting supply chain control measures act check counterfeiting medical products serious growing global problem world health organization defines counterfeit medicine one deliberately fraudulently mislabelled respect identity andor organisational effectiveness source estimates counterfeiting substandard formulation contamination fakery active ingredient substitution constitute billion us dollar market practice gvp regulations meeting evolving illegally imported medicines may also stored expectations health authorities around world handled properly could contaminated damaged medical compliance organisation sets strategy degraded patients ultimate victims criminal standards provides full visibility quality activity compliance activities answer increasing global supply chain challenges new quality management system sets structure international criminal activities roche initiated responsibilities procedures help us identify measure tenyear programme increase security supply chain control enhance core quality compliance processes implementing number new technologies alongside simplifying global processes including overt covert anticounterfeiting features procedures well associated documents barcoding mass serialisation techniques tamperevident training support implementation new quality packaging well tracking tracing systems management system training increased supply serialised products significantly assignments completed particularly china us ensure significant compliance issues completion programme anticipated quickly tracked acted upon developed new every roche product folding box case pallet procedures corrective action involved unique identification cooperation health introduction tracking reporting tools addition authorities trading partners ultimately comprehensive suite training materials guidance enable tracking tracing manufacturing facilities conduct root cause analysis rolled global distribution channels patient also working international trade organisations support industrywide efforts improve safety security pharmaceutical supply chain addition collaborate health authorities law enforcement bodies government agencies countries products sold traceability guidelines regulations continue explore potential new technologies support worldwide trend towards digitisation drug employees supply chains ongoing advances technology expect intelligent packaging allow interaction trained new quality within healthcare systems driving innovation compliance processes efficiencies areas operations healthcare generally roche annual report responsible business roche roche using new technologies including barcoding tamperevident packaging bolster supply chain security biosimilars clinical profile noncomparable biotherapeutic products biologic medicines manufactured biological sources expected innovator biological become essential part modern medicine demand medicine remains unknown due lack quality continues rise innovative roche biologics sidebyside assessment showing similarity andor lack mabtherarituxan actemraroactemra kadcyla perjeta comparative clinical data potentially significant play important role improving lives differences could put patients risk poor health outcomes patients noncomparable biologics time second group products developed commercialised manufacturers unknown quality clinical claim similar original biologic medicine biosimilars name implies products similar profile pose significant identical original product meet claim burden healthcare systems similar follow guidelines set biosimilar must similar terms quality safety efficacy society already licensed reference product producing biosimilars however far complicated view risk noncomparable biologics producing generic versions offpatent chemically patients public health must minimised eliminated synthesised medicines complex molecular structure appropriate comparative evaluations consistent unique manufacturing process required make products guidelines biosimilars implementation difficult reproduce oversight however uneven globally national regulatory agencies appropriate frameworks place challenges producing biosimilars given rise whilst others process adapting third group products noncomparable biologics new continue meanwhile implement strategy innovate term proposed international federation expand protect biologic medicines keep ahead pharmaceutical manufacturers associations describe potential competition amended roche medicinal products intended copy position biosimilars reflecting new developments original biologics fail meet sciencebased standards found rochecom direct comparison also meet guidelines quality safety efficacy essential medicines health products general information counterfeit medicines guidelines evaluation similar biotherapeutic products sbps roche annual report responsible business spotlight mental health roche annual report spotlight mental health responsible business medical treatment one part solution lee dunster lee instrumental creating international working group patient groups policy makers work towards holistic view treating schizophrenia also helping build global network improving alzheimers care roche annual report understanding wider implications mental illness lee dunster believes social inclusion extremely important facet mental illness treatment working organisations worldwide improve support people challenging area looked diseases impact people one four many different perspectives began career research scientist microbiology went run world people worldwide health organization collaboration centre kenya viral hemorrhagic fevers like ebola rift valley fever living wife helped set early response diagnostic network east africa diseases remains mental disorder active day drawing experience worked adviser egypt focusing regional preparedness support measles eradication became head research information uk multiple sclerosis society able bring policy manager bring together policy experts fundamental change research funding create new mental health associations around world programme focused nonmedical intervention improve could understand needs people affected quality life patients schizophrenia learned real benefits would come society provided support opportunities joined roche working global public policy could achieved many different stakeholders year later found new role support efforts working together improve treatment people living schizophrenia milestone international collaboration us think schizophrenia connection critically acclaimed report made possible grant visible symptoms hallucinations delusions selfharm roche schizophrenia time commit policy change fact hidden symptoms schizophrenia lack report brought together leading psychiatrists motivation speech problems withdrawal people advocacy groups provide concrete recommendations even debilitating long term leading policy change isolation exclusion family society collaborations patient organisations europe roche developing treatment address hidden united states canada australia japan hong kong symptoms schizophrenia outset however south africa brazil resulted formation clear treatment alone would unlikely provide international working group iwg social inclusion meaningful change improve everyday living people schizophrenia many organisations little schizophrenia goal senior international public regular contact yet shared common goalspotlight mental health responsible business million people worldwide living dementia aim working together identify policy changes could respond needs people affected schizophrenia introduce new initiatives improve lives found hidden symptoms schizophrenia could lee developing dementia forum leading patient associations field tackled increasing social inclusion challenging alzheimers disease stigma also true managing many types mental illness sharing experience identify opportunities integrate people schizophrenia even though clinical programme ended roche continues society includes education jobs help support social inclusion efforts international individuals regain selfesteem independent living working group iwg knows changing policy social interaction lengthy process beginning personal experience helped shape thinking roche develops presence field neuroscience social inclusion yearold daughter autism building experience gained remains struggle convince local authorities international working group recently started provide support include everyday activities like develop dementia forum leading patient associations mainstream schooling wife want field alzheimers disease insights gained opportunities everyone else develop talents partnership patient groups shaping lead full independent life way conduct research development well policy objectives across roche neuroscience portfolio includes multiple sclerosis alzheimers disease autism working overcome stigma downs syndrome associated mental illness provide opportunities effective treatment requires inclusion society vision whole person factors influencing high hopes roche therapy bitopertin individuals quality life treating schizophrenia unfortunately final stages trials failed demonstrate sufficient efficacy halted early nevertheless studies generate areas social inclusion plays crucial role valuable data openly shared medical effective treatment requires vision whole person community provided insights developing future factors influencing individuals quality treatments design clinical trials life whilst medical treatment important one part solution world health report mental disorders affect one four people alzheimers association alzheimers dementia enews roche annual report key facts people people roche annual report people key facts employees proud work roche overall employee engagement average employee profile roche years years current role years old employees north america europe asia latin america africa australia roche annual report roche people engaging energising people great companies defined people embrace shared sense purpose put extra energy passion jobs identify common goals kind engagement aim roche concept engagement reflects evolving needs research shows level engagement strong workforce world around us stay aligned longterm predictor organisational performance drives employees ask feedback regular intervals global employee opinion survey geos survey includes questions measure global employee opinion survey results engagement drivers statements belief commitment action employees take geos seriously know percentage points percentage points opinions matter concrete actions taken based participation since engagement since feedback first survey results resulted development leadership commitments become foundation manage lead people roche engagement directly linked business success target achieve employee engagement end achieved result still puts us among best class industry roche annual report people roche applause peers across globe people roche work colleagues multiple functions locations around world online tool applause employees recognise directly ecards reward point nominations simple fast widely appreciated launched applause live roche affiliates countries ten languages peertopeer recognitions amongst employees recognising rewarding employees also numerous benefits employees vary recognition key driver site site may include discounts buying employee engagement people roche stocks pension schemes health insurance childcare onsite fitness medical facilities flu vaccinations want acknowledged preventative health screenings discounts local retailers appreciated others transportation workplace also offer international sos service employees dependents emergency situation arises travelling results global employee opinion survey living abroad triggered paradigm shift culture roche recognition firmly embedded leadership wellbeing week held second commitments launched innovative consecutive year roche sites around world programme peertopeer recognition applause wide range activities organised around four whilst emphasis recognising colleagues managers main themes healthy lifestyle emotional wellbeing notified time employee receives applause prevention practices wellbeing resources award strive performancedriven culture based continuous dialogue feedback managers employees employees surveyed internal pulse check agreed feedback discussions manager support daytoday tasks development roche employees terms compensation try strike balance highly competitive base salary performance satisfied linked rewards addition bonuses linked individual achievements roche offers rewards linked overall benefits roche success company results global employee opinion survey roche annual report roche people appreciating everyones contribution roche strive create environment everyone regardless gender race ethnicity sexual preference religious background contribute women mission delivering innovative diagnostics total workforce solutions developing lifesaving drugs diversity inclusion women high priority management level us diversity inclusion high priority want inclusion events many roche sites across world diversity go beyond visible differences include events demonstrate commitment enthusiasm different educational backgrounds professional knowledge become diverse inclusive organisation personality types thinking styles life experiences activities marked fundamental shift toward viewing actively support encourage environment diversity inclusion critical success factor everyone feels free speak mind business element successful leadership levels way discover best ideas develop truly company maintain momentum innovative solutions diversity champions leading efforts largest sites senior leaders members corporate various parts worldwide organisation different executive committee participated various diversity points diversity inclusion journey certain corporate goals apply worldwide freedom affiliates adapt local culture priorities female representation among key leadership positions common understanding diversity inclusion roche corporate executive committee discussed agreed diversity inclusion means company definitions help ensure employees across globe share common understanding diversity refers mix wide range visible invisible differences exist among people include goal achieve women representation key leadership limited values beliefs physical differences positions end achievement exceeded target diversity inclusion linked future growth emerging markets important growth driver access programmes address local needs roche next five ten years succeed customers patients markets must reflect diversity decision making means ensuring global leaders recruited countries china brazil turkey russia viceversa encourage roche leaders developed countries share best practices gain handson experience emerging markets creating diverse group decisionmakers half story practicing inclusion equally important roche leaders need draw expertise knowledge different cultural norms integrating wide range perspectives crucial developing new medicines daniel oday chief operating officer roche pharmaceuticals roche annual report people roche ethnicity age gender experiences thinking styles actively included treated fairly respectfully backgrounds preferences behaviours equal access opportunities resources contributing fully organisations inclusion refers making mix work proactive success behaviours create environment people preparing workplace future world changing rapidly particularly terms groups people engaged productive requires demographics employee expectations technology leadership competence sensitive towards individual industrialised countries western europe japan needs well flexible solutions terms compensation example median age population steadily work arrangements technology professional development increasing birth rates decreasing means social responsibility shortages skilled labour years ahead attract retain best talent roche broad outreach programme includes strong presence global company roche social media platforms facebook linkedin thinking ahead beyond traditional recruiting universities business trends mean future schools collaborate actively academic institutions workplace webinars sharing business cases roche also offers number internships postdoctoral research positions experienced employees postpone retirement many developed countries earlyincareer people roche taken innovative approach seeking begin employment five generations working together capable people positioning globally aligned talent traditionalists baby boomers generations x scouts priority areas business specialists z proactively search qualified candidates build diverse talent pipelines positions difficult fill different generations common requirements critical business talent scouts also help cover well different values priorities keeping diverse prioritised gaps internal succession planning world population ageing department economic social affairs united nations roche annual report roche people building future open plan offices meeting rooms building roche investing three billion swiss francs new tallest building switzerland also one research infrastructure attractive workspaces basel energy efficient using waste heat generated headquarters next ten years first part production processes warmth ground water construction project building slated completion cooling stateoftheart video conferencing feature open communication zones enhance telepresence technology limit need travel collaboration among employees modular office spaces helping us keep environmental footprint control adapted required mix single offices developing full potential leaders results geos catalyst clarifying results geos show employees expectations managing leading people appreciate approach taking since roche intensive workshops involving many managers scores senior leadership risen percentage different levels produced succinct clearly worded points percentage points people focus leadership commitments embraced percentage points keeping promises managers levels company commitments cascaded global organisation addition developing current leaders also leaders giving personal examples mean welldefined succession talent management process daily practice developed roche roche ensure roche robust diverse pool commitments basis good leadership qualified candidates critical positions identify leadership high potentials early career provide commitments continued translated targeted development tangible processes define way manage lead people leadership commitments embedded leadership experience emerging markets performance management tool degree appraisals roche adapting leadership programmes reflect managers employee recognition interview guide global megatrends worlds future economic hiring new leaders growth come emerging markets roche investing heavily countries includes leadership leadership commitments also touchstone acceleration programme pharmaceuticals every development programme design around encourages leaders developed countries job leadership managers went rotations emerging markets viceversa goal leadingroche suite programmes catalyst addresses achieve critical mass diverse experience personal leadership strengths challenges regard decisionmaking reflect special needs patients leading change leading leadersroche physicians healthcare providers stakeholders increased selfawareness ability build trust areas world commitment engagement people complex environments leading peopleroche focuses bringing leadership commitments life role modelling million key positions visits career filled internal website candidates roche annual report people roche leadership commitments firmly believe person roche deserves great leader every day strive lead example consistently demonstrating values integrity courage passion take genuine interest people listen carefully tell truth explain empower trust people make decisions discover develop potential people strive excellence extraordinary results set priorities simplify work congratulate people job well done making employee careers personal initiative selfawareness starting points roche welldeveloped online jobs marketplace employee development roche offer number offers opportunities around world including online tools help individuals identify strengths well personalised alerts desired job profiles posted skill gaps plan training job experience employees want experience working another needed achieve career goals function country pursue shorterterm secondments job rotations return previous jobs leaders focused people business results recognise time learn develop outside important part job help employees roche also important certain criteria selfassessment career planning structured met employees may also take time work conversations supported practical guidelines sabbatical programmes roche learning organisation invests heavily global leadership development training courses improve skill base people includes huge online offering employees access location complete pace participants participants catalyst leading leadersroche leading peopleroche increase due rollout leading leadersroche june leading peopleroche roche annual report people spotlight professional development roche annual report spotlight professional development people unique chance share skills lifechanging experience katrin khhirt roche secondment year uganda katrin touched lives many children orphanage adapted realities local healthcare needs made lasting contributions gained new insights roche annual report learning overcome personal barriers katrin khhirt demonstrated leadership skills courage takes leave normal life behind work entire year africa always felt deep sense satisfaction helping worlds poorest countries sharing skills others perhaps goes back childhood east knowledge employees human impact goes germany berlin wall fell remember vividly beyond conventional financial aid return jobs thrill receiving packages food clothing invaluable insights healthcare needs relatives west germany parts world thanks hard work parents able finance chose work kids africa programme uganda education pharmacist intended volunteer swissbased charity created school farm work graduation instead took position healthcare clinic ten individual homes run local foster roche basel switzerland mothers orphaned abandoned children motto family children put adoption current job quality site manager solid dosage grow together healthy environment receive forms means inspect thirdparty manufacturers education contribute society liked ensure quality drugmaking process whenever combination selfhelp sustainability walk pharmacy see roche medicines part work first months uganda easy used tropical heat humidity food mostly never forgot desire humanitarian work consisted rice beans cornflour mash known got chance roche secondment programme posho projects planned didnt materialise programme allows employees meet certain criteria immediately accustomed work rapid pace spend one year handson project switzerland learn slow local population lives ugandans live kilometres away less health facility dollar dayspotlight professional development people one biggest challenges year kids projects planned africa taking charge ten children house didnt materialise immediately regular mummy away four weeks got kids ready school cleaned washed clothes accustomed work rapid cooked well entertained counselled pace switzerland also mentored several children including kevin learn slow stubborn boy barely spoke avoided eye contact gradually gained trust grew close kevin like son talk phone regularly particularly good kids steep learning curve settling helped helping children uganda transformed older children prepare school exams taught courses open people freer emotions hygiene diseases sexual education first aid work focused really important soon realised many children could see properly experience also strengthened connection organised eye examinations raised money roche remarkable company sends employees network family friends europe purchase abroad full year personal development eyeglasses amazing difference simple pair continuing pay salaries guaranteeing glasses make life child jobs return initiatives connection professional training mission company help people innovative improved process purchasing storing medicines medicines small way year uganda filled medical records simple notecards extension philosophy caring children child set sick bay put together firstaid kits may changed lives experience certainly changed mine day nurse left children often came hurt learned overcome fear blood helped bandage wounds also accompanied kids visits doctors hospitals one day made trip local hospital one boys cyst throat removed waiting room young girl approached warm smile right arm amputated elbow face severely scarred burns first reaction turn away would let still smiling looked eyes led hand stump arm traced burn marks face fingers intense moment acceptance love little girl taught something profound humanity overcoming barriers reach others remarkable company sends employee abroad full year personal development katrin mentored kevin year uganda still close bond besides financing high school studies kids outside kids africa community help children founded association sells jewellery sandals made local artist wwwmukisach ministry health ugandas health sector strategic investment plan promoting peoples health enhance socioeconomic development republic uganda poverty status report structural change poverty reduction uganda roche annual report key facts environment community environment community roche annual report environment community key facts share sustainable energy improvement ecobalance reduction roche accident rate years supporting mobile healthcare clinic south africa roche annual report roche environment community reducing environmental footprint whilst production sales grow strongly roche safety security health environmental protection forms integral part operations approach level commitment business related activity striving continuous improvement wherever possible economically viable monitor performance regularly ensure compliance addition spending million swiss francs high standards objectives well ensuring environmental purposes investments operating cost processes equipment state art safety security amounted million swiss prevention however key effective management francs hence total spending measures devote special attention main tool million swiss francs compared million professional risk management swiss francs decrease approximately midterm goals share improvement sustainable energy co emissions per employee improvement energy consumption per employee roche accident rate improvement ecobalance per employee roche illness rate goals based figures roche annual report environment community roche total investments projects amounted group audits million swiss francs increase compared internal audits improving monitoring performance followup company global production operations roche first time exposed risks could possibly damage people goods external audits environment reputation audits consulting followup training environmental protection occupational first time health safety minimise risks safety health enviromental protection employ people worldwide additionally people security expert teams followed earlier audits confirmed roche site identify risks develop mitigation plans improvements made interim period communicate policy guidelines employees recommended improvements following audits stakeholders motivate implement necessary included increasing involvement line management measures improving risk analysis effectiveness management system materiality reviewed frequently employees encouraged identify group constantly aware material areas improvement recommend changes required issues regularly gather information concerning using database best practices employees related risks opportunities roche affiliates well frequently share knowledge exchange new ideas consult listen stakeholder groups topics proposals database step match stakeholder issues adopted areas within organisation internal strategic priorities risks framework produce materiality matrix education awareness using method able identify material training best ways topics stand areas interest group stakeholders topics actively managed foster employee engagement group responsibility climate change compliance diseases civilisation see mind conduct regular training sessions energy resources regional conferences workshops provide online extremism organised crimes see tools local languages employees itsystems employees participated approximately hours natural disasters training occupational mental health pharmaceuticals environment audits assessments politics legislation policy audit critical sites chemical water pharmaceutical diagnostic manufacturing facilities every three years relevant sites periodically clear defined process roche creates progress according risk audits assess performance target setting series workshops aimed internal standards stipulate future roche group well discussions internal improvements plant management local officers external experts midterm targets set conduct frequent checks inspections assess period knowing material issues compliance standards want achieve able set targets initiate action plans new goals feasible challenging expect contract manufacturers suppliers service areas people environment business providers meet standards information see related roche websites ensure compliance thirdparty auditors retained us periodically inspect operations suppliers issue recommendations improvement event noncompliance may either terminate contract refuse renew roche annual report roche environment community occupational mental health absences work due occupational accidents accident rates roche occupational diseases including unhealthy stress negative impact company providing safe low working healthy workplace employees therefore priority towards reductions primary objectives keep roche accident rate rar reducing reduce roche illness rate rir less rar corresponds number working rar low level single accidents resulting days lost due occupational accidents per employee longer absences result sharp fluctuations per year rir corresponds number working days lost due occupational illness per employee per year incidence reported cases occupational illnesses increased furthermore related working approach days lost also increased previous responsible employer important us year increased overall roche illness rate everything possible prevent workrelated accidents higher illnesses therefore continuously improve occupational health safety measures set realistic employee safety health goals run projects aimed keeping accidents minimum established health safety committees virtually roche sites engaged technical activities roche accident rate production laboratories workshops roche illness rate warehouses many sites according risk levels number workrelated ccidents updated one group directives include workrelated f atalities mental health protection integral part working days lost per workplace risk assessment sites perfom year due accidents evaluation risks mental health furthermore workrelated ccidents maintain integrated programme employee consultation per million working workplace inspections training across business hours areas approach promote strong safety culture allows employees report address safety issues expect similarly rigorous policies occupational accident illness profile remains contractors consistent slips trips falls repetitive strains representing majority workrelated incidents performance sincerely regret thirdparty passenger died recorded injuries resulting roche road traffic accident indianapolis indiana carrying accident rate number days lost due duties injuries decreased number employees increased worked hours went rar went investments employees consider health safety important roche annual report environment community roche environmental sustainability research pharmaceutical diagnostic manufacturing water obtain view demand place dependent natural resources becoming earths ecosystems points added increasingly threatened roches environmental strategy related total number employees enables aims using natural resources raw materials fuel us monitor environmental impact per employee water sustainable manner company decreases environmental footprint turn benefits ecobalance stakeholders society reducing greenhouse gas ghg emissions preventing water scarcity well environmental health problems less roche primary depends nonrenewable resources less vulnerable energy supply constraints volatile market prices raw material water roche generate highvalue products relatively emissions low levels energy used operations air total energy use per million swiss francs products sold emissions terajoules compares well water pharmaceutical companies chemical industries landfilled setting goals able expand business waste utilising less energy hence reduce emissions part ecobalance commitment sustainable development proactively environmental seek employ new sustainable technologies impact processes minimise environmental footprint ecobalance per million achieve chf sales improvement ecobalance environmental impact per employee million impact points ecobalance established groupwide goal ecobalance ecobalance refers consumption energy allows local site management freedom develop resources emission byproducts waste locally appropriate strategies objectives reducing business activities describes total environmental environmental impact total environmental impact operations allocating environmental impact impact per employee decreased points ecologically relevant parameters approximately comprised emissions air consumption natural resources emissions air approximately co energy use roche annual report roche environment community improvements decreasing energy consumption share sustainable energy actual data goal volume withdrawn water emissions air water increase headcount positive effect environmental impact total use raw material increased raw material efficiency kg raw materials used per kg products produced improved natural capital roche committed conserving ecosystem services biodiversity order provide us overarching nonsustainable sustainable metric assesses compares risks opportunities across operations products supply chains today approximately energy used roche exploring idea natural capital evaluation comes fossil fuels nonrenewable depleting means placing monetary value environmental sources coal oil natural gas result impacts along entire supply chain business produce ghg mainly co waste products contribute climate change air pollution roche however faced number challenges associated natural capital evaluation lack aim maximise efficient harmonised framework difficulties gain access data impact analysed lies beyond company energy usage increase premises general putting impacts regional use sustainable energy context find data adequate quality also great challenges investigating best way forward continuing expand global business energy management roche committed minimising environmental footprint meaningful ways contributing sustainable energy future transform vision reality set cuttingedge technology optimised energysaving action plans across sites include constructions implementation innovative technologies continuous partnered department energys flexlab upgrading infrastructure improve energy efficiency lawrence berkeley national laboratory california picture purchase energyefficient equipment including hybrid use stateoftheart technology optimise energy dieselefficient cars review employees travel needs efficiency new buildings mounted rotating platform also change work processes complex task provides realistic model new building test highly regulated approved facilities focusing effects sunlight building temperature measure effects steady transition use sustainable thermal properties walls windows get precise energy idea comfort internal environment employees data incorporated design flexlab provides stateoftheart technology optimise energy efficiency new buildings helping save energy water roche annual report environment community roche new buildings significantly reduce heating californian sun approximately vehicles cooling demand energy water furthermore four electric vehicle chargers added allowing employees plug electric cars energy intensity consumption purchase electricity needed commute home roche actively reducing energy intensity measured roche energy used per employee well increasing energy consumption terajoules use energy sustainable sources energy conservation benefits environment avoiding air pollution reducing ghg emissions benefits roche total energy lowering costs increasing reputational value energy efficient use energy also ensures business continuity sustainable sustainable future generations come sources energy goal twofold first aim reduce energy intensity consumption gigajoules gj per employee per employee levels expect reduce energy gj consumption per employee approximately employee baseline levels second plan increase proportion sustainable energy used total energy consumed energy use type energy consumption decreased sales grew thus decoupling energy consumption natural gas growth business energysaving activities resulted grid electricity decrease energy used buildings stationary district heating equipment gas fuel oil waste electricity district heating decrease car fuel consumption air travel increase sustainable energy use bringing total waste share sustainable energy consumption oil reduction efforts around business travel started show effect although energy consumption air car fleet travel increased compared comprising total energy consumption air emissions energy intensity improved reaching aim avoid reduce control air pollutants line gjemployee end year therefore ecobalance goals despite increased production successfully reached surpassed roche group mid resulting continued strong growth term energy goal gjemployee well taking one overall objective keep emissions air low step towards reaching goal gj levels achieved past years employee emissions strategy prescribes continuous improvement absolute terms decreased overall energy manufacturing sites includes using flue gas consumption last five years energy scrubbers reduce nitrogen oxides sulphur dioxide intensity behaved similarly decreasing gj various incineration freezing processes employee gjemployee reduce release volatile organic compounds vocs may also reduce energy use solar power genentechs newest tool minimising impact environment sun new kilowatt photovoltaic system represents first foray world solar energy step forward roches global efforts use energy needs sustainable sources power generated provides electricity dixon california us site power generated pretty much year round adequate sunshine even winter solar arrays installed new parking lot canopies well buildings roof also offer shade roche annual report roche environment community emissions air tonnes developed softwarebased tool calculate intercompany direct delivery shipments uses one standard logistics service providers vocs provide data basis required manage scope particulates emissions coming years certified nitrogen oxides compliant eu iso standard requirements sulphur dioxide shipments modes transportation assessed single shipment basis allows us identify emissions drivers focus methods emission reduction emissions air roche sites low level means new processes activities well another initiative reduce ghg emissions roche timing sampling result fluctuations seen reduce use halogenated refrigerants used past years cooling equipment remain atmosphere long period time since made significant greenhouse gas emissions climate change progress reducing emissions halogenated hydrocarbons ghg emissions originated within eliminating halons reducing fully halogenated facilities scope amounted tonnes compounds except us genentech ghg emissions originating transformation ventana sites came later reduction purchased energy consumed us scope made programmes later target dates plan total amounted tonnes reduce halogenated refrigerants roche sites however recent acquisitions lack roches responsibility environment means actively alternatives countries means fulfilling goal drive programmes reduce ghg emissions unrealistic nevertheless continue examine majority ghg emissions originate alternatives work refrigeration suppliers make transformation use energy goal improving reductions companies integrated roche energy efficiency also applies ghg emissions ie group recently separate timelines set reduction measured tonnes per employee levels favour use carbon offset halogenated hydrocarbons tonnes alternative driving efforts reduce emissions expect achieve reductions substituting fossil fuels energy sustainable sources inventory emissions combined scope ghg change scope relating ownership percent occupancy building emissions cut carbon disclosure project reduction achieved implementing energysaving carbon disclosure project cdp ranked roche measures reducing amount fuel use heat cool second healthcare pharmaceuticals biotech operate sites sector dach region austria germany switzerland roche scored carbon disclosure index transportation via logistics service providers also achieved carbon performance rating score contributes ghg emissions reduce co footprint qualified us climate disclosure leadership index transportation need monitor overall emissions second successive year disclosure score confirms terms carbon accounting system understand business issues related climate co equivalent emissions metric tonnes base year scope halogenated hydrocarbons scope scope total total emissions per million chf sales tonnes includes co business flights roche annual report environment community roche change building climaterelated risks half water draw used cooling opportunities core business roches performance score circuits even though water chemically signals measuring verifying managing contaminated analyse directly discharged carbon footprint cdp publishes two indices rest purified treatment plants released order increase transparency ghg emissions reporting waterways performance record organic emissions water processing waste water treatment plant total organic carbon toc discharge waste waters pollutants comply fully relevant regulations including pretreatment requirements approximately measured toc water management reduction elimination rates waste water treatment business dependent reliable supplies high plants already high seek minimise quality water almost chemical biotech pharmaceutical contamination water diagnostics manufacturing processes involve water reducing discharges toxic poorly biodegradable reagent solvent cleaning cooling agent substances heavy metals pharmaceutical industry globally poor quality water reducing generation waste water resulting higher costs purification greater risk treating pretreating waste water ozone product contamination also use water energy cases non poorlydegradable contaminants carrier refrigeration heating installations use water remained relatively unchanged approach past years withdrew million water roche aware demand fresh water increasing different sources approximately effective water management crucial avoiding consumed becoming constituent part product water scarcity therefore roche sites either working vaporised refrigeration air conditioning plants implementing programmes reduce water consumption used irrigation water chemically recycle reuse water view water supply contaminated could therefore directly discharged use best managed monitored locally reason sent treatment plants chemically contaminated shegoal reduce water consumption waste water resulting discharge tonnes per employee weighted according water organic matter kilogrammes heavy metals stress region small increase discharges also support global efforts promote water protection conservation improve access clean drinking compares favourably water furthermore aim reduce total waste water sales growth seen toxicity baseline meantime continue investigate reliable performance indicators measurement methods establishing waste water toxicity baseline roche annual report roche environment community roche aware sites located regions roche produced tonnes chemical waste water scarce thus valued commodity tonnes general waste comprised sites monitor water situation locally procedures tonnes construction demolition waste activities place ensure efficient water usage business sites clarecastle ireland indianapolis indiana continuity waterrelated issues affect reputation nutley new jersey contributed increase seen investors increasingly showing interest water policy performance therefore roche participated natural disasters cdps water programme roche operations regions world susceptible natural disasters earthquake tornados waste management flooding financial risk event however accept responsibility waste generated minimal necessity suspend procedures operations including previously deposited sites due natural disaster roche possibility transfer landfills permit landfilling last resort operations another site thereby ensuring continual even inert materials slag incineration supply access products minimise damage ash depending availability suitable local waste operations managed issue treatment plants may dispose nonhazardous general example ensuring threatened sites earthquake waste authorised landfills proof built withstand tornados performance waste parameter ecobalance waste reduction targets reflected goal improve groups ecobalance compared waste reduction goals set local level primarily large yeartoyear fluctuations waste construction demolition activities example security protecting employees physical assets critical information preventative measures integrity brands products principal concerns roche priority aspects security one focus launch global logistics security programme pharmaceuticals division furthermore new group directive issued goal improve systematically protection reporting year give guidance adequate security products theft manipulation transportation measures exposed roche personnel families storage thirdparty warehouses small team working highrisk countries led global pharma supply chain comprising security logistics experts different regions performed system security training sessions delivered guidance risk assessment roche continually aware issues surrounding auditing local logistics security officers security vulnerability systems ever growing necessity protect intellectual property second security focus set latin implications digital fraud go far beyond financial risks american security workshop held rio de janeiro brasil despite protective measures already taken site security officers sites latin america roche occurrence cyberattack considered discussed challenges good practices three key possible effort towards minimising events topics region personnel security logistics security identify attackers threats assess likely target product counterfeiting assess impact attack organisation finally identify assets high impact require prioritising terms protection roche annual report environment community roche pharmaceuticals environment traces pharmaceutical products enter environment roches bestselling variety ways including manufacturing process improper disposal unused medicines natural antibodies judged metabolic processes following normal patient use far represent significant risk patient use generally recognised primary contributor environment evidence suggests exposure resulting trace concentrations surface ground drinking water rituxan avastin herceptin lucentis monoclonal pose harm human health risks aquatic life antibodies generated large proportion roches thought greater scientific studies identified group sales belong defined class shortterm effects exposure lowlevel active pharmaceutical ingredients apis exempt concentrations pharmaceuticals research european medicines evaluation agency ema guideline conducted evaluate potential longterm impacts environmental risk assessment low excretion rate judged present significant risk sewage roche acting concerns impact works surface waters therefore termed benign pharmaceuticals environment considering nature constitute environmentally sustainable entire lifecycle products many crucial compounds chemical products however diagnostic tests lifesaving medicines two goals subjected rigorous environmental risk asessment first safeguard ecosystem secondly protect business potential longterm financial reputational risks legislation compliance meet local laws regulations however group chemicals reach requirements globally policies often rigorous external standards harmonised system classification labelling fully track registration chemical chemicals eleven consecutive years prior materials according european legislation incurred significant fines sherelated violations registration evaluation authorisation restriction incurred fines roche annual report roche environment community focusing remediation management waste inevitable byproduct industrial phase technical investigation based findings operation pharmaceutical sector exception competent authorities decided landfill required since roche researching developing remediation two years refined planning complex manufacturing marketing highquality innovative remediation project permitted excavation solutions unmet medical needs nature work commences required infrastructure finalised synthesis chemical pharmaceutical substances comprising bypass road new temporary ship landing results desired compound also dock metre deep pile wall surrounding byproducts ultimately disposed excavation pit chemical waste historically insufficient knowhow along lack appropriate technical resources resulted project track completed area landfilling common disposal method however remediated enclosed waste material improved knowledge geological characteristics including contaminated soil groundwater adverse impacts associated chemical contamination removed waste packed stored special soil groundwater faced potential long transport containers transported rail term risk people environment disposal facilities europe thermal treatment careful planning stepbystep procedure roche ensure safe efficient execution complex roche accepts full responsibility remediation programme remediation take place waste generated quickly possible however delivering flawless execution utmost priority completion remediation operations including area available industrial redevelopment previously deposited landfills information available wwwkesslergrubecom roche ceased business operations site roche believes existing landfills contain hazardous nutley new jersey years facilitate sale wastes thereby threatening environment repurposing property roche accelerated addressed proactively even means applying solutions remediation efforts oversight exceeding countrys legal framework new jersey department environmental protection njdep us environmental protection agency roche deposited waste material kesslergrube landfill grenzach germany mids roche already taken initial cleanup action address former gravel pit turned landfill received wastes soil groundwater contamination prepares years thereafter evolving legislation submits final remediation plans njdep approval contaminated site management triggered historical multi site nutley new jersey soil samples collected evaluated part extensive remediation efforts roche annual report environment community roche remediation complex process wide range roche actively technologies explored determine best remedies clean site safely quickly part manage historical contaminated nutley site environmental investigation soil site issues also strive avoid samples collected evaluated future liabilities cleanup soil expected completed end groundwater cleanup take longer roche conducting quarterly monitoring continue remediation process also involves transparent several years ensure remedies local officials residents communities positive impact contamination divesting site surrounding nutley site regarding extent anticipated end roche retain contamination impact roche plans address responsibility environmental cleanup monitoring roche hosted two public meetings may remedial activities nutley site october host additional meetings future information available wwwrocheusacom roche annual report environment community spotlight sustainability roche annual report spotlight sustainability environment community sustainability part everything katie excoffier katie switched careers become sustainability manager genentech enthusiasm ability connect people moved needle engaging employees reducing companys environmental footprint roche annual report employees drive sustainability broad employee participation helped genentech reduce energy water usage waste five major buildings two years years working r management costs saved leading laboratory equipment manufacturer california us decided take time break saw compelling documentary urgency act climate change inspired reevaluate career goals reflect could contribute positive change decided pursue mba sustainable management led job sustainability intern genentech knew reputation company million usd scientific background genetics living san francisco bay area thrilled hired fulltime sustainability manager sustainability crossfunctional issue often requires meaningful way work many employees expertise input range different people environmentalists home sure bring important part job connect right people lifestyle workplace enlisting employees resources across genentech make things happen sustainability ambassadors educational assembled sustainability council develop outreach able overcome challenge sustainability strategy goals encourage cross functional collaboration also liaise companies tenure green genes grown share best practices sustainability leverage total genentech employees leading benchmark collective influence realise sustainability benefits terms employee engagement sustainability addition green guides deeper level training environmental expertise guides lead one tasks connect teams energy water recycling transportation right people resources make wellbeing green biopharma work team set activities recycling month earth week beach things happen cleanups lunch learns awareness events high level engagement evolved organisational started position sustainability manager structure gave us solid foundation new initiative already successful programme called green genes alongside leading companies participated engaged employees environmental sustainability us green building councils best buildings challenge part role provide deeper opportunities committed reducing energy waste water usage employees live commitment sustainability within two years aim achieve thesespotlight sustainability environment community reductions peremployee basis five high occupancy buildings included energy water intensive lab buildings one challenges faced launched initiative known internally dash lack detailed data installed new water meters smart lighting sensors wifienabled energyuse strips office cubicles specific information able prioritise efforts share progress employees touch screen dashboards dash buildings june concluded dash results exceeded expectations reducing energy water usage waste per employee financial returns investments showed sustainability also makes good business sense saved million gallons green genes engagement environmental sustainability exists high levels water two years helping employees welcome suggestions implement workplace conserve historic drought california partnership usgbc building health initiative joining companies make buildings water savings particularly important healthy occupants first important community given based california step require increased transparency suppliers experiencing one worst droughts history content building materials office furniture areas farmers struggling irrigate crops make informed decisions wells drinking water drying finetuning purchase airconditioning systems replacing waterthirsty lawns droughtresistant landscaping initiatives see increasing number employees want saved million gallons litres something environment build momentum water two years efforts helped prevent mobilise colleagues families friends mandatory water restrictions might jeopardise make meaningful difference impact world production lifesaving medicines around us energyefficient new building currently construction contribute efforts significantly reducing heating cooling demand energy water construction optimised using innovative flexlab technology see energy water consumption e c r eas e waste roche annual report roche environment community making difference philanthropy since foundation almost years ago roche committed supporting people need innovative sustainable partnerships carefully choose projects based criteria commitment collaboration continuity ensure engagement impact longlasting pillars philanthropic engagement community humanitarian science art environment education culture involvement social projects focus ongoing initiatives sustainable projects sponsorship sustainable health partnerships contribution essential component programmes transnetphelophepa healthcare train mobile clinic sustainability bringing medical care medicines remote communities south africa celebrated th anniversary recognised around world innovation immense main external sponsor roche proud initiatives service people phelophepa twice sigma success significant impact since start phelophepa theta tau award prestigious nursing award provided primary care dental eye checks treatments united nations public services award diagnosed conditions health education counselling million people japan chugai pharmaceutical co ltd member roche group also milestone anniversary one hallmark philanthropic projects years counselling hygiene running chugai donated specially equipped paratransit prevention could improve vehicles five organisations providing welfare services senior citizens disabled people throughout japan since health many people villages programme began chugai donated visited trains vehicles support people receiving longterm nursing care home service many people region come meanwhile roche childrens walk gives every employee rely every year phelophepas two medicalised trains visit chance raise funds children need half combined total communities many donations given local projects rest goes one doctor many patients support schools orphan day care centres malawi trains operated resident staff team volunteer roche sites participated childrens walk student doctors nurses since first journey largest number participating sites since phelophepa counts volunteers whose first walk far donations helped support roche annual report environment community roche orphan children school uniforms another important initiative reporting year million meals disaster relief earthquake victims china severe earthquake killed injured people innovative disaster response ludian county yunnan province august roche roche also provides support donations following natural china immediately activated disaster response plan disasters order ensure sustainable response reaching local red cross donating value collaborate early stage local roche affiliates swiss francs doses onsite implementation partners contributions rocephin addition roche china employees organised range material goods logistic support transfer fundraising activities support ongoing disaster response knowledge experience efforts region supporting innovation arts science natural disaster occurs roche also supports groundbreaking contemporary art roche listens needs cultural projects activities explore parallels innovation art science forms ground works local basis unique collaboration roche partners provide sustainable lucerne festival lucerne festival academy roche commissions roche young commissions support funded two philanthropic activities promote non mainstream classical contemporary music composers typhoon yolanda one strongest tropical storms ever olga neuwirth named winner roche recorded devastated several parts philippines commissions series austrian composer ranks among november many small povertystricken coastal important figures contemporary classical music communities naborot island province iloilo today compositions premiered among worst hit help restoration performed lucerne festival academy orchestra efforts roche philippines committed support families collaborated myshelter foundation install solar bottle lights homes naborot innovative technology uses recycled onelitre plastic bottle small solar panel battery led light provide free source ecofriendly light installed myshelter foundations liter light project initiative supported roche philippines bottle lights brighten homes phelophepa tswana sotho dialects means good clean health roche annual report key facts corporate governance remuneration report corporate governance remuneration report roche annual report corporate governance remuneration report key facts foundation roche years specialised leader researchfocused healthcare combined strengths pharmaceuticals diagnostics th consecutive year roche recognised dow jones sustainability indexes djsi group leader sustainability within pharmaceuticals biotechnology life sciences industry roche annual report roche corporate governance corporate governance roche committed serving stakeholders basis printed annual report contains selected links successful implementation commitment roche website wwwrochecom readers thus corporate governance principles accordingly put focus provided snapshot company business activities sustainable value creation reporting date also directed sources innovation prescribe management culture conforming consult time uptodate information recognised standards corporate governance corporate governance roche whereas annual policy transparent communication report covers single financial year ending december website contains information permanent strong board directors represents interests nature well latest roche news companys shareholders stakeholders highly articles incorporation bylaws curricula vitae skilled managers act integrity extremely members board directors corporate important executive committee published website th consecutive year roche details please refer following report recognised dow jones sustainability indexes djsi group leader sustainability within pharmaceuticals biotechnology life sciences industry sustainability core business practices award reflects commitment running business way ethical responsible creates longterm value stakeholders corporate governance report sets structures processes rules roche takes basis wellfunctioning corporate governance roche complies relevant corporate governance requirements particular applicable laws swiss stock exchange six swiss exchange directives including commentaries thereto swiss code best practice corporate governance promulgated swiss business federation economiesuisse companys internal governance framework particularly articles incorporation bylaws embodies principles needed ensure companys businesses managed supervised manner consistent good corporate governance including necessary checks balances httpwwwrochecomaboutrochecorporategovernancehtm roche annual report corporate governance roche board directors implementing ordinance excessive board directors corporate compensation listed corporations verordnung gegen executive committee bermssige vergtungen bei brsenkotierten aktiengesellschaften vegv th annual general board directors also already introduced meeting agm roche holding ltd march executed occasion agm march shareholders approved corresponding required amendments mandatory votes remuneration well articles incorporation elected members remote electronic ballot means authorisations board directors standing election chairman instructions independent proxy board directors members remuneration committee independent proxy oneyear term september arthur levinson resigned board directors remuneration committee shareholders elected christoph franz new chairman immediate effect board directors succeeding franz b humer franz b humer william burns decided stand forthcoming agm march board reelection retired board furthermore directors nominates chairman remaining members agm elected andr hoffmann pius baschera john bell board directors reelection following paul bulcke deanne julius arthur levinson andreas members board directors members oeri severin schwan peter r voser beatrice weder remuneration committee christoph franz andr hoffmann di mauro members board directors new peter r voser additionally board directors nominates term one year provided articles incorporation bernard poussot richard p lifton election first time agm elected christoph franz andr board directors moreover bernard poussot nominated hoffmann arthur levinson peter r voser board directors election new member members remuneration committee remuneration committee organising meeting immediately following agm board directors nominates bdo ag board directors determined structure independent proxy period composition remaining committees shown conclusion ordinary annual general meeting composition december see also pages shareholders election agm name year birth first elected board directors dr christoph franz c e chairman andr hoffmann c e vicechairman representative shareholder group pooled voting rights dr andreas oeri e representative shareholder group pooled voting rights prof pius baschera e prof sir john irving bell b e paul bulcke b e dame deanne julius b e dr severin schwan f peter r voser c e prof beatrice weder di mauro b e secretary dr gottlieb keller board directors honorary chairman dr fritz gerber board directors corporate governance sustainability committee b audit committee c remuneration committee presidiumnomination committee e nonexecutive director f executive director committee chairperson roche annual report roche corporate governance corporate executive committee memberships corporate executive committee information member corporate executive remained unchanged committee enlarged corporate executive committee listed composition december richard scheller head genentech research early see also pages board development gred member enlarged corporate directors corporate executive committee executive committee retired december january michael varney former head small molecule drug discovery became head gred member enlarged corporate executive committee roche name year birth position corporate executive committee dr severin schwan ceo roche group daniel oday coo division roche pharmaceuticals roland diggelmann coo division roche diagnostics dr alan hippe chief financial officer silvia ayyoubi head group human resources dr gottlieb keller general counsel enlarged corporate executive osamu nagayama chairman ceo chugai committee december dr richard scheller head genentech research january dr michael varney early development gred prof john c reed head roche pharma research early development pred dr stephan feldhaus head group communications dr sophie kornowskibonnet head roche partnering secretary corporate perolof attinger executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey since chief compliance officer dr urs jaisli roche annual report corporate governance roche information relating corporate governance group structure shareholders capital structure roches operating businesses organised two information roches capital structure provided divisions pharmaceuticals diagnostics finance report notes financial statements pharmaceuticals division comprises two business roche holding ltd additional details segments roche pharmaceuticals chugai whereas contained articles incorporation roche genentech former third segment holding ltd integrated roche pharmaceuticals diagnostics movement recognised amounts last three division consists following four business areas financial years detailed finance report diabetes care molecular diagnostics professional notes financial statements roche holding ltd diagnostics tissue diagnostics business activities carried group company share capital swiss subsidiaries associated companies detailed francs divided fully paid bearer shares information roche holding ltd significant nominal value swiss franc subsidiaries associated companies including restrictions exercise voting rights company name listing information domicile share shares upon deposit shares voted without capital equity interest listed finance restrictions report note roche group consolidated authorised conditional capital financial statements subsidiaries associates addition nonvoting equity securities nes issued bearer form major shareholders listed finance report form part share capital confer voting notes roche group consolidated rights nes confers rights one share financial statements equity attributable roche participate available earnings liquidation shareholders related parties pages proceeds following repayment share capital note financial statements roche roches nes rights pertaining thereto including holding ltd significant shareholders provisions protecting interests nes holders addition significant shareholders published described articles incorporation relevant webpage disclosure office roche holding ltd six exchange regulation httpwwwsixexchange information debt instruments issued regulationcomobligationsdisclosuremajor outstanding bonds provided finance shareholdersenhtml report note roche group consolidated andr hoffmann vicechairman board financial statements debt directors chairman remuneration committee information employee stock options provided andreas oeri member board directors finance report note roche group chairman boards corporate governance consolidated financial statements equity sustainability committee serve respective compensation plans including detailed capacities board committees information stocksettled stock appreciation representatives shareholder group pooled rights ssars plan roche restricted stock voting rights receive remuneration set forth unit plan roche performance share plan roche remuneration report finance connect roche option plan report note roche group consolidated roche issued options apart employee stock financial statements related parties options provided finance report note relationships exist shareholders roche group consolidated financial statements equity pooled voting rights compensation plans options issued crossshareholdings connection debt instruments neither options awarded employees debt instruments issued effect roches share capital httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm roche annual report roche corporate governance board directors corporate executive responsibilities defined detail bylaws committee board directors information member board directors committees chaired independent directors including years first election according bylaws board directors member corporate executive committee listed board meeting may convened without chairman pages members board directors present request members roche age limit restriction term office board meets year assess chairmans curricula vitae current former members performance meeting attended last five years bodies information chairman chaired one vicechairmen including information board memberships additional part management information system mis positions memberships activities available board directors informed continuously updated internet important issues sales performance etc monthly rules pursuant article para point vegv basis board access electronic information number permitted activities board directors platform provides timely information board corporate executive committee members directors boards committees outlined articles incorporation roche system controls set forth holding ltd board directors established system since annual general meeting elects controls continuously monitored audit members board directors chairman committee corporate governance board directors members remuneration sustainability committee board directors committee annual basis elections consists following elements nominee voted separately see articles report operating financial risks incorporation roche holding ltd minutes risk management system th annual general meeting roche holding ltd roche group established risk management held march process covering entire company system exception severin schwan none place identify manage type risks members board directors office end potentially affecting business including economic member roches corporate environmental social impacts risks executive committee served executive capacity opportunities containing stakeholder input group subsidiary three financial years board directors highest governance proceeding current reporting period body involved roches risk management policy sets lack existing business connections group approach accompanying responsibilities subsidiary independent pharmaceuticals diagnostics divisions principles governance principles delegation global functions conduct formal risk assessment competence reservation powers management process least year must develop risk group companies executive bodies plans material risks company include economic environmental social monitored deviations reviewed regular topics principles together internal performance dialogues consolidated group risk organisation board directors division report including target risk profile discussed authority responsibilities board corporate executive committee approved management remits board committees together group business plan material information control mechanisms available risks reviewed board yearly basis board dealings corporate management process subject regular reviews governed bylaws findings presented audit committee board directors roche holding ltd organised full board effectiveness risk management ensure group conducts businesses process monitored group risk advisory responsibly focus longterm value creation team overall process regularly reviewed end roche board delegated certain external auditors last external review responsibilities several committees composition findings presented corporate executive chairpersons december described committee audit committee committees authorities board httpwwwrochecomaboutrochemanagementboardofdirectorshtm httpwwwrochecomaboutrochemanagementexecutivecommitteehtm httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm httpwwwrochecomaboutrochecorporategovernanceannualgeneralmeetingshtm httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm httpwwwrochecomaboutrochecorporategovernancecommitteeshtm httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm roche annual report corporate governance roche details risk management including risk factors conducting operational audits group audit risk management policy see risk determines managements response risks management compliance website financial surrounding business processes systems risk management specifically described evaluates appropriateness completeness finance report efficiency processes controls action plans system internal controls financial reporting implement necessary changes enhancements see pages finance report developed together businessauditee internal audit tracked completion group audit reports general counsel statutory auditors see direct access gives regular briefings audit chief compliance officer compliance officers committee ongoing activities audit reports subsidiaries see chief audit risk advisory executive attends safety health environmental protection audit committee meetings external department auditors corporate sustainability committee group audit independent appraisal function science ethics advisory group seag evaluates reviews groups activities issues relating genetics genetic engineering service management annual audit plan established yearly defined focus areas eg emerging markets members corporate executive committee thirdparty management validated senior invited attend meetings board directors management presented audit committee report person agenda items concerning roche group committed maintaining high situation warrants members standard internal control throughout worldwide enlarged corporate executive committee may also operations management responsible assessing invited attend board committees invite business risks aspects operation chairman board corporate executive implementing effective efficient processes committee members deliver reports committee controls whilst ensuring compliance internal meetings may elect commission independent external rules regulations expert reports call services consultants board board committees attendance corporate g overnance presidium nomination remuneration audit sustainability board c ommittee c ommittee c ommittee c ommittee number meetings ch franz hoffmann p baschera j bell p bulcke julius schwan oeri p r voser b weder di mauro franz b humer william burns ad levinson member committee invited guest board committee meetings httpwwwrochecomcorporateresponsibilitybusinessethicsriskmanagementandcompliancehtm additional information provided finance report note roche group consolidated financial statements risk management httpwwwrochecomcorporateresponsibilityenvironmenthtm httpwwwrochecomcorporateresponsibilityhtm httpwwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm roche annual report roche corporate governance year several blackout periods imposed following rules remuneration shareholdings senior employees prohibited trading loans board directors board company stock following blackout periods corporate executive committee cec set forth effect articles incorporation aoi december january april april rules aol june july october october content board cec blackout periods changed chairman rules principles applicable board directors circumstances warrant performancerelated pay board directors met meetings rules principles generally hours length addition allocation equity securities convertible rights options fullday meeting day visit major subsidiary board committees met additional amount payments members executive follows committee appointed vote presidium board directorsnomination pay general meeting committee meetings approx hours shareholders remuneration committee meetings approx rules loans credit facilities hours postemployment benefits audit committee meetings approx hours rules vote pay agm corporate governance sustainability committee meetings approx hours composition boards committees remained participatory rights shareholders unchanged since march exception participatory rights shareholders defined members board directors retired roches articles incorporation roche shares board directors regularly conducts assessment issued bearer restrictions admission selfassessmentassessment third parties via annual general meetings exception electronical survey performance shares must deposited within specified period members corporate executive committee date meeting admittance card maximum ordinary notice period twelve months must issued shareholders name provided management contracts fall within articles incorporation shareholder scope subsection annex six directive elect represented third party annual information relating corporate governance general meeting articles incorporation contain restrictions remuneration shareholdings loans exercise voting rights quorum details regarding remuneration shareholdings requirements stipulated conformity loans content method determining swiss code obligations compensation shareholding programmes articles incorporation shareholders basic principles elements compensation representing shares nominal value least shareholding programmes serving former million swiss francs request placement members board directors corporate items agenda annual general meeting executive committee together description must done later days date authorities procedure determining meeting set forth separate remuneration report rules issue instructions independent pages finance report notes proxy rules electronic participation roche group consolidated financial agm laid corresponding invitation statements equity attributable roche shareholders agm regulated articles related parties pages incorporation listed note financial statements roche holding ltd board executive shareholdings figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activities remuneration committee members recuse deliberations decisions matters affect interests httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm roche annual report corporate governance roche change control defensive measures statutory auditors elected year articles incorporation contain provisions annual general meeting mandatory bid rule swiss law applies changeofcontrol clauses auditing services provided legally required components remuneration based roche nes would terminated event acquisition auditrelated services include assurance accounting vesting period restrictions preexisting awards services provided auditors would removed options could necessarily provided statutory auditor exercised immediately services include audits pension funds employee benefit plans internal control reviews go beyond relationship statutory auditors legal requirements attestation services annual general meeting roche holding ltd comfort letters consents consultation march shareholders voted appoint kpmg ag kpmg statutory auditors based tax services include services respect compliance existing legal requirements swiss code tax returns tax advice except services related obligations article concerning maximum audit tax term office seven years auditor charge ian starkey replaced predecessor john morris services include advice relating process auditorincharge starting business year improvements regulations trainings information long auditors auditorin charge serving capacities provided company formal policy governing statutory auditors participate audit engagement statutory auditor nonaudit committee meetings prepare written oral services policy prohibits certain services reports results audits audit committee provided permits certain services limits oversees assesses auditors makes agreed audit committee potential nonaudit recommendations board information service engagement reviewed policy authorities responsibilities audit committee authority proceed given see article bylaws statutory auditors participated meetings audit committee relationship independent proxy recent years bdo ag served independent proxy first time annual general meeting reports statutory auditor consolidated march shareholders elected bdo ag financial statements financial statements independent proxy period found pages respectively conclusion ordinary annual general meeting years finance report shareholders bdo ag paid services according expenditure totalling swiss kpmg received following remuneration francs swiss francs services statutory auditors roche holding ltd auditors roche companies including rules issue instructions independent chugai proxy rules electronic participation agm laid corresponding invitation agm regulated articles millions chf incorporation auditing services auditrelated services accounting assurance tax services services total httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm roche annual report roche corporate governance information policy uncertainties interpretation roche provided articles incorporation group code conduct reference documents corporate notices published swiss official furthermore serve platform ideas gazette commerce daily newspapers suggestions concerning documents designated board directors basler zeitung finanz und wirtschaft lagefi le temps neue zrcher addition roche established business ethics zeitung incident reporting beir system enables roche reports halfyear fullyear results chief compliance officer capture track monitor business reports published print online formats alleged violations initial reports local compliance media events addition detailed first officers resolution business ethics incidents thirdquarter sales figures published year recorded system local management april october current list publication receives specific concrete information dates available english german internet alleged violation roche group code conduct relevant information documents including one certain predefined categories corporate media releases investor updates presentations governance sustainability committee audit analyst investor conferences available committee board directors informed internet publications ordered email substantial violations fax telephone baselwebmasterrochecom chief compliance officer reports general tel counsel also submits regular reports fax corporate governance sustainability committee contact address investor relations audit committee board directors f hoffmannla roche ltd investor relations group finance basel switzerland nonapplicabilitynegative disclosure tel expressly noted information contained fax mentioned herein either nonapplicable omission construed negative declaration additional information including details specific provided six swiss exchange corporate contact persons available internet governance directive commentary thereto chief compliance officer compliance officers network chief compliance officer compliance officers network committed ensuring roche group code conduct consistently complied throughout roche group also serves contact person shareholders employees customers suppliers general public issues relating implementation compliance code employees parties become aware violations roche group code conduct bring attention managers supervisors report chief compliance officer urs jaisli direct phone number email ursjaislirochecom disclosures treated confidentially addition end employees may anonymously report irregularities complaints mother tongue via speakup hotline starting december new compliance tool group level socalled roche group code conduct help advice line introduced strives provide guidance case questions httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm httpwwwrochecommediahtm httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernancecodeofconducthtm httpwwwrochecomcorporateresponsibilitybusinessethicsriskmanagementandcompliancehtm roche annual report corporate governance roche roche annual report roche remuneration report remuneration report principles key principles underpinning policy roches success depends abilities dedication focus value creation entire people recognition forms basis pay performance remuneration policy system enabling employees share companys success balanced mix long shortterm remuneration roche strive create new innovative products components benefit patients requires outstanding performance market competitiveness employees takes continuous innovation help fairness transparency remuneration decisions patients sustain revenues create longterm value innovation enables us pay competitive compensation employees distribute rising dividends remuneration decision process shareholders dividend increase th year year remuneration committee roches board row directors meets least twice decides remuneration board members members groups corporate roche regularly reviews policy principles executive committee base pay bonuses stocksettled remuneration part framework employee stock appreciation rights ssars restricted stock units policies aimed motivating retaining current rsus policy decisions pension benefits employees attracting talented new ones helping terms performance share plan psp awards decided roche employees perform consistently high levels annually board directors acting upon remuneration policy designed foster value creation recommendations remuneration committee reinforce culture performance innovation first time total aggregate amounts applies nonmanagerial employees managers based decisions submitted general meeting approval implementing ordinance stocksettled stock appreciation rights ssars excessive compensation listed corporations verordnung restricted stock units rsus performance share plan gegen bermssige vergtungen bei brsenkotierten psp remuneration components intended align aktiengesellschaften vegv general meeting shall managements interests shareholders vote annually binding effect approval holders nonvoting equity securities give remuneration board directors resolved participating managers additional incentive achieve board directors corporate executive continued value growth form longterm total committee details see shareholder returns creating value roche investors management benefits well added value remuneration committee tracks market data salaries created investors management penalised receiving leading global pharmaceuticals companies less reports findings full board external consulting firm pricewaterhousecoopers pwc assists roche performing market comparisons advising remuneration committee information remuneration committees remit powers procedures making remuneration decisions found bylaws roche board directors also outlined sections principles governing specific remuneration components peer set abbott laboratories abbvie amgen astellas astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda compared without becton dickinson httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm roche annual report remuneration report roche summary main activities interests interests roches shareholders following key developments decisions groups longterm success performance share plan psp awards variable past three years proven decisive psp cycle targeted nes performance share plan year end prices awarded psp targeted nonvoting equity securities nes increased nes awarded case psp psp value shares led billion psp psp cycles swiss francs rise value company payouts awards targeted nes billion swiss francs billion swiss francs plans key performance metric award total represents increase shareholder return tsr calculated threemonth roche shares rose swiss francs moving average constant chf exchange rates see swiss francs past year nonvoting equity e performance share plan psp securities swiss francs swiss remuneration committee decided francs roches value rose line billion swiss chief executive officer ceo cec members francs billion swiss francs billion must acquire roche shares andor nonvoting equity swiss francs securities nes equivalent two annual base salaries dividends risen every year steadily past ceo one annual base salary cec members years dividend billion swiss francs respectively end retain holdings distributed long serve cec remuneration committee assisted addition applicable statutory provisions roches consultancy pwc regularly tracked base pay longterm incentive plans include option partially roche directors members corporate executive reclaim distributed compensation result special committee market data payments circumstances clawback details see leading global pharmaceuticals companies see footnote major swiss companies details please refer following sections base salaries fixed paid corporate executive remuneration report committee cec members except roland diggelmann remained unchanged bonus variable paid cec members financial year consist entirely cash payments except case ceo severin schwan reflects sales growth increase core earnings per share constant exchange rates cer progress product development pipeline stocksettled stock appreciation rights ssars variable ssars granted cec members vest together three years exercised within seven years grant date unexercised ssars lapse without compensation since fair value ssars calculated grant date using trinomial model american options details see restricted stock units rsus rights receive nonvoting equity securities threeyear vesting period plus value adjustment amount equivalent sum dividend paid vesting period attributable number nonvoting equity securities individual award granted introduced new remuneration component partially replacing ssars options value ssar awards reduced balance awarded form rsus aim strengthen alignment managements abb credit suisse holcim nestl swiss ubs zurich insurance group actelion nobel biocare sonova straumann synthes see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings calculations basis total number shares nes roche annual report roche remuneration report remuneration components disclose individual performance objectives base pay bonuses blocked nonvoting equity securities members corporate executive committee nes awards stocksettled stock appreciation rights ssars restricted stock units rsus performance december end reporting year january share plan psp support fundamental aims roches following reporting year remuneration committee remuneration policy remuneration components decides bonuses payable chairman board linked employees performance companys members corporate executive committee financial performance commercial success thus respect current reporting year based performance align interests roche employees aforementioned objectives time shareholders remuneration committee also decides form bonuses awarded cash payments andor blocked nonvoting explaining principles govern various equity securities andor blocked shares remuneration components report details amounts paid member board directors c stocksettled stock appreciation rights components chairmen boards remuneration ssars amount remuneration component paid stocksettled stock appreciation rights ssars plan member corporate executive committee introduced january establishing uniform financial year system remuneration throughout roche ssars entitle holders benefit financially increase value previous year board directors roches nonvoting equity securities grant separately submit total aggregate bonuses date exercise date chairmen board directors corporate executive committee general meeting ssar awards allocated individually remuneration financial year retrospectively binding approval committees discretion maximum amounts total aggregate remuneration restricted stock units rsus excluding bonuses board directors restricted stock units rsus rights receive corporate executive committee period nonvoting equity securities andor shares three year ordinary general meeting ordinary general vesting period plus value adjustment amount meeting tabled previous year equivalent sum dividend paid vesting general meetings prospectively binding approval period attributable number nonvoting equity see b securities individual award granted introduced new remuneration component base pay partially replacing ssars value ssar awards base pay cash payment determined position reduced balance awarded form based salary market data leading global rsus pharmaceuticals companies see footnote major swiss companies see footnote reflects rsu awards allocated individually remuneration individuals abilities experience performance committees discretion vested recipient time pay adjustments likewise linked individual three years thereafter resulting nonvoting equity performance take account prevailing market securities may remain blocked years conditions companys overall financial situation e performance share plan remuneration committee makes reviews final members corporate executive committee decision individual base pay paid chairman members senior management currently board directors members corporate individuals worldwide participate performance share executive committee remuneration plan psp established periods three members board years based threeyear comparison total shareholder return tsr peer companies b bonuses see footnote bonuses awarded individual contributions value creation business year meant incentive three overlapping performance cycles strive outstanding results create new business psp psp psp opportunities bonus amounts linked group psp closed december divisional profits sales growth operating profit capital charge opac earnings per share nes growth payment performance share plan determined product development pipeline achievement board directors annual basis acting upon measurable qualitative individual functional recommendations remuneration committee performance objectives competitive reasons roche roche annual report remuneration report roche f ratio corporate executive committee variable remuneration elements bonuses ssarsrsus psp relative fixed base pay criteria bonus ssarsrsus psp individual target value assessed max ssars consideration performance rsus based annual base pay competitors see footnote measured january macroeconomic development first year cycle relation value base pay minimum maximum relation value base pay cash payment value development value development blocked nesshares determined performance determined performance plus value adjustment starting psp dividends nes cycle plus value adjustment grant dividends nes grant performance criteria group objectives group individual contributions group performance divisional business upon remuneration tsr relation performance individual committees decision tsr performance objectives considering profit discretion peer set sales growth opac operating profit capital charge earnings per share nes growth product development pipeline split group objectives na b individual objectives na roche annual report roche remuneration report remuneration board directors retrospective approval corporate executive committee total aggregate bonus amounts corporate executive committee chairman board directors resolution financial year ended submitted retrospectively year remuneration committee roches board ordinary agm separate binding approval directors decides remuneration board members members roches corporate executive committee b prospective approval base pay bonuses ssars rsus policy decisions board executive aggregate remuneration pension benefits terms performance share plan submitted prospectively board directors decided annually board directors acting upon separate binding approval period two recommendations remuneration committee ordinary agms remuneration committee tracks market data salaries leading global pharmaceuticals companies see following pages provide detailed information footnote major swiss companies see footnote remuneration paid member board directors reports findings full board information member corporate executive committee committees remit powers procedures making financial year include comparisons remuneration decisions found bylaws remuneration paid previous years roche board directors articles incorporation approval changes general remuneration members board meeting march also outlined directors members board directors preceding sections report principles governing received fixed remuneration cash payments shown specific remuneration components remuneration members board directors table board activities roche paid salaries bonuses chairman board legally required employers contributions total directors members corporate executive swiss francs swiss social security programmes providing committee decided remuneration committee retirement disability unemployment benefits ahviv taking account revisions roches remuneration policy alv members board directors beside market comparisons management changes legally required contributions separately stated christoph franz franz b humer remuneration vicechairman board board members consists fixed cash payments set basic remuneration board directors discretion remuneration committee remained unchanged since remuneration remuneration committee assisted consultancy members board directors remain pwc tracked cash payments roche directors unchanged market data directors pay leading global pharmaceuticals companies see footnote major exception christoph franz franz b humer swiss companies see footnote bonus form blocked shares severin schwan members board directors awarded b policy procedure submitting total shares nonvoting equity securities ssars rsus board executive remuneration shareholder approval annual general meeting year annual general meeting agm capacity member international advisory shareholders approve total remuneration decided council iac chugai pharmaceutical co ltd andr board directors remuneration committee hoffmann received honoraria amounting total board directors corporate executive committee us dollars swiss francs arthur levinson received payments consulting work serving according approval agm roche board genentech amounting us dollars committed obtaining separate binding swiss francs resignation board shareholder approvals total remuneration paid directors september william burns received board directors corporate executive honoraria amounting total us dollars committee follows swiss francs serving member board directors chugai pharmaceutical co ltd retired march since october william burns new member international advisory council iac chugai pharmaceutical co ltd received honoraria amounting total us dollars swiss francs httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm list members positions committee memberships chairmanships see roche annual report remuneration members board directors additional additional c ompensation additional c ompensation additional special pecial remuneration committee c ompensation remuneration committee c ompensation emberschairs memberschairs chf chf chf chf chf chf ch franz see b total remuneration paid chairman board directors hoffmann see p baschera j bell p bulcke julius oeri schwan see highest total remuneration paid see highest total remuneration paid severin schwan member corporate severin schwan member corporate executive committee remuneration received executive committee remuneration received primary function ceo reflected total primary function ceo reflected total remuneration corporate executive committee remuneration corporate executive committee p r voser b weder di mauro remuneration members board directors retired franz b humer wm burns see ad levinson see b gehrig na na na l j r de vink na na na total exception members presidium vicechairmen board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration serving chairman board period january march amounting chf bonus award chf form shares blocked years calculation number shares based share price date transfer april approval agm calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm employer contributions employee stock purchase plan roche connect prorated period january march amounting chf payments tax consulting services chf plus prorated remuneration pension fundsmgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits chf additionally employer contribution ahvivalv chf chf paid form part compensation franz b humer received advisory capacity presidium swiss francs said remuneration included amount total remuneration board directors ordinary general meeting ordinary general meeting shareholders approved agm total amount paid franz b humer received honoraria amounting total usd chf serving member international advisory council iac new member board directors chugai pharmaceutical co ltd starting april prorated remuneration period january march prorated remuneration period january september detidua remuneration report roche roche annual report b total remuneration paid chairman severin schwan executive member board directors board directors received remuneration primary function ceo chairman christoph franz received total remuneration reflected highest total remuneration paid shown remuneration committees member corporate executive committee included bonus proposal adopted late respect total amount paid corporate executive financial year payable april put committee shareholder binding vote ordinary annual general meeting agm total remuneration paid chairman board directors ch franz ch franz chairman board directors member board directors chf chf salary cash see remuneration members board directors bonus pension fundsmgbinsurances total value prorated remuneration member board directors period march december chairman board directors period march december bonus award form shares blocked years calculation number shares based share price date transfer april approval agm calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm c stocksettled stock appreciation rights e board remuneration subject approval ssars annual general meeting december severin schwan member board directors holding ssars due submission chairmens total aggregate position ceo members corporate bonuses binding vote annual general executive committee held stocksettled stock appreciation meeting rights ssars shown ssars table remuneration chairman board directors includes bonus award swiss francs form shares blocked years shown b total total remuneration paid board directors remuneration paid chairman board directors calendar year members board board directors submit remuneration directors received remuneration including bonuses totalling committees bonus proposal adopted late swiss francs swiss francs chairman board christoph franz respect excluding additional employers contribution paid ahviv financial year payable april together alv totalling swiss francs swiss bonus proposal adopted time former francs form part compensation aggregate chairman board franz b humer respect swiss francs swiss francs financial year payable april swiss francs form shares blocked years see loans credits granted members remuneration members board directors board directors footnote total amount swiss francs form shares blocked years excluding additional remuneration paid legally required employers contributions ahvivalv detailed calculation remuneration see annual report pages mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits additionally employer contribution ahvivalv chf chf paid form part compensation detidua detidua roche remuneration report roche annual report shareholder binding vote ordinary annual remuneration members corporate general meeting agm executive committee general provisions assigning authority decisions corporate executive committee b submission boards total aggregate remuneration remuneration committee future remuneration binding shareholder board directors outlined pages vote remuneration report board directors proposes ordinary agm approve board remuneration totalling severin schwan executive member board directors swiss francs excluding legally required received remuneration primary function ceo employers contributions ahvivalv excluding reflected highest total remuneration paid bonuses period ending ordinary agm member corporate executive committee see ordinary agm approved remuneration included total amount paid corporate period ordinary agm ordinary agm totalling executive committee see h total remuneration paid swiss francs excluding bonuses members corporate executive committee comparison ordinary agm ordinary agm actual remuneration amounted swiss francs excluding legally required employers contributions ahvivalv excluding bonuses highest total remuneration paid severin schwan member corporate executive committee chf chf chf salary ssars grant value according trinomial model american call options rsus restricted stock units pension fundsmgb insurances roche connect subtotal bonus blocked nonvoting equity securitiesshares psp total value calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market value detailed calculation remuneration see annual report number ssars grant value according trinomial model american call options chf trinomial model american call options value described remuneration members corporate executive committee c stocksettled stock appreciation rights ssars number rsus grant value chf nes average market price days period prior grant date march per rsu calculation value consideration reduction value due additional blocking period years reduced market value mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits shares blocked years calculation number shares based share price date transfer april approval agm calculation value consideration reduction value due blocking period years reduced market value total estimated value psp award originally targeted nes awarded nes total spread relevant period time ie year value calculated using yearend price december chf per nonvoting equity security nes psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted nes nes respectively subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation originally targeted nes december december respectively according tsr achieved includes annual expense allowance chf payments tax consulting services chf additionally employer contribution ahvivalv chf chf paid form part compensation detidua remuneration report roche roche annual report remuneration remaining members corporate executive committee base pay chf annual salary annual salary annual salary ayyoubi r diggelmann hippe g keller oday total including chf loss pension rights granted former employer contractual agreement b bonus except severin schwan members corporate remuneration committee board directors executive committee receive bonus determined corporate executive committee members cash payment due april severin schwan bonuses december based performance receive bonus form roche shares agreed objectives total aggregate amount blocked years bonus payment due april bonuses brought forward binding vote see annual general meeting bonus bonus bonus bonus total total total chf chf chf ayyoubi r diggelmann hippe g keller oday total c stocksettled stock appreciation rights fair value ssars calculated grant date ssars using trinomial model american options trinomial ssars shown ssars table model effective method valuation american call introduced roche january place options considers possibility exercising option stock options ssars entitle holders benefit financially time prior maturity called american option increase value roches nonvoting equity compared european option allows exercise securities nes grant date exercise maturity date date strike price ssars terms multiyear plan closing price roche nes grant numbers ssars strike prices expiry dates date ssars vest three years grant date grant values ssars shown ssars table vested ssars exercised converted nes numbers ssars calculated within seven years grant date unexercised ssars time issue entered values table lapse without compensation information trinomial model american options please refer boyle phelim p lattice framework options pricing two state variables journal financial quantitative analysis volume issue mar wwwrochecomtrinomialmodelpdf see strike prices table ssars detidua detidua roche remuneration report roche annual report stocksettled stock appreciation rights ssars ssars ssars ssars value chf value chf value chf ayyoubi r diggelmann hippe g keller oday total restricted stock units rsus component partially replacing ssars value restricted stock units rsus rights receive ssar awards reduced balance nonvoting equity securities three year vesting awarded form rsus period plus value adjustment amount equivalent sum dividend paid rsu awards allocated individually remuneration vesting period attributable number nonvoting committees discretion vested recipient equity securities individual award three years thereafter resulting nonvoting granted introduced new remuneration equity securities may remain blocked years restricted stock units rsus rsus rsus rsus rsus number value chf number value chf ayyoubi r diggelmann hippe g keller oday total calculation value number rsus multiplied grant value chf nes average market price days period prior grant date march per rsu calculation value consideration reduction value due additional blocking period years reduced market value calculation value number rsus multiplied grant value chf nes average market price days period prior grant date march per rsu calculation value consideration reduction value due additional blocking period years reduced market value e performance share plan psp psp psp psp members corporate executive committee closed without awards targeted nes members senior management currently individuals worldwide participate performance provisions plan number nonvoting share plan psp equity securities nes reserved participants cycle number securities actually psp moved overlapping threeyear awarded depend whether extent performance cycles new cycle beginning year investment roche securities shares nes thus three cycles progress psp outperforms average return investment psp psp whereas securities issued peer set peer companies psp closed december comparisons based securities market prices targeted nes awarded psp dividend yields ie total shareholder return tsr targeted nes awarded previous years psp calculated chf constant exchange rates detidua detidua remuneration report roche see footnote roche annual report reduce effect shortterm market fluctuations security nes reserved plan members prices averaged three months october corporate executive committee shown table december prior start performance cycle board directors decide three months october december actual level nes cash equivalent awards end cycle cycles close financial years respectively aim psp roche securities perform better average provide incentive participants achieve steady peer set roches tsr increases least value growth cycle board directors elect increase nes award maximum award double original level end psp cycle based three reserved target number nes according psp plan month average distributed dividends totalling starting psp cycle plus value adjustment billion swiss francs billion swiss francs amount equivalent sum dividend paid billion swiss francs billion swiss francs vesting period attributable number tsr roche securities nes shares ranked nonvoting equity securities individual award th compared peer set companies operating granted requires roche securities industry therefore according terms perform well better peer plan participants received originally set event investment roche securities targeted nes see table details underperforms average return delivered peer companies fewer nes awarded performance share plan psp total estimated awards value psp awards target target targeted nes nes nes number number number awarded awarded awarded nes nes nes psp psp psp psp psp psp value chf value chf value chf value chf ayyoubi r diggelmann hippe ga keller oday total f indirect benefits roche connect voluntary stock purchase plan offering employer contributions made social security employees opportunity buy roche nonvoting equity schemes pension plans groupwide employee stock securities nes amount equal purchase plan roche connect respect members annual salary discount nes purchased corporate executive committee shown plan subject holding period four years indirect benefits employer contributions table switzerland employer contributions shown total estimated value psp award originally targeted nes awarded spread relevant period time ie year value calculated using yearend price december chf per nonvoting equity security nes psp estimated value calculated using yearend price december chf per nonvoting equity security nes based number nes originally targeted subject changes number value nes awardable plan december december respectively spread relevant period time ie year board directors vote actual allocation originally targeted nes december december respectively according tsr achieved detidua roche remuneration report roche annual report indirect benefits employer contributions pension payments pension payments funds tax funds tax mgb ahviv roche consulting mgb ahviv roche consulting insurances alv connect services insurances alv connect services chf chf chf chf chf chf chf chf ayyoubi r diggelmann hippe g keller oday total g remuneration emoluments loans executive remuneration subject approval members corporate executive committee annual general meeting additionally receive annual expense allowances swiss francs totalling swiss francs based submission executive total aggregate bonuses contractual obligations roche paid individual binding vote annual general meeting members corporate executive committee board directors proposes awarding members childrens schooling costs foreign tax obligation corporate executive committee bonuses totalling totalling swiss francs expense allowances swiss francs respect financial year aforementioned additional payments included swiss francs excluding legally required total remuneration members corporate executive employers contributions ahvivalv submit committee proposed total amount ordinary annual general meeting agm binding vote loans credits granted members corporate executive committee b submission executive total future aggregate remuneration binding pensions totalling swiss francs paid shareholder vote former corporate executive committee members board directors proposes ordinary agm approve remuneration corporate executive maximum regular period notice members committee totalling swiss francs corporate executive committee months excluding legally required employers contributions ahv changeofcontrol clauses employment contracts ivalv excluding bonuses period ending ordinary agm ordinary agm approved h total remuneration paid members remuneration period ordinary agm ordinary corporate executive committee agm totalling swiss francs calendar year members corporate excluding bonuses comparison ordinary executive committee received remuneration including agm ordinary agm remuneration amounted bonuses totalling swiss francs swiss francs excluding legally required swiss francs excluding additional employers contribution employers contributions ahvivalv excluding paid ahvivalv totalling swiss francs bonuses swiss francs form part compensation aggregate swiss francs amount executive total future aggregate swiss francs remuneration composed base pay longterm incentives ssars rsus calculated grant value additional remuneration mentioned without considering reductions value due blocking payments paid current former members periods applicable psp calculated time corporate executive committee reservation nonvoting equity securities taking mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits ahvivalv swiss social security programmes providing retirement disability unemployment benefits detidua detidua remuneration report roche roche annual report roche remuneration report account potential double contributions pension upon termination employment result serious benefits excluding legally required employers contributions misconduct ssars rsus granted outstanding ahvivalv well contributions expenses whether vested unvested shall lapse immediately without payments tax consulting services roche connect compensation according ssars plan rules serious misconduct participant may include inter alia activity leading serious disciplinary action alignment interests managers repeated willful failure perform duties shareholdersholders nonvoting equity reasonably assigned roche securities violation law public regulation ssars rsus psp remuneration components commission crime intended align managements interest gross negligence willful misconduct employment shareholders holders nonvoting equity securities engaging conduct bringing disgrace disrepute give participating managers additional incentive roche andor subsidiaries achieve continued value growth form longterm violation roches directives guidelines total shareholder returns creating value roche relating business conduct investors management benefits well added value created investors management penalised according regulations psp programme receiving less originally targeted awarded nes shall lapse without compensation upon notice termination employment given reason clawback redundancy disability retirement addition applicable statutory provisions roches longterm incentive plans include option partially reclaim distributed compensation result special guidelines security holdings circumstances clawback board directors decided ceo cec members must acquire shares andor nes employee voluntarily serves notice termination equivalent two annual base salaries ceo one employment ssars rsus unvested annual base salary respectively end date termination employment lapse immediately retain holdings long serve cec without compensation type security value ceo shares andor nes x annual base salary members corporate executive committee shares andor nes x annual base salary roche annual report security holdings parties note financial statements directors andr hoffmann andreas oeri members roche holding ltd significant shareholders founders families closely associated addition december december belong shareholder group pooled voting respectively members board directors rights end group held shares persons closely associated members issued shares detailed information cec persons closely associated held group found finance report note shares nes shown table security holdings roche group consolidated financial statements related security holdings december december close close relatives relatives security security holdings holdings shares nes number others shares nes number others number number type number number number type number board directors ch franz hoffmann p baschera j bell p bulcke julius oeri schwan see security holdings see security holdings corporate executive committee corporate executive committee p r voser b weder di mauro retired directors board f b humer na na na na w burns na na na na ssars see annual report levinson na na na na total shares held shareholder group pooled voting rights listed detidua remuneration report roche roche annual report security holdings december december close close relatives relatives security security holdings holdings shares nes number others shares nes number others number number type number number number type number corporate executive committee schwan ssarsrsus ssarsrsus see see ayyoubi ssarsrsus ssarsrsus see see r diggelmann ssarsrsus ssarsrsus see see hippe ssarsrsus ssarsrsus see see g keller ssarsrsus ssarsrsus shares see shares see oday ssarsrsus ssarsrsus see see total shares shares detidua roche remuneration report roche annual report ssars number ssars held current former members corporate executive committee december total corporate executive committee schwan ayyoubi r diggelmann hippe g keller oday total strike price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options values according corresponding annual reports former position options held options shown table issued roche employee stock options option entitles holder purchase one roche nonvoting equity security nes terms multiyear option plan strike price options shown closing price roche nes grant date options shown nontradable onethird options subject vesting period one year onethird vesting period two years onethird vesting period three years unvested options lapse without compensation employment terminated voluntarily reasons retirement vested options must exercised within limited period time restricted stock units rsus number rsus held members rsus rsus corporate executive committee december number number schwan ayyoubi r diggelmann hippe g keller oday total grant value chf chf nes average market price days period nes average market price days period prior grant date march per rsu prior grant date march per rsu detidua detidua remuneration report roche roche annual report roche report statutory auditor report statutory auditor general meeting roche holding ltd basel audited accompanying remuneration report audit involves performing procedures obtain audit dated january roche holding ltd year evidence disclosures made remuneration ended december audit limited report regard compensation loans credits information according articles ordinance accordance articles ordinance excessive compensation stock exchange listed procedures selected depend auditors judgement companies ordinance contained sections marked including assessment risks material blue line including respective footnotes pages misstatements remuneration report whether due remuneration report fraud error audit also includes evaluating reasonableness methods applied value components responsibility board directors remuneration well assessing overall presentation board directors responsible preparation remuneration report overall fair presentation remuneration report accordance swiss law ordinance believe audit evidence obtained excessive compensation stock exchange listed sufficient appropriate provide basis opinion companies board directors also responsible designing remuneration system defining individual opinion remuneration packages opinion remuneration report year ended december roche holding ltd complies swiss auditors responsibility law articles ordinance responsibility express opinion accompanying remuneration report conducted audit accordance swiss auditing standards standards require comply ethical requirements plan perform audit obtain reasonable assurance whether remuneration report complies kpmg ag swiss law articles ordinance ian starkey franois rouiller licensed audit expert licensed audit expert auditor charge basel january roche annual report report statutory auditor roche roche annual report roche independent assurance report independent assurance report roche corporate responsibility reporting corporate governance sustainability committee roche group internal corporate reporting manual roche holding ag basel roche version group reporting manualsustainability reporting engaged perform assurance procedures defined guidelines people provide limited assurance aspects contributions key figures internally gathered collated corporate responsibility cr reporting roche included aggregated annual report report accuracy completeness cr indicators subject scope subject matter inherent limitations given nature methods limited assurance engagement focused following determining calculating estimating data data information disclosed cr reporting roche assurance report therefore read connection consolidated subsidiaries year ended roches internal guidelines definitions procedures december reporting cr performance management reporting processes respect cr reporting material aspects preparation responsibility methodology safety security health environmental protection roche corporate governance sustainability contributions people key figures well committee responsible subject matter related control environment relation data criteria well selection preparation presentation aggregation key figures selected information accordance criteria materiality determination process roche group responsibility form independent opinion based level according requirements gri g limited assurance procedures whether anything guidelines disclosed pages report come attention indicate identified key figures including greenhouse gas emissions cr information selected contained report scope scope resulting business travel stated material respects accordance tables graphs pages people reporting criteria key figures disclosed pages report consolidated data information roche group planned performed procedures accordance level relation contributions breakdown disclosed international standard assurance engagements report isae assurance engagements audits people key figures disclosed roches website within reviews historical financial information standard section nonfinancial reporting subsection requires comply ethical requirements plan performance perform assurance engagement obtain limited assurance identified cr information criteria management reporting processes respect subject matter provide limited cr reporting key figures assessed assurance nature timing extent procedures internal policies procedures set forth following gathering sufficient appropriate evidence deliberately roche group internal cr reporting guidelines based limited relative reasonable assurance engagement responsible care health safety environmental complied independence ethical protection reporting guidelines published european requirements code ethics professional chemical industry council cefic sustainability accountants issued international ethics standards reporting guidelines g published global board accountants founded fundamental reporting initiative gri principles integrity objectivity professional competence due care confidentiality professional behaviour roche annual report independent assurance report roche performed tasks services believe evidence obtained sufficient roche would conflict independence appropriate provide basis assurance responsible preparation part conclusions report therefore qualify independent defined code ethics applicable legal regulatory conclusion requirements based work performed described report identified cr reporting nothing come summary work performed attention causing us believe material respects assurance procedures included amongst others roche group internal cr reporting guidelines based following work gri g sustainability reporting guidelines well evaluation application roche group cefic guidelines applied guidelines roche materiality determination process disclosed reviewing application roche group internal adhere principles guiding factors corporate cr contributions guidelines eg soundness stakeholder determination peer review site visits management inquiry relevance regulatory environment integration key visiting selected sites roches pharmaceuticals organisational values objectives defined gri g diagnostics divisions us india brazil internal reporting processes collect aggregate selection based quantitative qualitative criteria contributions people data functioning interviewing personnel responsible internal cr designed provide appropriate basis reporting data collection sites visited disclosure roche group level determine understanding cr information mentioned subject matter application roches internal cr guidelines disclosed within cr reporting roche annual assessment key figures report referenced webpages performing tests sample basis evidence supporting stated accordance reporting criteria selected contributions people key figures roche accident rate energy consumption greenhouse gas emissions related energy consumption halogenated zurich january hydrocarbons water waste contributions healthcare institutions patient organisations public policy bodies pricewaterhousecoopers ag philanthropic organisations headcountfte data labour practice information training hiring costs concerning completeness accuracy adequacy consistency inspection documentation analysis relevant policies principles inspecting relevant documentation sample basis including roche group cr policies management christophe bourgoin stephan hirschi reporting structures documentation inspecting principles roche materiality process providing definition development adherence gris environmental social economic reporting requirements addressing soundness identification process determination impacted stakeholders peer competition review integration relevant regulatory requirements integration key organisational values objectives report prioritisation material aspects assessment processes data consolidation reviewing management ofand cr reporting processes contributions people key figures assessing consolidation process data roche group level carried work data reported prior reporting periods performed work respect projections targets conducted work data outlined subject matter defined roche annual report roche web web business review roche wwwrochecomabout business priorities wwwrochecompriorities investors wwwrochecominvestors personalised healthcare phc wwwrochecompersonalisedhealthcare sustainability wwwrochecomsustainability pharmaceuticals pharmaceuticals wwwrochecomproducts pharmaceutical supply chain initiative wwwpharmaceuticalsupplychainorg diagnostics solutions diagnostics wwwrochecomproducts innovation product development portfolio wwwrochecompipeline clinical trials wwwrochecomclinicaltrials patient safety wwwrochecommanagingmedicationsafety research development locations wwwrochecomrndlocations research technologies wwwrochecomresearchtechnologies patents intellectual property wwwrochecompatents global standards wwwrochecomglobalstandards animal welfare wwwrochecomanimalwelfare access healthcare access healthcare wwwrochecomaccesstohealthcare making innovation accessible wwwrochecommakinginnovationaccessible genentech access solutions wwwgenentechaccesssolutionscom patient organisations wwwrochecompatientgroups roche annual report web roche responsible business nonfinancial reporting wwwrochecominvestorsreportingnonfinancialreporting materiality wwwrochecommateriality key performance indicators wwwrochecomperformance gri g index wwwrochecomgriindex reporting centre wwwrochecomreporting stakeholder engagement wwwrochecomstakeholderengagement code conduct wwwrochecomcodeofconduct roche supplier code conduct wwwrochecomrochesuppliercodeofconductpdf business partner information wwwrochecombusinesspartners suppliers service providers wwwrochecomforpartnershipsuppliers responsibility download centre wwwrochecompositionspoliciesdownloads human rights wwwrochecomhumanrights risk management compliance wwwrochecomriskmanagementandcompliance business integrity responsible marketing wwwrochecombusinessintegrityandresponsiblemarketing anticounterfeiting wwwrochecomcounterfeiting people employees wwwrochecomaboutpeopleemployeeshtm people wwwrochecompeople sustainability employees wwwrochecomforemployees careers httpcareersrochecom roche group employment policy wwwrochecomemploymentpolicypdf environment community safety health environment wwwrochecomenvironment goals performance wwwrochecomourshegoalsandperformance policies guidelines position papers wwwrochecomourshepoliciesguidelinesandpositionpapers roche commissions wwwrochecomrochecommissions roche continents wwwrochecontinentsnetrochecontinents roche childrens walk wwwrochecomchildrenswalk corporate governance remuneration report httpwwwrochecomaboutrochecorporategovernancehtm httpwwwrochecomaboutrochecorporategovernancearticleofincorporationhtm httpwwwrochecomaboutrochemanagementboardofdirectorshtm httpwwwrochecomaboutrochemanagementexecutivecommitteehtm httpwwwrochecomaboutrochecorporategovernanceannualgeneralmeetingshtm httpwwwrochecomaboutrochecorporategovernancecommitteeshtm httpwwwrochecomcorporateresponsibilitybusinessethicsriskmanagementandcompliancehtm httpwwwrochecomcorporateresponsibilityenvironmenthtm httpwwwrochecomcorporateresponsibilityhtm httpwwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm httpwwwrochecommediahtm httpwwwrochecominvestorshtm httpwwwrochecominvestorscontactshtm httpwwwrochecomaboutrochecorporategovernancecodeofconducthtm httpwwwrochecomtrinomialmodelpdf roche annual report roche imprint published cautionary statement regarding forwardlooking f hoffmannla roche ltd statements basel switzerland annual report contains certain forwardlooking tel statements forwardlooking statements may fax identified words believes expects anticipates projects intends seeks estimates future media office similar expressions discussion among things group communications strategy goals plans intentions various factors may basel switzerland cause actual results differ materially future tel reflected forwardlooking statements contained fax annual report among others pricing product initiatives competitors legislative regulatory investor relations developments economic conditions delay inability basel switzerland obtaining regulatory approvals bringing products tel market fluctuations currency exchange rates fax general financial market conditions uncertainties discovery development marketing new products website new uses existing products including without wwwrochecom limitation negative results clinical trials research projects unexpected side effects pipeline marketed corporate sustainability committee products increased government pricing pressures tel interruptions production loss inability obtain email corporatesustainabilityrochecom adequate protection intellectual property rights litigation loss key executives employees order publications adverse publicity news coverage tel fax statement regarding earnings per share growth email baselwebmasterrochecom profit forecast interpreted mean roches earnings earnings per share next annual general meeting subsequent period necessarily match exceed march historical published earnings earnings per share roche trademarks mentioned enjoy legal protection links thirdparty pages provided convenience express opinion content thirdparty pages expressly disclaim liability thirdparty information use roche annual report published german english report consists actual annual report finance report contains annual management report annual financial statements consolidated financial statements printed nonchlorine bleached fsccertified paper roche annual report issued f hoffmannla roche ltd basel group communications roche annual report believe urgent deliver medical solutions right even develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world roche